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Abstract 
 
Posttraumatic stress disorder (PTSD), a prevalent psychiatric disorder, is caused by exposure 
to a traumatic event. Individuals diagnosed for PTSD not only experience significant 
functional impairments but also have higher rates of physical morbidity and mortality. 
Despite intense research efforts, the neurobiological pathways affecting fear circuit brain 
regions in PTSD remain obscure and most of the previous studies were limited to 
characterization of specific markers in periphery or defined brain regions. In my PhD study, I 
employed proteomics, metabolomics and transcriptomcis technologies interrogating a foot 
shock induced PTSD mouse model. In addition, I studied the effects of early intervention of 
chronic fluoxetine treatment. By in silico analyses, altered cellular pathways associated with 
PTSD were identified in stress-vulnerable brain regions, including prelimbic cortex (PrL), 
anterior cingulate cortex (ACC), basolateral amygdala (BLA), central nucleus of 
amygdala(CeA), nucleus accumbens (NAc) and CA1 of the dorsal hippocampus. With RNA 
sequencing, I compared the brain transcriptome between shocked and control mice, with and 
without fluoxetine treatment. Differentially expressed genes were identified and clustered, 
and I observed increased inflammation in ACC and decreased neurotransmitter signaling in 
both ACC and CA1. I applied in vivo 
15
N metabolic labeling combined with mass 
spectrometry to study alterations at proteome level in the brain. By integrating proteomics 
and metabolomics profiling analyses, I found decreased Citric Acid Cycle pathway in both 
NAc and ACC, and dysregulated cytoskeleton assembly and myelination pathways in BLA, 
CeA and CA1. In addition, chronic fluoxetine treatment 12 hours after foot shock prevented 
altered inflammatory gene expression in ACC, and Citric Acid Cycle in NAc and ACC, and 
ameliorated conditioned fear response in shocked mice. These results shed light on the role of 
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immune response and energy metabolism in PTSD pathogenesis. Furthermore, I performed 
microdialysis in medial prefrontal cortex and hippocampus to measure the changes in 
extracellular norepinephrine and free corticosterone (CORT) in the shocked mouse and 
related them to PTSD-like symptoms, including hyperaroual and contextual fear response.  I 
found that increased free CORT was related to immediate stress response, whereas 
norepinephrine level, in a brain region specific manner, predicted arousal and contextual fear 
response one month after trauma. I also applied metabolomics analysis to investigate 
molecular changes in prefrontal microdialysates of shocked mice. Citric Acid Cycle, 
Glyoxylate and Dicarboxylate metabolism and Alanine, Aspartate and Glutamate metabolism 
pathways were found to be involved in foot shock induced hyperarousal. Taken together, my 
study provides novel insights into PTSD pathogenesis and suggests potential therapeutic 
applications targeting dysregulated pathways. 
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1. INTRODUCTION 
 
1.1. History, epidemiology and diagnosis of PTSD 
The term Trauma was originally used to describe physical wound or injury (Spiers and 
Harrington, 2001).  Later in medicine and psychiatry literature, trauma was referred to a 
wound inflicted upon the mind rather than the body (Caruth, 1996). During the 19
th
 century 
and into the mid-20
th
 century, there was an ongoing debate whether traumatic disorder was 
psychological or physiological. Not until post-World War II was the concept of interaction 
between psychology and neurophysiology for traumatic disorders identified and recognized 
(Abram, 1970; Selye, 1974).  
What we call PTSD nowadays was first classified as “Stress Response Syndrome” caused by 
tremendous stress reaction under the category of transient situational personality disorder in 
the first edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-I) published 
by the American Psychiatric Association (APA, 1952). In 1980, PTSD was first officially 
mentioned in DSM-III (APA, 1980). The revised DSM-III (APA, 1987) then separated the 
cause of PTSD from ordinary stressors. In the current DSM-5 (APA, 2013) PTSD was 
officially removed from anxiety disorder to a new category of trauma- and stress-related 
disorder with more distinct diagnoses based on behavioral symptoms.  
The epidemiology of PTSD was not recognized until 1980 in DSM-III (APA, 1980). 
Described by the National Comorbidity Survey (NCS), the life-time prevalence of PTSD was 
10.4 % in females and 5.0 % in males of the U.S. population (Kessler et al, 1995), while in 
Germany was reported to be 2.2 % in females and less than 1 % in males (Perkonigg et al, 
2000). The definition of PTSD starts with an exposure to trauma, a stressor that is not in the 
range of normal human experience. Among those individuals who were exposed to severe 
trauma, about 10-20% will develop PTSD. The risk for developing PTSD depends on the 
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stress dose and coping strategy of the affected individual. Other risk factors including 
childhood stress/trauma, domestic violence, gender or pre-existing anxiety/depression also 
impact the onset of PTSD (Foa et al, 2006; Yehuda et al, 2011a). 
The development of PTSD is often preceded by acute stress disorder. The symptoms usually 
begin within the first three months after encountering the trauma but may also initiate more 
than six months after the stressor (Ballenger et al, 2000; Brunello et al, 2001; Kessler, 2000). 
To date, the diagnosis of PTSD relies much on self-reports, clinical expert interviews and 
clinical behavioral monitoring. According to DSM-5, five criterions should be met for the 
diagnosis of PTSD:  
Criterion A – The patient was exposed to a traumatic event, such as death threat, serious 
injury or sexual violence or has witnessed another person being exposed to such tragic events, 
with the response of intense fear. 
Criterion B – Intrusion (re-experiencing) symptoms which include intrusive memories, 
flashbacks as well as nightmares of the traumatic event. Re-experiencing symptoms are 
usually triggered by environmental cues that remind the patients of the tragic experience. 
Criterion C – Symptoms which involve avoiding thoughts, feelings, places, activities or 
people associated with the traumatic event.  
Criterion D – Emotional numbing, decreased interest and symptoms of negative alterations in 
cognition and mood related to the traumatic experience. 
Criterion E – Hyperarousal symptoms, including sleep difficulties, hypervigilance, 
exaggerated startle response, aggressiveness, loss of concentration or self-destructive 
behavior.   
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1.2. Neurobiology of PTSD 
 
1.2.1. Alterations in the neuroendocrine system 
Upon stressor stimulation, glucocorticoids (GC) and catecholamines play a major role in 
regulating stress response and result in brain metabolism and behavior changes.  Immediate 
release of catecholamines induces an acute response to the stressors and is regulated by 
sympathetic-adrenal-medullary (SAM) axis. GC secretion, on the other hand, affects long-
term adaption processes and is regulated by hypothalamic-pituitary-adrenal (HPA) axis.  
HPA axis is composed of the paraventricular nucleus (PVN) of hypothalamus, the anterior 
pituitary and the cortex of the adrenal gland. Stressor first simulates corticotropin-releasing 
hormone (CRH) release from parvocellular secretory neurons which project from the 
hypothalamic PVN to the median eminence of the hypothalamic-hypophyseal portal 
circulation. CRH is then transported to anterior pituitary via the blood vessel system and 
stimulates the secretion of adrenocorticotropic hormone (ACTH). Subsequently, ACTH is 
transported to the adrenal cortex, where it rapidly stimulates biosynthesis and release of GC 
(cortisol for human and corticosterone for rodents) (Papadimitriou and Priftis, 2009) as well 
as the mineralocorticoids (Funder, 2010). Under physiological conditions, HPA axis 
activation is regulated by two negative feedback loops, inhibitory effects of cortisol on the 
ACTH-secreting cells in the anterior pituitary and the CRH-secreting neurons in the 
hypothalamus. In addition, limbic brain regions involved in emotional response to stress 
modulate HPA axis activity, with frontal cortex and hippocampus inhibiting while amygdala 
increasing HPA axis activity (Herman et al, 2005).  
In addition to HPA axis, stress exposure activates SAM axis immediately, which leads to 
production and release of the catecholamines (norepinephrine, epinephrine) from adrenal 
medulla. Meanwhile, stressors induce norepinephrine release from locus coeruleus (LC) 
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neurons in the forebrain regions, including frontal cortex, hippocampus and amygdala 
(Robertson et al, 2013). Increased GC and catecholamines evoke physical stress response, the 
“fight-or flight” response, by increasing heart rate, blood pressure and pupil dilation while 
inhibiting digestion, urination or reproductive functions (Carrasco and Van de Kar, 2003) to 
prepare the organism to survive and deal with stressors.  
Many studies have indicated HPA and SAM axes activity dysregulations in PTSD patients. 
However, in clinical studies, inconsistent findings of cortisol levels were observed in PTSD 
patients. Increased cortisol reactivity in response to psychosocial stress has been observed in 
sexual and physical childhood abuse patients (Heim et al, 2000). On the other hand, lower 
cortisol secretion has been reported in patients with PTSD (Morris et al, 2012; Yehuda and 
Seckl, 2011b). Yet, Wingenfeld et al. (Wingenfeld et al, 2015) found lower cortisol levels 
only in patients with lifetime PTSD, but not in patients with current PTSD. This phenomenon 
may underlie the biological significance reflecting dose-dependent and time course effects of 
cortisol release. In addition to PTSD, abnormalities in cortisol secretion and HPA axis 
activity were also reported in other depressive and anxiety-related disorders. 
Hypercortisolism was found in major depression patients, with hypersecretion of cortisol at 
baseline and in the dexamethasone suppression test (Parker et al, 2003). Abelson and Curtis 
(Abelson and Curtis, 1996) observed that alterations in HPA system in panic disorder patients 
are modulated by illness severity and treatment seeking behavior. The shared dysregulation 
of HPA axis in major depression, PTSD and other stress-related disorders might in part 
explain the high comorbidity of these psychiatric disorders.  
Release of GC induces massive changes throughout the whole body, primarily activating 
adaptation mechanisms. Chronic stimulation of GC release by stress may initiate differential 
regulation of its downstream targets, i.e. GC receptors. Two types of receptors mediate GC 
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actions in the brain. Mineralocorticoid receptors (MR) bind cortisol with nearly ten-fold 
higher affinity than glucocorticoid receptors (GR) (Veldhuis et al, 1982). At basal or during 
mild stressful conditions cortisol mostly binds to MR to enhance synaptic strength (LTP). 
During cortisol level elevation, GRs become fully occupied and LTP induction is impaired 
(de Kloet et al, 2005; Joëls et al, 2006). This dual system may work in opposing directions 
regulating the behavioral responses (Pavlides et al, 1995). Chronic GC hypersecretion results 
in MR and GR downregulation. In a rat model of single-prolonged-stress PTSD, MR and GR 
levels were found decreased (Zhe et al, 2008). In addition, GC sensitivity correlates with 
symptom changes in combat veteran PTSD patients and GC receptor hypersensitivity has 
been shown to develop after childhood trauma and (later) PTSD, indicating the important 
roles of MR and GR in the clinical state (McGowan et al, 2009; Yehuda et al, 2014). 
Moreover, GC regulates the HPA system via a negative feedback loop by inhibiting ACTH 
and CRH secretions. Elevated CRH levels are associated with increased fear-potentiated 
startle response (Keen-Rhinehart et al, 2009; Pelton et al, 1997) and enhanced fear 
conditioning (Roozendaal et al, 2002). Higher concentrations of CRH in the cerebrospinal 
fluid were observed in PTSD patients (Baker et al, 1999). 
Catecholamine (norepinephrine) not only regulates sleep and arousal, but also attention, 
learning and memory. Activation of the norepinephrinergic system mediates consolidation of 
memories associated with emotional events (Barsegyan et al, 2014; Soeter and Kindt, 2011). 
Dysregulated norepinephrine signaling has been linked to PTSD symptom severity, with 
chronic PTSD patients showing greater CNS norepinephrinergic activity than healthy 
subjects (Geracioti et al, 2001). In another study, facilitation of norepinephrine signaling by 
using the α2 selective antagonist yohimbine resulted in increased anxiety in PTSD patients 
(Bremner et al, 1997a; Southwick et al, 1997). However, administration of the β receptor 
antagonist propranolol showed mixed results both in clinical trials and in animal models of 
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PTSD (Brunet et al, 2008; Cohen et al, 2011; Dębiec et al, 2011; Pitman et al, 2002; Stein et 
al, 2007). These studies indicate a dual role of norepinephrine, both adaptive and 
deteriorating, in the mediation of the post-stress response (Jett and Morilak, 2013; Lapiz and 
Morilak, 2006). In addition to regulation of stress responses, norepinephrine and GC interact 
with each other and mediate downstream events. Several studies indicated that GC affects α1-
adrenergic receptor function and modulates α- and β-adrenergic receptor-coupled signaling 
(Duman et al, 1989; Stone et al, 1987). Moreover, local administration of β-adrenergic 
receptor antagonist propranolol in the amygdala prevented GC-induced memory 
enhancement from emotional arousal-induced norepinephrine activation (Quirarte et al, 1997; 
Roozendaal et al, 2006).  In PTSD patients, interaction between norepinephrine and cortisol 
was shown to be predictive for negative intrusive memories in PTSD (Nicholson et al, 2014). 
  
1.2.2. Neurotransmitter system in PTSD 
Central neurotransmitter imbalance has been linked to the pathophysiological mechanisms of 
PTSD. Traumatic experiences activate certain neuronal circuits and induce long-lasting 
changes in neurotransmitter systems. In addition to the abnormalities in norepinephrine and  
GC signaling described in chapter 1.2.1, monoaminergic neurotransmitters, including 
serotonin and dopamine, were found dysregulated in PTSD. Clinical studies showed that 
combat-related PTSD (CR-PTSD) is associated with enhanced norepinephrinergic activity 
and diminished serotonin activity (Spivak et al, 1999). In addition, hypofunction of 
serotonergic system was associated with PTSD symptoms, i.e. increased startle response and 
impulsive aggression in chronic CR-PTSD. Treatment of CR-PTSD patients with SSRIs 
showed improvements in symptoms including arousal, intrusion, irritability and avoidance 
(Marmar et al, 1996). Increased central serotonin function has been shown to play an 
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important role in stress adaptation in animal studies (Joseph and Kennett, 1983). A 
significantly lower binding affinity of amygdala serotonin transporter was found in PTSD 
patients compared to healthy subjects (Murrough et al, 2011). A meta-analysis revealed an 
association between SS genotype of the serotonin transporter (5-HTTLPR) polymorphism 
and PTSD in high trauma-exposed patients, implicating the role of 5-HTTLPR polymorphism 
as a risk factor for developing PTSD (Gressier et al, 2013). Taken together, serotonin deficit 
is an important factor for the development and persistence of PTSD symptoms.  
The mesolimbic dopaminergic pathway also plays an important role in fear and anxiety. It 
was shown that over-activation of dopamine transmission resulted in increased fear response 
(Pezze and Feldon, 2004). Dysfunction of dopamine in frontal cortex is associated with 
intrusive thoughts and insufficient extinction of trauma-related memory, which are core 
features of PTSD (Morrow et al, 1999; Seamans and Yang, 2004). A clinical study showed 
that the decline of dopamine metabolite homovanillic acid levels was associated with 
laboratory-induced symptoms in chronic PTSD patients (Geracioti et al, 2013). On the other 
hand, higher urinary excretions of dopamine, norepinephrine and epinephrine were observed 
in PTSD outpatients, and dopamine and norepinephrine levels were correlated with the 
severity of PTSD (Yehuda et al, 1992). Similar to serotonergic transporters, dopamine 
transporter single nucleotide polymorphisms are associated with the occurrence of PTSD 
among trauma survivors (Segman et al, 2002). Meanwhile, cross talk between norepinephrine, 
serotonin and dopamine has been reported such that norepinephrine stimulates serotonin and 
dopamine release while serotonin release from norepinephrine neurons reduces 
norepinephrine release (Fink and Göthert, 2007). These studies implicate the importance of 
balanced monoaminergic neurotransmitter signaling for PTSD underlying mechanisms. 
Besides dysfunctional monoaminergic pathways, alterations in amino acid neurotransmitter 
signaling have been implicated in PTSD. Higher levels of gamma-aminobutyric acid (GABA) 
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in dorsolateral prefrontal cortex and anterior cingulate cortex were identified in PTSD 
patients (Michels et al, 2014). However, in human plasma, low GABA levels after 
encountering a traumatic event may predict subsequent PTSD development (Vaiva et al, 
2004). In addition to GABA itself, imbalance between GABA and glutamate is associated 
with hippocampal neuronal apoptosis in the PTSD animal model (Gao et al, 2014). 
Glutamatergic neurotransmission is known to be involved in the stress response and anxiety-
related disorders (Popoli et al, 2012). The glutamatergic system regulates acquisition and 
extinction of fear conditioning. Stress-induced glutamate release facilitates memory 
consolidation by inducing long-term potentiation (Anwyl, 2009). Treatment with the 
anticonvulsivant drug, phenytoin, which may reduce glutamate neurotransmission, has 
demonstrated significant efficacy in combat PTSD by reducing avoidance and arousal 
symptoms (Bremner et al, 2005a).  Furthermore, blocking N-methyl-D-aspartate (NMDA) 
receptors prior to exposure to a predator scent stress prevented anxiety-like behaviour in 
rodents (Blundell et al, 2005). Thoreinger et al. showed that AMPA receptor GluR1 signaling 
in dentate gyrus is involved in consolidation of remote fear memories via CRH receptor type 
1 pathway (Thoeringer et al, 2012). These studies provide evidence for the involvement of 
glutamatergic signaling in PTSD pathogenesis. Interestingly, recent findings suggest that 
polyamine modulates ionotropic glutamate receptors and the metabolism was shown to be 
disrupted in anxiety and depression (Fiori and Turecki, 2008; Vaquero-Lorenzo et al, 2009).  
Finally, neuropeptides, e.g. neuropeptide Y (NPY), has been shown to be involved in PTSD 
development (Sah and Geracioti, 2013). Recent studies suggest a protective effect of NPY for 
PTSD via its function in regulating fear conditioning and extinction and suppressing startle 
responses (Fendt et al, 2009; Karl et al, 2010b). Another neuropeptide, PACAP, which 
stimulates CRH secretion in the hypothalamus (Grinevich et al, 1997), has been shown to be 
associated with female PTSD (Ressler et al, 2011).  
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1.2.3. Alterations of the immune system 
As mentioned in chapter 1.2.1, physical and psychological stress induces the release of stress 
hormone. Stress hormones alter the status of the immune system (Glaser and Kiecolt-Glaser, 
2005), and in turn, immune system disturbance affects CNS function via humoral and cellular 
pathways conveying signals to the brain (Maier and Watkins, 1998). Recent studies have 
indicated an altered inflammatory response in various psychiatric disorders, including 
schizophrenia (de Baumont et al, 2015; Neelamekam et al, 2014), major depression (Maes, 
1995, 2008), and anxiety-related disorders (Ogłodek et al, 2015; Solati et al, 2015). It is 
known that chronic stress exposure affects sympathetic and steroid hormone pathways, and 
results in alterations of lymphocyte migration and numbers (Silberman et al, 2004).  Upon 
stressors, the expression of cytokine and chemokine genes for mobilizing the immune cells is 
regulated so that the tissue function can be restored upon intrusions (Black and Garbutt, 
2002). Depending on the nature, intensity, and duration of the stressor, different types of 
immune response are challenged and stress effects on the immune system differ. Exposure to 
prolonged stressors induces immunosuppression and results in anti-inflammatory response 
that makes the subject more susceptible to diseases (Cohen et al, 2012). On the other hand, 
repeated defeat stress (e.g., repeated social defeat) prevents the GC-induced suppression of 
inflammation via inhibition of nuclear factor κ B (NFκB) pathway and results in an 
enhancement of the immune response (Barnes and Adcock, 2009; Chrousos et al, 1996).  
Recent studies have shed light on the role of the immune response in anxiety-related 
disorders. Studies on adult male Sprague-Dawley rats revealed that chronic unpredictable 
restraint stress exposure selectively increases the number of microglial cells and results in a 
transition of microglia from a ramified-resting state to a non-resting state in certain stress-
vulnerable brain regions, including anterior cingulate cortex, infralimic medial prefrontal 
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cortex, nucleus accumbens, medial amygdala, dorsal bed nucleus of the stria terminalis, CA3 
region of the hippocampus and periaqueductal gray (Tynan et al, 2010). These finding 
indicate that microglial activation might play an important role in the regulation and/or 
adaptation to stress. In addition, women with PTSD due to childhood sexual or physical 
abuse showed enhancement in delayed-type hypersensitivity skin test which suggests higher 
cell-mediated inflammatory reactions (Altemus et al, 2003). In the psychogenic stress-
exposed rats, treatment of minocycline, an anti-inflammatory, anti-apoptotic and 
neuroprotective tetracycline agent, reduced local levels of the cytokines interleukin-1 (IL-1), 
IL-6 and tumor necrosis factor-α (TNF-α) in the hippocampus, frontal cortex and 
hypothalamus, and attenuated anxious-like behaviors (Levkovitz et al, 2015). Taken together, 
dysregulations in immunological processes upon psychological and physiological stress may 
disturb the adaptation/resilience to stress and therefore results in PTSD development.  
 
1.2.4. Pathoanatomical alterations associated with PTSD 
Development of PTSD involves memory- and stress-related processes (Siegmund and Wotjak, 
2006). Maintenance of strong memory of an aversive encounter due to resistance to 
extinction, memory reinstatement, too fragile inhibitory mechanisms, overgeneralization or 
disturbance of declarative memory is a potent cause for PTSD (Bremner et al, 1992; Charney 
et al, 1993; McFarlane et al, 2002; Solomon et al, 1987). Different brain structures are 
associated with the memory process in PTSD. Brain imaging studies in PTSD patients during 
fear conditioning and in response to trauma-related stimuli showed an increased activity in 
amygdala, the brain region responsible for expression of conditioned fear, and decreased 
activity in prefrontal cortex, the brain region related to extinction (Bremner, 2002; Bremner 
et al, 2005b). In addition, the size of the hippocampus (a brain structure for contextual fear 
memory formation) seems to have an inverse correlation with the susceptibility of developing 
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PTSD (Gilbertson et al, 2002). Traumatic events not only result in the formation of 
associative memories but also sensitize individuals in a non-associative manner, increasing 
the general responsiveness to potentially harmful stimuli. The hyper-responsiveness in 
amygdala and medial prefrontal cortex observed in PTSD patients is in accordance with 
slower habituating activity in response to trauma-related stimuli (Shin et al, 2005). 
Meanwhile, studies with rats and mice have demonstrated that a single exposure to an 
extreme stressor may cause long-lasting changes in neurochemistry (Martí et al, 2001; van 
Dijken et al, 1993), startle response (Balogh et al, 2002) and electrical excitability of the fear 
circuit (Adamec et al, 2005; Adamec et al, 2001). 
In addition to an investigation of the role of individual brain region, recent studies have 
aimed to establish a functional neuronal network in which local circuits interact to transfer 
signals across different brain regions for the generation of behavioral responses that are 
relevant for mental disorders (Bielczyk et al, 2015; Robinson et al, 2014). The amygdala is a 
key brain region regulating acquired and innate fear and anxiety-related behaviors (Krettek 
and Price, 1978; Maren and Quirk, 2004). Basolateral amygdala (BLA), which exhibits 
cortex-like function, receives sensory afferents from somatosensory cortex as well as 
thalamus (Pape and Pare, 2010; Tovote et al, 2015). Strong inputs from the ventral 
hippocampus and the medial prefrontal cortex (mPFC), with the prelimbic cortex contribute 
to sustained fear. The infralimbic cortex is critical for fear memory extinction (Quirk and 
Mueller, 2008) and projects to both BLA and intercalated cells between BLA and central 
nucleus of amygdala (CeA). Activated intercalated cells in turn directly or indirectly inhibit 
CeA output neurons (Pare and Duvarci, 2012). On the other hand, BLA also sends 
projections to forebrain structures, including the ventral hippocampus and mPFC (Pitkänen et 
al, 2000) to regulate fear acquisition/extinction and anxiety-related behaviors. mPFC and 
amygdala send excitatory afferents to the ventral tegmental area (VTA), and dopamine 
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neurons from VTA project to nucleus accumbens (NAc) as well as to the mPFC (Fields et al, 
2007). Synaptic connections between mPFC, amygdala, hippocampus, VTA and NAc reflect 
a neural circuit that underlies pathological behavior responses in anxiety-related disorders 
(Figure 1). 
 
Figure 1. Brain circuits involved in fear perception. Simplified scheme depicting different 
projections from distinct brain regions for regulation of fear response. Red, blue and yellow 
arrows represent DA, glutamate, and GABA projections, respectively. Adapted from Lüthi 
and Lüscher (Lüthi and Lüscher, 2014). 
          
1.2.4.1.  Prefrontal cortex 
The prefrontal cortex integrates sensory information received from various brain regions 
within the limbic system, regulates emotions and initiates goal-oriented behaviour (Gray et al, 
2002; Miller et al, 2002a). Preclinical studies have shown that medial prefrontal cortex 
(mPFC) plays a crucial role in both the acquisition and extinction of fear response (Markham 
et al, 2012; Morgan et al, 1993). The mPFC is composed of anterior cingulate (ACC), 
1. INTRODUCTION 
13 
 
prelimbic (PrL) and infralimbic (IL) cortices. PrL is associated with increased fear expression 
while IL has inhibitory functions for the fear response (Corcoran and Quirk, 2007; Fenton et 
al, 2014; Laurent and Westbrook, 2009). PTSD is associated with diminished responsivity in 
the adjacent ventral mPFC (vmPFC) (Shin and Liberzon, 2010). Functional neural imaging 
studies of PTSD revealed a failure or decreased activation of ACC  during the presentation of 
trauma-related stimuli (Hou et al, 2007; Yang et al, 2004) and negative, non-traumatic 
stimuli (Kim et al, 2008; Williams et al, 2006). In addition, activation of ACC appears to be 
inversely related to PTSD symptom severity (Kim et al., 2008; Williams et al., 2006) and 
positively associated with symptomatic improvement following treatment (Felmingham et al, 
2007; Peres et al, 2007). Furthermore, decreases in vmPFC (Shin et al, 2010) and ACC 
(Corbo et al, 2005) volumes were found in PTSD patients and smaller ACC volumes have 
been linked with greater PTSD symptom severity (Woodward et al, 2006). Studies with rats 
exposed to chronic retrain stress demonstrated reductions in prefrontocortical (ACC and 
prelimbic area) dendrite lengths (Radley et al, 2004) which might underlie the mechanism for 
PFC volume loss and cognitive impairments in stress-related disorders.  
 
1.2.4.2.  Hippocampus 
The hippocampus is involved in formation and maintenance of contextual and declarative 
memory, as well as in memory consolidation for generating long-term memory (Elzinga and 
Bremner, 2002). Hypoactivation of hippocampus was found in PTSD patients and inversely 
correlated with symptom severity (Shin and Liberzon, 2010). Other studies, however, have 
reported increased activation in the hippocampus in PTSD (Geuze et al, 2007; Werner et al, 
2009).  
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Some, but not all studies reported a reduction in hippocampal volume in PTSD patients 
(Bossini et al, 2008; Golier et al, 2005; Karl et al, 2006; Pederson et al, 2004). Studies with 
twins demonstrated decreased hippocampal volumes may be a familial risk factor for 
developing PTSD following traumatic events (Gilbertson et al, 2002). Moreover, N-
acetylaspartate (NAA), a marker for neuronal integrity, has been associated with 
dysfunctional hippocampal neuronal networks in PTSD patients (Schuff et al, 2006), a 
finding also observed in the PTSD mouse model applied in the current study (Siegmund et al, 
2009). The mechanisms underlying stress-induced hippocampal shrinkage still remain elusive. 
GC has been proposed to be involved in the development of hippocampal volume loss. 
Chronic exposure to GC has neurotoxic effects (You et al, 2009), partially mediated by GC-
induced increase in hippocampal glutamate levels and subsequent excitotoxic effects 
(McEwen, 1997). Studies in PTSD rat models suggested that stress-stimulated alterations in 
hippocampal expression levels of GC receptors (Kohda et al, 2007) and NMDA receptors 
(Yamamoto et al, 2010) might aggravate the neurotoxic effects of increased GC and 
glutamate levels. Furthermore, Golub et al. found a long-lasting reduced hippocampal volume 
possibly due to shrinkage of axonal protrusions in an electric foot shock-induced PTSD 
mouse model (Golub et al, 2011). 
 
1.2.4.3.  Amygdala 
Hyperactivation of the amygdala has been repeatedly shown in PTSD patients (Bremner et al, 
2005b; Morey et al, 2009; Vermetten et al, 2007). In addition, some studies have 
demonstrated that the activation of amygdala correlated positively with PTSD symptom 
severity (Dickie et al, 2008; Rauch et al, 2000). As hippocampus and PFC exert inhibitory 
actions on the amygdala, hypoactivity of these two brain regions might further result in 
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enhancement of amygdala hyperresponsivity which in turns deteriorates emotional processing 
upon stress (Rauch et al, 2006). Moreover, PTSD resilience was associated with reduced 
amygdala activation (Osuch et al, 2008) and amygdala lesions may decrease the occurrence 
of PTSD (Koenigs et al, 2008).  
Several studies reported shrinkage of amygdala volume in PTSD patients (Karl et al, 2006; 
Rogers et al, 2009). Findings from animal studies suggested that apoptosis in the amygdala 
contributes extensively to the volume loss (Ding et al, 2010; Liu et al, 2011). Increases in 
dendritic arborisation and spine density were found in animal models of PTSD and were 
proposed to be involved in hyperactivation of the amygdala (Adamec et al, 2012; Mitra et al, 
2005). Furthermore, the abnormalities in the dendritic spine density are thought to affect the 
long-term maintenance of fear memories, which is found disturbed in PTSD (Mitra et al., 
2005). 
 
1.2.4.4.  Nucleus accumbens 
Nucleus accumbens (NAc) is the brain structure involved in motivation and addiction. Upon 
acute stressor (Wang et al, 2005) or arousing environmental stimuli (Merali et al, 2004), 
CRH is released from paraventricular nucleus of hypothalamus and acts on the NAc. 
Subsequently, dopamine release is increased through co-activation of CRH R1 and R2 in the 
NAc, and facilitates cue-elicited motivation (Peciña et al, 2006) and social bonding (Lim et al, 
2007). In a mouse study, severe stress exposure abolished CRH’s capacity to regulate 
dopamine release in the NAc and switch the positive-affective state of CRH-dopamine 
interaction to an aversive state (Lemos et al, 2012). These studies demonstrated that severe 
stress produces a persistent dysregulation of CRH-dopamine interactions in the NAc and 
results in depression-like phenotype in the mouse. Krishnan et al. observed increased BDNF 
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protein levels in NAc of social defeat susceptible mice. Furthermore, reducing BDNF release 
from ventral tegmental area (VTA) to NAc enhances resistance to stress (Krishnan et al, 
2007).   
In both animal and human studies, increased alcohol consumption and drug addiction are 
closely associated with traumatic event encounter (Bremner et al, 1996; Cross et al, 2015; 
Volpicelli and Ulm, 1990). Studies on women exposed to childhood rape report turning to 
alcohol to reduce PTSD symptoms (Epstein et al, 1998). Furthermore, 40% of inpatients 
receiving treatment for substance abuse also met the criteria or PTSD (Dansky et al, 1997). It 
is known that drug addiction acts on the mesocorticolimbic system, which consists of the 
VTA and the brain regions that are innervated by projections from VTA, such as NAc, PFC 
and amygdala (Swanson, 1982). Studies have shown that addictive drug use induces synaptic 
potentiation in the VTA and subsequently triggers synaptic alteration in downstream brain 
structures (NAc and PFC), with further drug exposure (van Huijstee and Mansvelder, 2014). 
These findings indicate that abnormal neuronal signaling in the NAc, which is part of the 
mesocorticolimbic system, plays an important role in the comorbidity of alcohol and drug 
addiction in PTSD patients. 
 
1.3. Risk factors and biomarkers for PTSD 
 
1.3.1. Risk factors  
The term risk factor refers to factors that preclude a causal involvement in disease. On the 
other hand a biomarker serves as an indicator for disease development and therapy response. 
As mentioned in chapter 1.1, only 10-20% of individual exposed to severe trauma will 
develop PTSD. To date, several important risk factors both externally (e.g. lack of social 
support) and internally (e.g. innate versus acquired) have been identified for PTSD 
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development. A prior exposure to trauma or chronic stress increases dramatically the 
occurrence of PTSD (Davidson et al, 1991). In addition, the type and exposure time of the 
trauma are potent factors, with prior assaults at a young age upon subsequent traumatization 
raises the prevalence of PTSD significantly (Bremner et al, 1993; Breslau et al, 1999). Social 
and demographic factors, such as family instability, lower education and income, and being 
widowed or divorced are also associated with PTSD development (King et al, 1996). A past 
history of psychological problems or psychiatric disorder increases the risk for the occurrence 
of PTSD (McFarlane, 1989). Furthermore, epidemiologic studies showed that antisocial 
(Schnurr and Vielhauer, 1999) or neurotic personalities (Breslau et al, 1998) prior to the 
traumatic event predicted the development of PTSD. 
Abnormalities in cortisol secretion and HPA axis activity underlie the pathophysiological 
mechanism for PTSD. Lower basal cortisol has been proposed to be a pre-existing risk factor 
for PTSD (Zoladz and Diamond, 2013). Studies showed that individuals with lower cortisol 
levels immediately after trauma have a greater risk for developing PTSD (Delahanty et al, 
2005; Ehring et al, 2008; McFarlane et al, 2011). It is possible that lower cortisol leads to 
chronic enhancement of glucocorticoid receptor hypersensitivity which in turn results in the 
development of later PTSD after trauma (van Zuiden et al, 2013; Wingenfeld and Wolf, 
2011). 
Additional risk factors including genetic and epigenetic ones are considered to contribute to 
an individual’s predisposition to develop PTSD. Studies on trauma-exposed twin pairs 
revealed that approximately 30% of the PTSD symptoms are heritable and comorbidity of 
PTSD with other disorders may be partly due to shared environmental and genetic influences 
(Afifi et al, 2010). Investigations on the candidate genes for association of Single Nucleotide 
Polymorphisms (SNP) with PTSD symptoms have aimed to identify specific genetic regions 
involved in PTSD (Cornelis et al, 2010). Identification of candidate genes mainly focused on 
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searching for genetic variations associated with the HPA axis. SNPs in the CRH receptor 1 
(CRHR1) gene (Amstadter et al, 2011) and in the FK506 binding protein 5 (FKBP5) gene 
(Binder et al, 2008) were found to be associated with PTSD symptoms. FKBP5 regulates the 
cortisol-binding affinity of the glucocorticoid receptor and it is hypothesized that genetic 
variations in the CRHR1 and FKBP5 genes lead to the dysregulation of the HPA axis upon 
stress exposure and result in PTSD development.  Besides genetic variations, epigenetic 
modifications caused by DNA methylation or histone modification also contribute to the risk 
for PTSD occurrence. Environmental factors like early-life stress can modify gene activity 
via epigenetic mechanisms. A study on holocaust survivors showed that maternal PTSD 
increases the risk for offspring to develop PTSD. This finding illustrates the transgenerational 
transmission of potential trauma-induced epigenetic modifications (Yehuda et al, 2008). In a 
study of survivors of the Rwandan genocide, increased DNA methylation at the nerve growth 
factor-induced protein A (NGFI-A) binding site of the GR gene was found to be related to 
less intrusive memory of the traumatic event and reduced PTSD risk in male but not female 
survivors. These findings indicate that epigenetic modification of GRs is associated with 
gender-specific PTSD risk (Vukojevic et al, 2014). A recent study showed that a SNP in the 
PAC1 receptor, which is involved in stress response by stimulating CRH gene expression, is 
associated with PTSD in female patients. Furthermore, methylation of the PAC1 receptor 
gene has been correlated with PTSD symptom severity (Ressler et al, 2011). Taken together, 
the findings on genetic and epigenetic variations of HPA axis associated genes underscore the 
importance of the neuroendocrine stress response system for PTSD pathogenesis and 
vulnerability. 
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1.3.2. Biomarkers 
The term biomarker was defined by the Biomarker Definitions Working Group at National 
Institutes of Health as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacological responses 
to a therapeutic intervention” (Biomarkers Definitions Working Group, 2001). In addition to 
providing a diagnostic tool in the clinical setting, the search for new biomarkers aims to 
further elucidate the mechanisms underlying pathogenic processes. A wide variety of 
indicators can serve as biomarkers: genomic alterations such as single nucleotide 
polymorphisms (SNPs), alterations in gene or protein expression, or changes in metabolite 
profile. Genomic alterations or mutations are trait biomarkers that can predict the likelihood 
of developing a disease and indicate disease susceptibility. On the other hand, proteins and 
metabolites represent dynamic biomarkers, able to reflect the disease state. Besides molecular 
markers, altered brain activity evaluated by fMRI or PET imaging and other physiological 
parameters such as blood pressure or heart rate can also serve as biomarkers (Hampel et al, 
2010; Zhang et al, 2009).  
Biomarkers for PTSD comprise imaging, psychological, endocrine, and molecular measures. 
Due to the complex etiology and polygenic character of psychiatric disorders including PTSD, 
biosignatures rather than a single biomarker are expected to reflect more accurately PTSD 
pathophysiology. 
HPA-axis dysregulation has been frequently found to be associated with PTSD. Elevated 
levels of CRH were detected in cerebrospinal fluid (CSF) from PTSD patients (Baker et al, 
1999; Bremner et al, 1997b). However, another study reported decreased CSF CRH 
concentrations during exposure to a trauma-related audio-visual stimulus (Geracioti et al, 
2008). These clinical findings indicate the strong need for systemic analyses of HPA-axis 
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function and reactivity in larger cohorts of PTSD patients to clarify the inconsistencies. 
Hyperactivity of the SAM was found in PTSD patients (Pitman et al, 2012; Strawn and 
Geracioti, 2008), which is reflected by elevated urine and plasma norepinephrine levels 
(Kosten et al, 1987; Yehuda et al, 1998). In addition, adrenoreceptor blockers were reported 
to improve PTSD symptoms, but not in all studies. Norepinephrinergic hyperactivity has been 
associated with several symptoms of PTSD, including night mare and exaggerated startle 
response (Dierks et al, 2007). Besides the association with SAM hyperactivity, startle 
response was found to be positively correlated with cortisol levels (Grillon et al, 2006) and 
cortisol suppression by dexamethasone reduces exaggerated startle responses in PTSD 
patients (Jovanovic et al, 2011). Brain region specific structural and functional abnormalities 
were reported in PTSD patients and animal models of PTSD. Reductions in the volume of the 
amygdala, the hippocampus and the anterior cingulate cortex have been described (Karl et al, 
2006). Furthermore, lower levels of NAA, a marker for neuronal density, have been reported 
in the hippocampus of PTSD patients (Karl and Werner, 2010a; Schuff et al, 2008). NAA 
levels not only serve as a risk factor for PTSD susceptibility as described in chapter 1.3.1, but 
also as a diagnostic marker for PTSD.  
Protein biomarkers for PTSD are mostly immunological factors. The cytokines IL-2, IL-6 and 
IL-8 have been reported to be increased in PTSD patients (Baker et al, 2001; Maes et al, 
1999; Song et al, 2007). On the other hand, proteins involved in the immune response, such 
as C-reactive protein, serum amyloid, and neopterin were found to have decreased levels in 
PTSD patients (Atmaca et al, 2002; Söndergaard et al, 2004; von Känel et al, 2010).  
 
1.4. Pharmaco- and psychological therapy of PTSD 
The earliest pharmacotherapy for psychological trauma-related psychopathology dates back 
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to Weir Mitchell in 1885 (Mitchell, 1885). Following exposure to trauma, he self-
administrated and described ‘the mischievous tale of bromides, opium, chloral and brandy’. 
Due to the complex etiology and symptomatology of PTSD, not all patients respond to 
treatment and at present there is no drug that acts on all the PTSD symptoms mentioned in 
chapter 1.1. The main goals of PTSD pharmacotherapy can be summarized as follows: (1) to 
reduce core PTSD symptoms; (2) to improve resilience to stress; (3) to reduce comorbidity, 
and (4) to prevent relapse over follow-up (Brunello et al, 2001). Serotonergic agents, such as 
selective serotonin reuptake inhibitors (SSRIs), are currently the most commonly used 
pharmaco-treatment options. SSRIs increase serotonin functioning by inhibiting its uptake 
from the synaptic cleft into pre-synapse. Treatment with SSRIs increased tolerance to 
aversion and decreased stress-fear response. Currently, SSRIs including fluoxetine, 
paroxetine, sertraline and fluvoxamine have been officially approved by the U.S. food and 
Drug Administration (FDA) for treatment of PTSD (Ravindran and Stein, 2009). In addition 
to SSRIs, noradrenergic agents, such as the α2-adrenoreceptor agonist clonidine and β- 
adrenoreceptor antagonist propranolol, have been proven to be effective for the treatment of 
PTSD associated hyperarousal symptoms by correcting dysregulated norepinephrine 
signaling (Ravindran and Stein, 2009). However, other clinical trials have shown mixed 
results (Pitman et al, 2002; Stein et al, 2007). Meanwhile, dysregulation of HPA axis activity 
was found in PTSD patients. It is known that GCs regulate memory formation, inhibit 
unrelated information and enhance the consolidation of extinction memory (de Quervain et al, 
2009; Joëls et al, 2006; Karst et al, 2005) which makes targeting glucocorticoids a possible 
option for treating PTSD. In a double-blind study, one-month of low-dose cortisol treatment 
of chronic PTSD patients inhibited memory retrieval of traumatic events and reduced 
symptoms even beyond the treatment period (de Quervain, 2008). Besides the above 
mentioned antidepressants, neuropeptides and a combination of anti-inflammatory 
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compounds are potential treatment options for PTSD (Aga-Mizrachi et al, 2014; Steckler and 
Risbrough, 2012).   
Currently, a combination of trauma-psychotherapy and pharmacotherapy, mainly employing 
SSRIs, is considered as the golden standard for PTSD treatment (Berger et al, 2009). 
Cognitive-behavioral therapy, the dominant psychological treatment for PTSD, applies the 
approaches of exposure and cognitive therapies. Exposure therapy aims to reduce emotional 
association with traumatic memories. It helps PTSD patients to learn effective regulation of 
stress with relaxation training and stress coping techniques while they are being progressively 
exposed to the fearful stimulus (Smith et al, 2015). The cognitive therapy aims to modify the 
inaccurate thoughts and emotions attributed to the traumatic memories of the patients. Studies 
from Resick and Schnicke (1992) showed that cognitive therapy improved PTSD and 
depression measures and the improvements were maintained for 6 months in rape victims. 
 
 
1.5. Animal models of PTSD 
To study the underlying mechanisms of psychiatric disorders and potential pharmaceutical 
treatments, animal models provide researchers a nice tool to investigate the affected pathways. 
However, modeling psychiatric disorders in animals is challenging since diagnosis of the 
symptoms are not objectively measureable and it is impossible to model the complex etiology 
and expression of human psychiatric disorders. Therefore, animal research focusses more on 
the basic emotional process which is shared by humans and other mammals (LeDoux, 2000; 
Ohman and Mineka, 2001). The aim for animal research is to model selected endophenotypes 
proposed to reflect features of the respective psychiatric disorder.  
A valid animal model should fulfil the following three criteria (Chadman et al, 2009; 
Siegmund et al, 2006):  
Face validity describes how closely core symptoms of the human disorder are reflected by 
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the animal model. In the case of PTSD, the key to differentiate it from other anxiety disorders 
is the encounter of a traumatic event (see chapter 1.5.1). The stressor should be intense but of 
short duration and the severity of symptoms increase with the intensity of the stressors. The 
core symptoms for PTSD need to include behavioral phenotypes of hyper-responding 
(exaggerated fear responses to trauma-related cues), hyperarousal and hypo-responding 
(emotional numbing). In addition, behavioral alterations are expected to last for a long time 
from weeks to months.  
Construct validity represents the underlying pathophysiological mechanisms for disorders 
which are similar or correlate with humans with the animal model employed. In the animal 
model of PTSD, studies have suggested hippocampal hypotrophy and hyperactivity of the 
amygdala or the CRH system which correlates with the observations in PTSD patients 
(Bremner, 2002; Thoeringer et al, 2012). 
Predictive validity represents the treatment options human disorders are applicable to and 
can be verified in animal research. Although there is no golden standard for treatment of 
PTSD, SSRIs have shown to be effective in PTSD patients (Albucher and Liberzon, 2002). 
Therefore, application of SSRIs can be verified for the predictive validity in animal models. 
 
1.5.1. PTSD animal model 
PTSD animal models can be generated by applying physical, psychosocial, psychogenic or 
early life stressors. Restraint stress is induced by placing a mouse or rat in restraining tubes 
for 2-6 hours which results in increased anxiety behaviour and changes in neuronal 
morphology within brain regions involved in fear and anxiety (Miller and McEwen, 2006; 
Vyas et al, 2002). Another physical stressor model, single prolonged stress (SPS), combines 
the administration of different stressors (restrain stress, forced swim and ether exposure). SPS 
is widely used for PTSD animal studies because the combination of complex stressors 
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mimics the situation for PTSD development in humans (Liberzon et al, 1997; Pitman et al, 
2012; Takei et al, 2011). In another model animals are subjected to a variety of psychosocial 
stressors, such as social defeat and social isolation. When exposing to chronic social 
instability, animals exhibit long-lasting changes in anxiety-like behaviors resembling human 
PTSD symptoms (Zoladz et al, 2008). In another commonly used PTSD animal model a 
predator is used as a psychogenic stressor (Dielenberg and McGregor, 2001). In this model, 
animals receive threat but no pain. The exposure to species-relevant predators or odor/scent 
lead to long-lasting manifestations of anxiety and acoustic startle response (Hebb et al, 2003; 
Roseboom et al, 2007; Zoladz et al, 2012). In another model, animals were re-exposed to a 
trauma reminder which allows the study of underlying neural mechanisms for persistent re-
experiencing and intrusive memories, the core symptoms of PTSD (Ritov et al, 2014). In 
humans, trauma exposure during development leads to long-term HPA axis abnormality and 
increases the risk of developing PTSD later in life (Delahanty and Nugent, 2006). Similarly, 
in the early life stress induced PTSD mouse model, maternal separation results in enhanced 
stress and anxiety responses upon exposure to severe stress later in life (Diehl et al, 2012; 
Tsoory et al, 2007).  
The PTSD model used in the current study fulfils all the above mentioned criteria (face, 
construct and predictive validities) (Siegmund and Wotjak, 2007). Two inescapable electric 
foot shocks (FS) with 1.5mA amplitude and 2 seconds duration were given to the mice as 
traumatic encounters. After 28 days of incubation, the shocked mice were assessed for 
behavioral phenotypes of PTSD-like symptoms. In the shocked mice, both the conditioned 
fear and generalized fear responses are increased. The conditioned fear response is evaluated 
by the freezing behavior in the shock context and the generalized fear response is assessed by 
measuring the freezing response in a completely neutral context or in a context resembling 
the dominant feature (the metal grid) of the shock context (Siegmund and Wotjak, 2007). In 
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addition, shocked mice show a hyperarousal phenotype which can be evaluated by the 
intensity of the acoustic startle response when presenting the mice different intensities of 
neutral tone (Siegmund and Wotjak, 2007) or to startle-response provoking white noise 
(Golub et al. 2009). For the treatment of PTSD, early intervention and chronic administration 
of fluoxetine in shocked mice has been shown to ameliorate PTSD-like symptoms (Siegmund 
and Wotjak, 2007). Until now, the pathophysiological mechanisms and affected molecular 
pathways underlying PTSD development still remain elusive. Shrinkage of hippocampus 
volume and dysregulations of CRH system were observed in the PTSD model we applied, 
which resembles the clinical findings in PTSD patients (Golub et al, 2011; Thoeringer et al, 
2012). Taken together, the face validity (traumatic foot shock, increased contextual fear and 
hyperarousal phenotype), predictive validity (fluoxetine treatment) and constructive validity 
(sharing similar biological alterations) are met in our PTSD mouse model.  
 
 
1.6. Hypothesis-free –omics: quantitative proteomics and metabolomics, 
and RNA-seq transcriptomics 
PTSD is a complex and polygenic disease. Therefore data integration from a variety of 
approaches including -omics-based systems biology is critical for a better understanding of 
disease pertinent molecular pathways (Barabási and Oltvai, 2004; Kitano, 2002). Functional 
genomics, including transcriptomics, proteomics and metabolomics add an important 
dimension to the study of psychiatric disorders for the analysis of spatial and temporal 
alterations (Geschwind and Konopka, 2009; Turck et al, 2005). Both transcriptomics and 
proteomics approaches have been applied to study the underlying mechanisms of PTSD 
(Henningsen et al, 2012; O'Donovan et al, 2011; Tylee et al, 2015). Transcriptomics analysis 
examines mRNA expression which reflects the genes that are actively expressed at any given 
time. To date, RNA-seq technology is used to study the transcriptome (Szabo, 2014). In 
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addition to transcriptomics, the proteomics approach facilitates organelle specific analyses, 
e.g. synapse specific alterations and is able to detect protein post-translational modifications 
(PTM) which play an important role in protein function and activity. Since mRNA levels do 
not always reflect protein expression levels complementary proteomics analyses have merit.  
The metabolome represents the final product of interactions between gene expression, protein 
expression, gene and protein interaction and the cellular environment (Kaddurah-Daouk and 
Krishnan, 2009). With the advance of instrumentation and data analysis strategies, 
metabolomics technology is able to complement transcriptomics and proteomics 
investigations in the field of systems biology and pathway analysis. The integration of 
transcriptomics, proteomics and metabolomics analyses can help delineate dysregulated 
molecular pathways in disease. The following chapters describe proteomics (1.6.1) 
metabolomics (1.6.2) and transcriptomics (1.6.3) technologies with a focus on the methods 
that were used over the course of the thesis project.  
 
1.6.1.  Quantitative proteomics 
Traditional proteomics strategies mainly exploited two-dimensional gel electrophoresis for 
high resolution protein separation and relative protein quantification. Complex protein 
mixtures are first separated based on their isoelectric point in the first dimension and by 
molecular weight in the second dimension. Staining of the proteins allows the detection of 
both quantitative (expression level) and qualitative (post-translational modification) protein 
differences. Differentially expressed proteins between disease/treatment vs. control can then 
be identified using mass spectrometry (O'Farrell, 1975). Today quantitative proteomics is 
carried out with mass spectrometry (MS) due to its high sensitivity and reproducibility. By 
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utilizing sensitive MS in combination with multidimensional protein and peptide separation 
techniques thousands of proteins can be identified and quantified in a sample. 
1.6.1.1. Mass spectrometry based proteomics 
The main components of a mass spectrometer are an ionization source, a mass analyzer and 
an ion detector. A variety of ionization methods are available for introducing the ions into the 
mass analyzer. For proteins and peptides the preferred methods are matrix-assisted-laser-
desorption ionization (MALDI) (Karas and Hillenkamp, 1988)and electrospray ionization 
(ESI) (Whitehouse et al, 1985; Wilm and Mann, 1996a; Wilm et al, 1996b). Depending on 
the analytical question, different kinds of mass analyzers exhibiting distinct strengths can be 
utilized: linear ion trap (LTQ), Orbitrap, time-of-flight (TOF), quadrupole (Q) mass filter, 
magnetic sector and combinations thereof like LTQ-Orbitrap, Q-TOF or triple-quadrupole 
(QqQ) instruments. 
MS measures the mass-to-charge (m/z) ratio of ions. The mass spectrum is the final readout 
of the mass spectrometer and represents the signal intensity of the ions and their m/z ratios 
(Steen and Mann, 2004). Precursor ions can be fragmented to product ions via methods such 
as collision-induced dissociation (CID), electron transfer dissociation (ETD) or high energy 
collision dissociation (HCD). Parent and fragment masses are compared against a database 
for protein identification (Eng et al, 1994; Perkins et al, 1999).  
With its high mass accuracy (<5 ppm) and high sensitivity (sub-femtomol range for peptides) 
the LTQ-Orbitrap hybrid mass spectrometer fulfils the requirements for sensitive and 
comprehensive proteomics analysis. In addition, the LTQ-Orbitrap has a high dynamic range 
(>10
3
) and high mass resolution (up to 100.000 at m/z 400) (Yates et al, 2006).  
1.6.1.2. Quantitative proteomics using stable isotope labeling 
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According to the isotope dilution theory (de Leenheer and Thienpont, 1992), peptides that 
differ only in isotopic composition behave identical during an MS experiment. As a result 
relative protein amounts are reflected by the unlabeled and labeled peptide signal ratios of the 
extracted ion chromatograms (Steen and Mann, 2004). A great variety of methods are 
available for relative protein quantification with stable isotopes (
2
H, 
13
C, 
18
O and 
15
N). These 
include post-synthesis labeling such as isotope-coded protein label (ICPL) (Schmidt, 2005), 
isotope-coded affinity tag (ICAT) (Gygi et al, 1999) and isobaric tag for relative and absolute 
quantitation (iTRAQ) (Ross et al, 2004). ICPL is based on adding a stable isotope tag to the 
free amino groups of intact proteins (N-terminus and lysine side chains) with the help of 
specific reagents. Protein mixtures are first subjected to reduction and alkylation. For a 
comparison of four samples the free amino groups are then derivatized with the ICPL_0, 
ICPL_4 (4 Deuteriums), ICPL_6 (6 
13
C) and ICPL_10 (4 Deuteriums + 6 
13
C) reagents. The 
samples are then combined for further separation and enzymatic digestion. After enzymatic 
cleavage, the relative abundance of identical peptides, which due to their different tags differ 
in their mass, can be quantified according to their signal intensities (Lottspeich and 
Kellermann, 2011; Schmidt et al, 2005). The chemical probes used for the ICAT method are 
composed of three elements: a reactive group that is able to label a specific amino acid side 
chain, an isotopically coded linker and a tag (e.g. biotin) for the affinity isolation of labeled 
peptides/proteins. For quantitative analysis of two protein samples, one sample is labeled 
with isotopically light (d0) tag while the other sample is labeled with the isotopically heavy 
(d8) tag. Both samples are subsequently mixed and subjected to enzyme (mostly trypsin) 
digestion, followed by an avidin affinity chromatography to isolate peptides labeled with 
isotope-coded tagging reagents. Relative protein levels of the two samples are then calculated 
based on the signal intensity ratios of differentially mass-tagged peptide pairs (Adam et al, 
2002). iTRAQ is based on covalent labeling of the N-terminus and lysine side chain amino 
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groups using tags of different masses. The derivatized peptides are isobaric and yield reporter 
ions following CID which can then be used to identify and quantify relative peptide 
abundance (Shadforth et al, 2005). 
Alternatively, stable isotopes are introduced into proteins via metabolic labeling with either 
‘stable isotope labeling using amino acids in cell culture’ (SILAC) (Ong et al, 2002) or 
‘stable isotope labeling of mammals’ (SILAM) (Oda et al, 1999) methods.  
For SILAC, one cell sample is cultured in media with standard essential amino acids, while 
the other cell sample is grown in media supplemented with the heavy stable isotope form of 
amino acids (e.g. 
13
C-lysine). Proteins are harvested from the two experimental cell samples 
and combined. After extraction and fractionation proteins are digested and peptides subjected 
to MS analysis. Unlabeled and labeled peptide pair peak intensity ratios reflect the relative 
abundance of the two proteins in the cell samples (Ong et al, 2002). SILAM has been applied 
to investigate proteome changes in animals. Animal proteomes can be uniformly labeled with 
15
N through feeding with a protein-based, 
15
N-labeled diet (Filiou et al, 2011). Labeled 
tissues can then be used as an internal standard when mixed with tissues of interest from an 
animal model. For SILAC and SILAM unlabeled and labeled samples are combined at the 
very beginning of sample preparation which results in high quantitation accuracy because 
potential experimental biases affect both labeled and unlabeled proteins in the same manner 
(Bantscheff et al, 2012). Therefore SILAC and SILAM represent the current gold standard 
for accurate relative protein quantification. 
 
1.6.2. Quantitative metabolomics 
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Quantitative metabolomics complements other –omics approaches and has been applied to 
psychiatric research (Dai et al, 2010; Su et al, 2011). The major challenges for metabolomics 
analyses are the large dynamic range of metabolites (>10
6
) and the absence of reliable 
automatic identification tools (Moco et al, 2007). To achieve a comprehensive and 
hypothesis-free global analysis, diverse complementary analytical methods need to be applied. 
Depending on the biological question, sub-metabolome or targeted analyses reveal significant 
insights into the system or particular pathways of interest. To date, most commonly used 
platforms are based on liquid chromatography-MS (LC-MS), gas chromatography-MS (GC-
MS) and nuclear magnetic resonance (NMR) (Moco et al, 2007; Theodoridis et al, 2012).  
LC-MS has become an important method in the field of quantitative metabolomics. 
Metabolites are first separated using chromatography and then introduced into the ionization 
source. Metabolite ions are subsequently generated by ESI in positive or negative modes or 
atmospheric pressure ionization (API). Ions are then measured by triple quadrupole or 
quadrupole-time-of-flight (Q-TOF) mass analyzers. Ion analyzers like FT-Orbitrap or FT-
ICR-MS of high mass resolution (100.000-1.000.000) and mass accuracy (>2 ppm) are used 
for metabolite identification. Metabolite identification is based on individual characteristic 
parameters, including metabolite mass, isotopic distribution, fragmentation pattern and 
retention time (Moco et al, 2007).  
Metabolomics can be performed by targeted analysis to assess and quantitate a selected list of 
metabolites or untargeted for comprehensive metabolite profiling. When configured in 
Selected-Reaction-Monitoring (SRM) mode molecules can be identified with high confidence. 
In addition, Multiple-Reaction-Monitoring (MRM) on Triple-Quadrupole mass spectrometers 
allows accurate quantification of metabolite precursor and product ions (Lu et al, 2008). 
Recently, a metabolomics platform using LC-MRM-MS was introduced. It allows the reliable 
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qualitative and quantitative determination of a wide range of metabolites (>300 metabolites) 
targeting major metabolic pathways, including Krebs cycle, glycolysis and metabolism of 
amino acids (Yuan et al, 2012). 
 
1.6.3. Quantitative transcriptomics 
Transcriptomics technology allows to catalogue all transcript species, to determine the 
transcriptional structure of genes and to quantify the expression levels of each transcript 
under different conditions. Various technologies have been developed to quantify and deduce 
the transcriptome, including hybridization- or sequence-based approaches. Hybridization-
based approaches involve incubating fluorescently labeled cDNA with custom-made or 
commercial high-density oligo microarrays. The sequence-based approach on the other hand 
directly determines the cDNA sequence by a tag-based sequencing approach, such as serial 
analysis of gene expression (SAGE) (Harbers and Carninci, 2005; Velculescu et al, 1995), 
cap analysis of gene expression (CAGE) (Kodzius et al, 2006; Shiraki et al, 2003) and 
massively parallel signature sequencing (MPSS) (Brenner et al, 2000; Reinartz et al, 2002). 
The tag-based sequencing approaches allow high throughput analyses and provide precise 
gene expression levels. However, only a portion of the transcript can be analyzed and 
isoforms are generally indistinguishable from each other. 
RNA sequencing (RNA-Seq) has clear advantages over existing approaches and has been 
introduced as a high-throughput sequencing method for both mapping and quantifying 
transcriptomes. A population of extracted RNA from sample tissue is converted to a library 
of cDNA fragments with adaptors attached to one or both ends. Subsequently, each molecule 
is sequenced in a high-throughput manner to obtain short sequences from one end (single-end 
sequencing) or both ends (pair-end sequencing). Following sequencing, the genomes are 
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aligned to a reference genome or transcript to produce a genome-scale transcription map that 
reflects the transcriptional structure and/or level of expression for each gene (Wang et al, 
2009).  
RNA-seq has been used to accurately monitor gene expression during yeast vegetative 
growth (Nagalakshmi et al, 2008), mouse embryonic stem-cell differentiation (Cloonan et al, 
2008) or brain development (Dillman and Cookson, 2014). With RNA-seq, RNA expression 
levels in a cell population can be determined accurately. Furthermore, differences in gene 
expression levels between disease/treatment vs. control can be compared directly to delineate 
dysregulated genomic pathways. 
 
1.6.4. Computational biology/Systems biology 
For the past decade, studies on complex interactions within a biological system have 
increased significantly and this biology-based interdisciplinary field of study requires data 
interpretation by computational biologists. Computational biology involves the application of 
large-scale data set analysis, mathematical modeling and computational simulation 
techniques to study biological systems (Biomedical Information Science and Technology 
Initiative, 2000). In systems biology complex data sets from multiple experimental sources 
are integrated and analyzed using interdisciplinary tools. The typical experimental platforms 
include trasncriptomics, genomics, epigenomics, metabolomics, lipidomics, glycomics, 
proteomics and phenomics. The study of a single component of a biological system is not 
enough to reflect the mechanisms that give rise to the function and behavior of one particular 
system. The aim of systems biology studies is to model and discover the properties of cells, 
tissues and organisms and how they function as a system (Bu and Callaway, 2011). With the 
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aid of computational biology techniques, algorithms and relations among various biological 
systems can be established. Computational and systems biology have been applied to the 
Human Genome Project and other genetic studies (Collins and Galas, 1993; Imam et al, 
2015). 
Computational and systems biology are also powerful tools to investigate neuronal networks 
and to come up with accurate models for delineating pathophysiological mechanisms. For 
psychiatric disorders, interactions between different transmitter systems are important to 
understand their complex etiology and polygenic characters. Neurocomputational models 
based on recurrent excitation within cell assemblies, synfire chains and single-cell bistability 
have been established to study the contributions of different synaptic and voltage-gated 
conductances and neuromodulation to the formation of working memory and their relevance 
for schizophrenia (Durstewitz et al, 2000). Only a limited number of modeling algorithms for 
classification was applied in PTSD studies (Glatt et al, 2013; Yang et al, 2013). In a study of 
male PTSD soldiers, a logistic regression analysis model based on factors of predeployment 
GR number, messenger RNA expression of GR target genes, including FKBP5, GILZ and 
SGK1, plasma cortisol and childhood trauma, was applied to predict PTSD symptoms 
development (van Zuiden et al, 2012). To date, there are no studies integrating heterogeneous 
data analysis for investigating the interaction networks of PTSD. 
 
1.7. Microdialysis  
Microdialysis can be applied to interstitial cell fluid of selected tissues (Rittenhouse and 
Pollack, 2000) and body fluids (Chan et al, 2002; Tsai et al, 2001) for dynamically 
monitoring endogenous substances or drugs and metabolites. A microdialysis system consists 
of a micordialysis probe, a micordialysis pump and a microvial in which the samples are 
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collected. During the process of microdialysis the probe is implanted into targeted tissue, e.g. 
specific brain region, and perfused with artificial cerebrospinal fluid (aCSF). aCSF perfusion 
of identical pH, osmolarity and ion composition as the brain extracellular fluid with an 
implanted microdialysis probe will not disturb tissue homeostasis, therefore making 
microdialysis a truly physiological method for the purpose of in vivo sampling. Commonly 
utilized methods for the analysis of micordialysates include UV, fluorescence and 
electrochemical detection equipped with high performance liquid chromatography (HPLC), 
as well as ELISA, radioimmunoassay and spectrophotometric biochemical assays (Guihen 
and O'Connor, 2009). 
Microdialysis is frequently used for the investigation of brain neurotransmission, 
neurochemistry and metabolism (Anderzhanova and Wotjak, 2013; Ungerstedt and Pycock, 
1974). Furthermore, by acquiring pharmacokinetic and pharmacodynamic data from living 
animals, microdialysis continues to be the method of choice for experimental 
neuropharmacology studies (Westerhout et al, 2012). Sampling of specific brain regions like 
the medial prefrontal cortex (Jalkanen et al, 2014; Tanda et al, 2015), hippocampus (Maki et 
al, 2014; Yau et al, 2015), paraventricular nucleus (Czell et al, 2012; Tachi et al, 2014), and 
amygdala (Hambrecht-Wiedbusch et al, 2014; Su et al, 2015) during behavioral experiments 
in freely moving rodents can be carried out with potent spatial and temporal resolution of 
millimetres and minutes, respectively, reflecting the actual physiological state of the animal 
under investigation. By targeting different brain regions, microdialysis enables assessment of 
release and metabolism of neuroactive endogenous substances which provides important 
insights into affected brain circuits underlying the physiological/pathological mechanisms. 
 
1.8. Aims of the thesis 
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The thesis project aimed to delineate affected molecular pathways in brain circuits involved 
in fear and stress response and the fluoxetine treatment effect in a mouse model of PTSD 
with the help of transcriptomic, proteomic and metabolomic technologies. Another aim was 
to investigate the effects of stress on neurochemical and neuroendocrine changes and their 
relations to PTSD-like symptoms. 
 
Specific aims of the individual manuscripts: 
Chapter 2.1.:  
Fluoxetine treatment rescues energy metabolism pathway and myelin sheath protein 
alterations in a posttraumatic stress disorder mouse model 
- To delineate affected molecular pathways in the brain circuit involved in fear and stress 
response in a mouse model of PTSD at the proteome and metabolome levels. 
- To identify potential targets upon fluoxetine treatment that may modulate these 
pathways. 
- To identify plasma metabolite biomarkers. 
 
Chapter 2.2.:  
Transcriptomic profiling reveals affected inflammatory pathway in a mouse model of 
posttraumatic stress disorder 
- To identify affected pathways in the brain circuit involved in fear and stress response in 
a mouse model of PTSD at the transcriptome level. 
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- To identify potential targets upon fluoxetine treatment that may modulate these 
pathways. 
 
Chapter 2.3.: Norepinephrine and corticosterone in the medial prefrontal cortex and 
hippocampus predict PTSD-like symptoms in mice. 
- To analyze early post-traumatic brain extracellular norepinephrine and free 
corticosterone (CORT) levels in the medial prefrontal cortex (mPFC) and hippocampus 
in a mouse model of PTSD. 
- To relate the levels of stress-induced norepinephrine and free CORT release in the 
mPFC and hippocampus to PTSD-like symptoms, including hyperarousal and fear 
memory retention. 
 
Chapter 2.4.: NextGen Brain Microdialysis – applying modern metabolomics technology to 
the analysis of extracellular fluids 
- To apply modern LC-MS metabolomics technology to the analysis of prefrontal 
microdialysates in a foot shock-induced PTSD mouse model for hypothesis free 
metabolite profiling. 
- To correlate prefrontal metabolite levels to foot shock-induced arousal change. 
- To identify foot shock-induced molecular pathway alterations in the prefrontal cortex of 
a PTSD mouse model. 
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Abbreviations 
PTSD posttraumatic stress disorder 
PrL prelimbic cortex 
ACC anterior cingulate cortex 
BLA basolateral amygdala 
CeA central nucleus of amygdala 
CA1 cornu ammonis 1 
NAc nucleus accumbens 
SSRIs selective serotonin reuptake inhibitors 
FS foot shock 
FDR false discovery rate 
DE differentially expressed 
KS Kolmogorov-Smirnov 
GSEA gene set enrichment analysis 
HMDB Human Metabolome Database 
MSEA metabolite set enrichment analysis 
ATP adenosine triphosphate 
CB1 cannabinoid type 1 
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NAA N-acetylaspartate 
 
 
 
Summary 
Posttraumatic stress disorder (PTSD) is a prevalent psychiatric disorder. Several studies have 
attempted to characterize molecular alterations associated with PTSD, but most findings were 
limited to the investigation of specific cellular markers in the periphery or defined brain 
regions. In the current study, we aimed to unravel affected molecular pathways/mechanisms 
in the fear circuitry associated with PTSD. We interrogated a foot shock induced PTSD 
mouse model by integrating proteomics and metabolomics profiling data. Alterations at the 
proteome level were analyzed using in vivo 
15
N metabolic labeling combined with mass 
spectrometry in prelimbic cortex (PrL), anterior cingulate cortex (ACC), basolateral 
amygdala (BLA), central nucleus of amygdala (CeA) and CA1 of hippocampus between 
shocked and non-shocked (control) mice, with and without fluoxetine treatment. In silico 
pathway analyses revealed an upregulation of Citric Acid Cycle pathway in PrL, and 
downregulation in ACC and NAc. Dysregulated cytoskeleton assembly and myelination 
pathways were identified in BLA, CeA and CA1. Chronic fluoxetine treatment prevented 
decreased Citric Acid Cycle activity in NAc and ACC and ameliorated conditioned fear 
response in shocked mice. Our results shed light on the role of energy metabolism in PTSD 
pathogenesis and suggest potential therapy through mitochondrial targeting. 
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Introduction 
Life threatening events, such as combat, sexual abuse or natural disasters are traumatic 
stressors that can lead to the development of posttraumatic stress disorder (PTSD). The core 
symptoms of PTSD include hyperarousal/hypervigilance, avoidance of trauma-related cues 
and excessive recall of traumatic memories (1). PTSD does not develop until weeks to 
months after trauma exposure. Hence, the long-lasting effect of molecular changes in brain 
regions involved in stress and traumatic memory (fear circuitry) play an important role in the 
pathogenesis of PTSD. 
Although clinical studies on PTSD have identified dysregulations in endocrine signaling (2, 
3), neurotransmitter system (4), as well as genetic and epigenetic risk factors (5, 6) there is 
still a lack of global investigations on altered cellular and molecular pathways and 
biomarkers of fear circuitry involved in PTSD development. Selective serotonin reuptake 
inhibitors (SSRIs) antidepressants, such as fluoxetine, have been widely used to improve 
PTSD symptoms in patients (7) and have shown therapeutic efficacy in animal studies (8). 
However, the underlying molecular mechanisms affected by fluoxetine in distinct brain 
regions still remain elusive. A global investigation of molecular pathways associated with 
fear circuitry with the help of PTSD animal models subjected to fluoxetine treatment can 
provide useful insights into molecular pathology and treatment efficacy. 
For PTSD, a complex and polygenic psychiatric disorder, the integration of different –omics-
based methods and systems biology is necessary for a better understanding of disease related 
molecular pathways (9, 10). These include non-hypothesis driven proteomics, metabolomics 
and transcriptomics methods for the identification of affected pathways and biomarkers.  
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In the present study, we investigated a previously published PTSD mouse model generated by 
inescapable foot shocks as traumatic stressors (8). Shocked mice showed PTSD-like 
symptoms, including conditioned fear response, which was ameliorated upon chronic 
fluoxetine treatment. To identify dysregulated pathways and therapeutic targets of fluoxetine, 
we applied proteomics and metabolomics for the analyses of specific mouse model brain 
regions believed to be involved in PTSD. We focused on brain regions involved in fear 
circuitry, including prelimbic cortex (PrL), anterior cingulate cortex (ACC), nucleus 
accumbens (NAc), basolateral amygdala (BLA), central nucleus of amygdala (CeA) and CA1 
region of hippocampus (11-13). For proteomics analysis 
15
N metabolically labeled reference 
material was used for quantitative mass spectrometry (14). We first identified altered 
molecular pathways upon foot shock exposure followed up by an investigation of the 
fluoxetine rescue effect on the proteome level. We then subjected PrL, ACC, NAc, BLA, 
CeA and CA1 punched tissue to targeted polar metabolomics profiling analysis to further 
corroborate our proteomics findings (15). Proteomics and metabolomics data were integrated 
to delineate affected pathways contributing to PTSD-like pathogenesis and fluoxetine targets. 
 
Experimental Procedures 
Animals 
Male C57BL/6NCrl mice, 7-8 weeks old (Charles River GmbH, Sulzfeld, Germany), were 
housed in groups of four in Makrolon type II cages (23×16.5×14 cm
3
) under standard 
conditions (inverse 12:12 h light-dark cycle, light off at 7:00, room temperature 23°C±2°C, 
humidity 60%) with food and water ad libitum. All experiments were carried out according to 
the European Community Council Directive 2010/63/EEC and approved by the local 
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government of Upper Bavaria (55.2.1.54-2532-41-09 and 55.2.1.54-2532-141-12). 
Laboratory animal care and experiments were conducted according to the regulations of the 
current version of The German Animal Welfare Act. 
 
PTSD mouse model and fluoxetine treatment 
A previously published PTSD mouse model (8, 16) was applied by performing fear 
conditioning (administration of an unsignaled foot shock (FS) in the shock chamber with 
house light on) during the active phase of the circadian cycle. Mice were conditioned in a 
plexiglas cage (161632 cm
3
) with a grid harness package (ENV-407, ENV-307A, MED 
Associates, 7 St. Albans, VT, USA) connected to a shock generator (Shocker/Scrambler: 
ENV-414, MED Associates). After 198 sec of habituation, animals underwent two electric 
FSs (1.5 mA, 2 sec of length) at moderate illumination (40 Lux) with a 60 sec interval in 
between. Animals remained in the shock chamber for another 60 sec before being returned to 
their home cages. Non-shocked (control) mice went through the same procedure, but without 
receiving FSs.  
Fluoxetine (20mg/kg/day; Ratiopharm GmbH, Ulm, Germany) or vehicle (tap water) 
treatment was applied to shocked mice 12 h after FSs for 28 days, followed by a 28-day 
wash-out period. To assess fluoxetine treatment efficacy, sensitized fear response was 
evaluated by exposing mice to a neutral tone (60 sec of length, 80 dB, 9 kHz) in a neutral 
cylindrical context on day 28 after FSs. Long-lasting effect of shock application and 
fluoxetine treatment was assessed after wash-out period, by placing mice into the neutral 
(cylindrical and hexagonal shaped) and shock chambers for contextual fear test for 3 min. In 
the cylindrical grid chamber, mice were additionally exposed to a neutral tone for 3 min to 
test sensitized fear (Supplemental Fig. S1). Freezing behavior was defined as immobility 
except for respiration movements and was video-taped for off-line rating. 
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Brain punch sampling 
Mice were euthanized by an overdose of isoflurane (Forene, Abbott, Wiesbaden, Germany) 
and sacrificed. Brains were harvested after decapitation and immediately fixed with ice-cold 
2-methylbutane (Merck, Darmstadt, Germany), snap frozen in liquid nitrogen and stored at -
80°C. For brain punch, brains were dissected with a cryostat (Microm, Walldorf, Germany) 
up to the appearance of target sub-regions. Punch specimens were isolated using cylindrical 
punchers (Fine Science Tools, Heidelberg, Germany) essentially as described (17). The 
location and length of the punches were selected based on a stereotaxic atlas (18) described 
as follows (in mm: starting point rostral-caudal to bregma, punch diameter, punch length): for 
prelimbic cortex (PrL) (2.3 mm posterior to bregma, 1.0 mm in diameter, 0.9 mm in length), 
anterior cingulate cortex (ACC) (0.86, 0.5, 1.0), nucleus accumbens (NAc) (1.7, 0.5, 1.0), 
basolateral amygdala (BLA) (-0.8, 0.35, 1.0), central nucleus of amygdala (CeA) (-0.9, 0.5, 
0.8), cornu ammonis 1 (CA1) region of the dorsal hippocampus (-1.5, 0.5, 0.8). The 
dissection site was verified by Nissl histological staining with a stereomicroscope. 
 
Experimental design and Statistical Rational 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative 
proteomics analysis 
Tissue pools (n=5 for non-shock-vehicle group, n=5 for shock-vehicle group, n=3 for shock-
fluoxetine group) from each bilaterally punched brain region (PrL, ACC, NAc, BLA, CeA, 
CA1) were subjected to extraction of cytosolic and membrane-associated proteins (19). To all 
samples, equal protein amounts of 
15
N-labeled internal reference standard were added (14). 
14
N/
15
N protein mixtures representing 50-60 μg were separated by SDS polyacrylamide gel 
electrophoresis, fixed and stained with Coomassie Brilliant Blue R-250 (Biorad, Hercules, 
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CA, USA). The gel was destained and each gel lane was cut into 2.5 mm slices (20-22 slices 
per sample) for tryptic in-gel digestion and peptide extraction as described previously (14).  
Tryptic peptide extracts were dissolved in 0.1 % formic acid and subjected to a nanoflow 
HPLC-2D system (Eksigent, Dublin, CA, USA) coupled online to an LTQ-Orbitrap mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany). Prior to peptide separation, 
samples were on-line desalted for 10 min with 0.1% formic acid at a flow rate of 3 μl/min 
(Zorbax-C18 (5μm) guard column, 300 μm  5 mm, Agilent Technologies, Santa Clara, CA, 
USA). RP-C18 (3μm). Desalted peptides were then separated by chromatography (in-house 
packed Pico-frit column, 75 μm  15 cm, New Objective, Woburn, MA, USA). A gradient of 
95% acetonitrile/0.1% formic acid from 10% to 45% over 93 min at a flow rate of 200 nl/min 
was applied for peptide elution. Column effluents were directly injected into the mass 
spectrometer via a nanoelectrospray ion source (Thermo Fisher Scientific). The mass 
spectrometer was operated in positive mode applying a data-dependent scan switch between 
MS and MS/MS acquisition. Full scans were recorded in the Orbitrap mass analyzer (profile 
mode, m/z 380-1600, resolution R=60000 at m/z 400). The top 5 most intense peaks in each 
scan were fragmented and recorded in the LTQ with a target value of 10000 ions in centroid 
mode. Other MS parameters were set as described previously (14, 20). 
 
Protein identification and quantitation 
Peptides were identified by 
14
N and 
15
N database searches using Sequest (v28, implemented 
in Bioworks v3.3.1, Thermo Fisher Scientific) against a decoy Uniprot mouse protein 
database (release 2010_02) containing 110,128 entries (including forward and reverse 
sequences). Enzyme specificity was set to trypsin. Mass accuracy settings were 10 ppm and 1 
Da for MS and MS/MS, respectively. Two missed cleavages were allowed, and cysteine 
carboxyamidomethylation and methionine oxidation were set as fixed and variable 
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modifications, respectively. Filtering parameters for peptide identifications were minimum 
Delta Cn: 0.08 and Xcorr: 1.90 (z=1+), 2.7 (z=2+), 3.50 (z=3+) and 3.00 (z≥4+). 
15
N peptide 
identification was assessed by a variable modification of -0.99970 Da for lysine and arginine 
for the frequent shift from 
15
N monoisotopic to the most intense 
15
N isotopomer as described 
previously (21). False Discovery Rate (FDR) of 0.1% was set as filtering criteria for peptide 
hits using PeptideProphet, 
14
N and 
15
N database searches were combined via iProphet and 
protein groups were identified by ProteinProphet (22). Keratin and proteins with one peptide 
identified were excluded. Relative protein quantification was performed with the ProRata 
software (v1.0) with default parameter settings (23). The identified peptides for every 
14
N/
15
N 
were filtered and quantified with a minimum signal-to-noise ratio cutoff of 2 and ambiguous 
peptides were excluded for further analysis. To correct potential mixing errors during sample 
preparation, quantification results were normalized by subtracting the median from all log2 
ratios of the quantified proteins.  
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium (24) via the PRIDE partner repository with the dataset identifiers PXD002231, 
PXD002271, PXD002272. 
 
LC-MS/MS quantitative metabolomics analysis 
Punched tissues from 15 mice for each brain region (PrL, ACC, NAc, BLA, CeA, CA1) were 
pooled into 5 biological replicates (three pooled mice tissue per analysis) and homogenized 
(2 min  1200 min
-1
, homogenizer PotterS, Sartorius, Göttingen, Germany) in 30-fold (W/V) 
ice-cold 80% methanol (Merck, Darmstadt, Germany). Homogenates were centrifuged 
(14,000 g, 10 min) at 4 °C and supernatants were incubated on dry ice for 2 h. Tissue pellets 
were further disrupted and homogenized with 6-fold (w/v) ice-cold 80 % methanol and 
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combined with previous supernatants. Extracts were lyophilized and stored at -80 °C for 
further analysis. 
Samples were re-suspended in 20 μl LC-MS grade water. Ten μl were injected and analyzed 
using a 5500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX, Framingham, MA, 
USA) coupled to a Prominence UFLC HPLC system (Shimadzu, Columbia, MD, USA). 
Samples were delivered to the mass spectrometer via normal phase chromatography using a 
4.6 mm i.d × 10 cm Amide Xbridge HILIC column (Waters Corp., Milford, MA, USA) at 
350 μl/min. HPLC running buffers and gradients were set as described preciously (Webhofer 
et al., 2013). Some metabolites were targeted in both positive and negative ion modes for a 
total of 320 SRM transitions using positive/negative polarity switching with previously 
described mass spectrometer parameter settings (Webhofer et al., 2013). Peak areas from the 
total ion current for each metabolite SRM transition were integrated using MultiQuant v2.0 
software (AB/Sciex). 
 
Statistics and data analysis 
Identification of differentially expressed (DE) proteins 
To compare protein expression levels between two experimental groups, profile likelihoods 
of both groups were combined via cross-correlation to get a probabilistic estimate of the 
indirect abundance ratio between two groups. For each protein, a p-value for the null 
hypothesis was derived from the profile likelihood by means of a likelihood ratio test to 
identify whether the estimated log2 ratio is significantly different from 0. All p-values were 
adjusted using the "Benjamini-Hochberg" method. 
 
In silico pathway analysis 
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To identify altered biological pathways and processes between different mouse groups in 
distinct brain regions, DE proteins (p < 0.05) were uploaded to DAVID Bioinformatics 
Resources (http://david.abcc.ncifcrf.gov/tools.jsp) with all quantified proteins as background. 
Functional enrichment of KEGG pathway and Gene ontology was acquired and pathways 
were considered enriched with p-value < 0.05 after Benjamini-Hochberg correction. 
 
One-sided Kolmogorov-Smirnov test based Gene Set Enrichment Analysis (GSEA) and 
Metabolite Set Enrichment Analysis (MSEA) 
GSEA and MSEA are commonly used statistical methods to identify enriched gene sets or 
metabolite sets by considering the genome-wide expression profiles of samples from two 
different groups (25). The one-sided KS test based on GSEA and MSEA is a variation of the 
typical GSEA/MSEA and uses random walk with permutation to estimate significance of 
enrichment. The one-sided KS test based GSEA/MSEA uses one-sided KS test to estimate 
whether genes or metabolites involved in the set distribute unevenly in the ranked list 
(Supplemental Fig. S2). 
Genes or metabolites are first ranked based on the Pearson’s correlation coefficients between 
their expression profiles and the group distinction pattern, i.e. the pattern using 0 and 1 to 
distinguish samples from the two different groups. Given a priori defined sets of genes or 
metabolites, e.g. the genes or metabolites involved in a given metabolic pathway, the 
distribution of ranks of these genes or metabolites is compared with the uniform distribution 
across the list using one-sided KS test, by trying two different null hypotheses: 1) the rank 
distribution of the defined gene set is not less than the uniform distribution; 2) the rank 
distribution of the defined gene set is not greater than the uniform distribution. The 
significance and the direction of the changes are determined based on the p-values for the two 
null hypotheses. 
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In this study, the metabolic pathway information, including genes and metabolites that are 
part of the pathways was obtained from the Small Molecule Pathway Database (SMPDB) 
(http://smpdb.ca/) and Human Metabolome Database (HMDB) (http://www.hmdb.ca/). 
 
Results 
Alterations on the proteome level in foot shock-induced PTSD mouse model. 
We applied a previously published PTSD mouse model to investigate the molecular changes 
in the brain (8). Adult C57BL/6 mice were subjected to two non-escapable electric foot 
shocks (FS) (1.5 mA. 2 sec), followed by a 28-day incubation to develop PTSD-like 
symptoms. Shocked mice showed significantly higher conditioned fear response when being 
exposed to neutral contexts (cylindrical and hexagonal shaped plexiglas chambers), neutral 
tone and shock context (cubic chamber with metal grid) compared to control (non-shocked) 
mice (Fig. 1).  
A quantitative proteomics platform based on 
15
N metabolic labeling and LC-MS/MS analysis 
was used to investigate FS-induced proteome changes in different brain regions involved in 
fear circuitry (14, 21). 
15
N-labeled proteins were used as internal standard for the indirect 
comparison between control and shocked mice. We punched brain subregions that are 
involved in fear circuity, including PrL, ACC, NAc, BLA, CeA and CA1 for further analysis. 
Due to the limited tissue amount punched brain tissues from 3-5 mice were pooled. Pooled 
brain tissues were then extracted for cytosolic and membrane-associated fractions. Non-
redundant protein groups were quantified for each brain region by direct comparison between 
test sample and reference material (Supplemental Table S1). Indirect comparison between 
control and shocked mice revealed significantly differentially expressed (DE) proteins (p < 
0.05) after multiple testing correction in both cytosolic and membrane-associated fractions 
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(Supplemental Table S1). ACC and NAc showed the strongest alterations in protein 
abundance, with 154 and 549 DE proteins in ACC, and 223 and 310 DE proteins in NAc in 
cytosolic and membrane-associated fractions, respectively.  
We next investigated enriched cellular processes in different brain regions as described 
in ’Materials and Methods‘ (Table 1). Cytoskeleton proteins (e.g. microtubule), possibly 
linked to axon growth, were significantly enriched in the cytosolic fraction of all brain 
regions investigated. Interestingly, the membrane-associated fraction of ACC, NAc and PrL 
showed a significant enrichment of proteins involved in the generation of precursor 
metabolites and energy metabolism including Citric Acid Cycle (Table 1). We therefore 
decided to further interrogate FS-induced metabolic pathway changes. 
 
Integration of proteomics and metabolomics profiling data in shocked mice reveals 
altered energy metabolisms in nucleus accumbens and anterior cingulate cortex. 
We applied the one-sided Kolmogorov-Smirnov (KS) test based Gene Set Enrichment 
Analysis (GSEA) to cytosolic and membrane-associated fraction proteomics data of the 
different brain regions to enrich affected metabolic pathways . Multiple metabolic pathways 
were enriched in the shocked mice in distinct brain regions (Supplemental Table S2). We 
found a decrease of Citric Acid Cycle enzyme abundance in the membrane-associated 
fraction of both ACC and NAc, as well increased enzyme levels in PrL. These findings were 
consistent with the DAVID analysis results. 
For further verification of these metabolic pathway alterations we subjected distinct brain 
region extracts (PrL, ACC, NAc, BLA, CeA and CA1) from control and shocked mice to 
metabolomics analyses. A total of 320 metabolites were quantified of which 268 were 
assigned to Human Metabolome Database (HMDB) annotated metabolites (Supplemental 
Table S3). Focusing on the brain regions PrL, ACC and NAc that had shown metabolic 
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pathway alterations based on the proteomics data we applied the one-sided KS test based 
Metabolite Set Enrichment Analysis (MSEA) to identify significantly altered metabolic 
pathways in shocked mice (Supplemental Table S4). We next employed the permutation-
based test by calculating Euclidean distance (De) for rank similarity between GSEA and 
MSEA analysis. The similarity test showed consistent output results between MSEA and 
GSEA in the membrane-associated fraction analysis of ACC and NAc (Benjamini & 
Hochberg corrected FDR < 0.1), suggesting that the proteomics and metabolomics data both 
implicate metabolic pathway alterations in these two brain regions. 
We found a trend for a down-regulated Citric Acid Cycle pathway in NAc in shocked mice 
from MSEA analysis (p = 0.077). Decreased levels of Citric Acid Cycle intermediates 
include oxalacetic acid, citric acid, aconitic acid, isocitric acid, and succinic acid (Fig. 2A). 
This was consistent with the proteomics data from DAVID and GSEA analyses that also 
support down-regulation of Citric Acid Cycle in NAc in shocked mice. In addition, MSEA 
analysis also revealed a decreased Citric Acid Cycle pathway activity in ACC in shocked 
mice, though with a weak trend (p = 0.27). The weak MSEA signal can be in part explained 
by the increased abundance of certain metabolites such as NAD and NADH, which in 
addition to Citric Acid Cycle are members of several other metabolic pathways. The majority 
of metabolites involved in Citric Acid Cycle including pyruvic acid, citric acid, aconitic acid 
and isocitric acid were found at lower levels, while only few intermediates (oxolutaric acid, 
succinic acid and oxalacetic acid) were found with small increases in ACC of shocked mice 
(Fig. 2B). We then applied the permutation-based test for the longest path of components 
with continuous decrease of expression in shocked mice, taking into consideration both the 
quantified enzymes and metabolites involved in Citric Acid Cycle in ACC. In the shocked 
mice, the observation that quantified enzymes and metabolites not only tended to have 
decreased abundance, but also tended to link with each other in one pathway (permutation 
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P=0.0367) supports the notion that Citric Acid Cycle in ACC was down-regulated in the 
shocked mice. 
 
Chronic fluoxetine treatment prevents FS-induced Citric Acid Cycle proteome 
alterations. 
Previously published results from our PTSD mouse model showed therapeutic efficacy of 
chronic fluoxetine treatment (8). Mice were treated with fluoxetine (20mg/kg/day) or vehicle 
for 28 days, 12 hours after the FS, followed by a 28-day wash-out period. Conditioned fear 
response, one of the key PTSD-like symptoms, was tested after the fluoxetine wash-out, and 
was ameliorated after chronic fluoxetine treatment in shocked mice (Fig. 1). We compared 
brain proteomes between shocked mice treated with fluoxetine and vehicle to investigate 
molecular changes associated with the fluoxetine rescue. Focusing on the proteins that were 
affected in the shocked mice, proteomic analysis revealed a rescue effect of fluoxetine 
treatment for FS-induced altered pathways. With chronic fluoxetine treatment we found most 
of the significant FS-induced alterations rescued in the membrane-associated fraction of ACC 
and CA1 (Table 2). Furthermore, fluoxetine treatment increased the expression level of 
proteins involved in the GO pathway ‘generation of precursor metabolites and energy’ 
(aconitate hydratase, isocitrate dehydrogenase and succinyl-CoA ligase) which were found 
decreased in ACC in shocked mice (Fig. 3B). In CA1 of the hippocampus, myelination 
pathway was found downregulated in the shocked mice (Table 1), while fluoxetine treatment 
rescued myelin sheath protein levels (Table 2), including myelin oligodendrocyte protein, 
cyclic nucleotide phosphodiesterase 1 and 2’,3’-cyclic-nucleotide 3’-phosphodiesterase. In 
addition, upon fluoxetine treatment, FS-induced down-regulation of most enzymes involved 
in Citric Acid Cycle in NAc, including fumarate hydratase, malate dehydrogenase, pyruvate 
dehydrogenase, citrate synthase, aconitate hydratase, isocitrate dehydrogenase and 
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oxoglutarate dehydrogenase, was rescued (Fig. 3A, Table 2). These findings suggest that 
fluoxetine treatment affects energy metabolism and myelination pathways in NAc, ACC and 
CA1 associated with FS-induced PTSD-like symptoms. 
 
Discussion 
In the present study we have for the first time combined proteomics and metabolomics data 
of a PTSD mouse model to unravel affected molecular pathways in brain regions believed to 
be involved in fear circuitry. Our data implicate energy metabolism alterations in nucleus 
accumbens (NAc) and anterior cingulate cortex (ACC) in the shocked mice. Chronic 
fluoxetine treatment prevents energy metabolism dysregulation in the same brain areas and 
ameliorates PTSD-like symptoms in shocked mice.  
We applied a foot shock (FS) induced PTSD model using inbred C57BL/6NCrl mice, a strain 
that is susceptible to PTSD-like symptoms development (16, 17, 26-28) Using a standardized 
proteomics platform based on 
15
N metabolic labeling and mass spectrometry we accurately 
quantified and identified significantly altered protein expression levels in affected brain 
regions and enriched altered cellular pathways by in silico pathway analyses. Proteomics 
findings were further corroborated by targeted metabolite profiling. By integrating proteome 
and metabolome data we were able to unravel altered molecular pathways associated with 
PTSD pathogenesis as well as potential therapeutic targets for fluoxetine treatment. 
Mitochondria are involved in intracellular processes regulating neuronal plasticity, survival 
and signal transduction (29-31). Dysregulated mitochondrial function has been implicated in 
psychiatric and neurodegenerative diseases. Filiou et al. showed that divergent mitochondrial 
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mechanisms, including energy metabolism, mitochondrial transport and oxidative stress 
contribute to anxiety-related behaviors in mice (14). Upon psychological trauma exposure, 
cellular metabolic responses are activated and chronic inflammation is produced in neurons 
(32, 33). Persistent dysregulated energy metabolism ultimately leads to bioenergetic 
impairment and chronic low-grade inflammation, and may result in chronic diseases such as 
PTSD (32) and schizophrenia (34). In this regard Flaquer et al. identified two mitochondrial 
variants located in the ATP synthase subunit 8 and NADH subunit 5 which were significantly 
associated with PTSD (35). 
Citric Acid Cycle produces NADH as precursor for oxidative phosphorylation and chemical 
energy in the form of adenosine triphosphate (ATP) (36). In our study, we observed an 
increased expression of proteins involved in Citric Acid Cycle in PrL in shocked mice (Table 
1, Supplemental Table S1). Persistent PrL activation was reported to associate with enhanced 
learned fear expression in female rats (37). Another study suggested that sustained 
conditioned responses in PrL correlated with fear extinction failure (38). Endocannabinoids 
have been shown to regulate PrL activity by activating cannabinoid type 1 (CB1) receptors 
and anxiety-like behaviors in rats (39). Furthermore, CB1 receptors are part of neuronal 
mitochondria membranes where they regulate respiration and energy metabolism (40). 
Persistent increased energy metabolism that we have observed in PrL may result in neuronal 
activity and signaling alterations causing exaggerated fear expression in the shocked mouse. 
ACC belongs to the prefrontal cortex and interacts with PrL to regulate top-down attention 
and stimulus-guided action (41) and is involved in emotional control and cognitive functions 
which are dysregulated in PTSD (42, 43). Previous studies indicate that ACC exhibits 
diminished activation in response to threat-related events in PTSD (44). In addition, increased 
activation in the ventral ACC correlates with symptom improvement after successful 
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treatment of PTSD by cognitive behavioral therapy (45). Another study reported reduced N-
acetylaspartate (NAA) levels in the right ACC of PTSD patients (46). NAA facilitates energy 
metabolism in neuronal mitochondria, and decreased NAA levels are associated with 
reversible neuronal or mitochondrial dysfunction (47, 48). In accordance with previous 
findings, our proteomics and metabolomics data revealed a down-regulation of Citric Acid 
Cycle pathway (Table 1, Fig. 2B), implying decreased mitochondrial/neuronal activity in the 
ACC of shocked mice. In another study with the same PTSD mouse model we have identified 
an increased inflammatory response in ACC in shocked mice (Kao et al., submitted). Pro-
inflammatory cytokines, including TNF-α and IL-1α, were shown to induce mitochondrial 
damage through suppression of pyruvate dehydrogenase activities (49), which is in 
accordance with our finding of decreased pyruvate dehydrogenase expression levels in the 
ACC in shocked mice (Supplemental Table S1). The dysregulated energy metabolism found 
in the present study in combination with an inflammatory response may cause perturbed 
neuronal function in ACC and underlie the deficits in emotional control and cognitive 
function in PTSD.  
NAc is associated with cognitive processing, such as motivation and reward (50, 51) and 
plays an important role in anxiety-like behaviors (52, 53), emotion (54) and depression (55, 
56). Emotional numbing and negative alterations in cognition are among the core PTSD 
symptoms (1). Previous studies showed a lower activation of the NAc in PTSD patients 
which may be related to decreased motivation and altered reward processing (57). Similar to 
our findings in ACC, we observed a decreased expression of proteins and metabolites 
associated with Citric Acid Cycle in NAc in shocked mice (Table 1, Fig. 2A). Proteomics 
analysis revealed that rats reared with control condition exhibited decreased expression of 
proteins involved in Citric Acid Cycle upon acute stress exposure while rats reared with 
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environmental enrichment, which produced a protective antidepressant-like phenotype, 
showed increased protein expression in NAc (58). Taken together, upon exposure to a 
stressor, persistent mitochondrial dysfunction results in downstream cellular metabolic 
changes (e.g. decreased Citric Acid Cycle activity) in NAc and may contribute to the 
pathogenesis of PTSD.  
In addition to energy metabolism perturbation, we also observed altered expression levels of 
cytoskeleton/microtubule and myelin sheath proteins in BLA and CeA (Table 1, 
Supplemental Table S1). Amygdala encompasses several nuclei with distinct functions, such 
as BLA, CeA and intercalated cell cluster, and plays an important role in emotional reactions 
and fear response (59, 60). BLA receives and processes sensory information for emotional 
events and projects to CeA for expression of fear-related behavior, such as freezing response 
(61-63). A recent study in rats has shown that repeated restraint stress elicits glutamatergic 
deficits in CeA and dendritic atrophy in pyramidal neurons in BLA (64, 65). Our observation 
of a long-term reduction of microtubule assembly pathway protein levels in BLA of shocked 
mice further supports these findings.  
Decreased cytoskeleton and myelin sheath protein levels were also found in CA1 of 
hippocampus in our PTSD mouse model (Table 1, Supplemental Table S1). It has been 
suggested that during contextual fear memory recall, inhibition of CA1 interferes with the 
perception of the context during testing, rather than the recognition of the context from earlier 
training (66). A previous study showed that chronic stress induced hippocampal volume loss 
which is associated with neuronal loss and dendritic atrophy in CA1 and reduced 
neurogenesis in DG (67). Taken together, stress-induced structural and synaptic 
organizational alterations in CA1 may contribute to generalized fear response (neutral context) 
in PTSD. 
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Fluoxetine is an SSRI antidepressant commonly used for treatment of major depressive 
disorder, obsessive-compulsive disorder, panic disorder, as well as PTSD (7, 68, 69). 
Psychotherapeutic actions of fluoxetine treatment are reported to be involved in cortical 
neurofilament alteration, increased synaptic remodeling and neurogenesis (70, 71). 
Furthermore, previous studies revealed an anti-inflammatory effect of fluoxetine treatment in 
vitro (72, 73), which was also observed in ACC in one of our studies applying the same 
PTSD mouse model (Kao et al., submitted). Early intervention of fluoxetine treatment 
improved long-term conditioned fear response and rescued downregulation of Citric Acid 
Cycle pathway in ACC and NAc in shocked mice after drug washout (Fig. 3), indicating a 
long-lasting effect of fluoxetine treatment on regulating mitochondrial functionality. Apart 
from serotonergic neurotransmission, several studies also indicated modulations of 
mitochondrial functionality after fluoxetine treatment. Upon norfluoxetine (active metabolite 
of fluoxetine) or other antidepressant treatment, a decreased transmembrane electrochemical 
gradient generated by the mitochondrial electron transport chain was observed in isolated rat 
heart mitochondria (74). Treatment of rats with paroxetine, another SSRI antidepressant, 
increased mitochondrial respiratory chain in prefrontal cortex, hippocampus, striatum and 
cerebral cortex (75). In line with previous animal studies, Zhao et al. demonstrated that 
fluoxetine and imipramine treatments regulate energy metabolism, amino acid metabolism 
and neurotransmitters in the hippocampus and showed anti-depressive effects in a chronic 
mild stress mouse model of depression (76). Furthermore, the anti-inflammatory effect of 
fluoxetine may improve stress-induced mitochondrial dysfunction and prevent neurons from 
cellular metabolism perturbations (77). Taken together, mitochondria appear to be the target 
of fluoxetine treatment by its ability to alter energy metabolism and production of amine. The 
modulation of neuronal energy metabolism might constitute a venue for treating PTSD. 
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In CA1 we also observed a fluoxetine treatment rescue effect on myelin sheath protein loss in 
shocked mice (Table 2). Activated microglia produce proinflammatory cytokines, reactive 
oxygen species and proteases which lead to apoptosis in oligodendrocytes and neurons (78, 
79). Decreased myelin oligodendrocyte glycoprotein expression and myelin loss in mice is 
blocked by fluoxetine by inhibiting microglial activation after spinal cord injury (80). 
Another study revealed that fluoxetine activates the sterol-regulatory element-binding protein 
transcription factor with subsequent upregulation of the downstream lipogenesis-related 
genes, which are important for myelin component synthesis (81). In summary, fluoxetine 
exerts different functions on cellular pathways which may counteract myelin protein loss in 
CA1 associated with PTSD. 
In conclusion, our proteomics and metabolomics data of a FS-induced PTSD mouse model 
have shown altered energy metabolism in PrL, ACC and NAc, dysregulated cytoskeleton 
protein expressions in BLA and CeA as well as myelin protein loss in CA1. Furthermore, 
fluoxetine treatment of PTSD mice rescued protein expression alterations associated with 
Citric Acid Cycle in ACC and NAc, and myelination in CA1. Through an integration of 
proteomics and metabolomics data we were able to provide novel insights into molecular 
pathways involved in PTSD and the potential for therapeutic mitochondrial targeting, which 
most recently is also considered for cancer (82) and neurodegenerative disorders treatments 
(83). Mitochondrial involvement has also been suggested for other psychiatric diseases (84, 
85). Further studies are needed to find out whether mitochondrial-related alterations are 
specific for different classes of neurons and their role in the pathogenesis of distinct mental 
disorders. 
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Table 1. Enriched molecular pathways in shocked mice. 
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Table 2. Rescued pathways upon chronic fluoxetine treatment in shocked mice. 
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Figure legends 
Fig. 1. Shock application and chronic fluoxetine treatment effects on contextual fear 
response in mice. Mice receiving electric foot shocks showed significantly higher expression 
of freezing response when exposed to neutral context (cylinder chamber) and grid context 
(hexagon Plexiglas chamber), neutral tone and shock context (cubic chamber with metal grids 
for shock application) compared to control (non-shocked) mice. Contextual fear response in 
shocked mice was ameliorated upon chronic fluoxetine treatment. All comparisons were 
assessed by one way ANOVA analysis with Bonferroni’s Multiple Comparison test. N = 5 
for control-vehicle group, N = 5 for shock-vehicle group and N = 3 for shock fluoxetine 
group. Data are presented as mean ± SEM (* p < 0.05, ** p < 0.01, ns- not significant). 
Fig. 2. Altered enzyme and metabolite levels of Citric Acid Cycle in nucleus accumbens 
(NAc) and anterior cingulate cortex (ACC) in shocked mice. In NAc (A) and ACC (B), 
enzymes and metabolites involved in Citric Acid Cycle were downregulated in the shocked 
mice. Oval- and rectangle-shaped boxes represent enzymes and metabolites of the Citric Acid 
Cycle, respectively. Red and blue boxes indicate increased and decreased levels, respectively, 
in the shocked mice compared to control mice. Red and blue box shade intensities represent 
the level of fold change expressed by log2 ratio. 
Fig. 3. Chronic fluoxetine treatment effect on the enzyme and metabolite levels of Citric 
Acid Cycle in nucleus accumbens (NAc) and anterior cingulate cortex (ACC) in shocked 
mice. Proteome comparison of shocked mice with vehicle or fluoxetine treatments revealed 
lower enzyme levels of Citric Acid Cycle in both NAc (A) and ACC (B). The results 
indicated that chronic fluoxetine treatment rescued decreased enzyme expressions of the 
Citric Acid Cycle in NAc (A) and ACC (B) in shocked mice. Red and blue boxes indicate 
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increased and decreased levels, respectively, in the shocked mice compared to control mice. 
Red and blue box shade intensities represent the level of fold change expressed by log2 ratio. 
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Abstract 
Background: Despite intense research efforts the molecular mechanisms affecting stress-
vulnerable brain regions in posttraumatic stress disorder (PTSD) remain elusive. In the 
current study we have applied global transcriptomic profiling to a PTSD mouse model 
induced by foot shock fear conditioning. 
Methods: We compared the transcriptomes of prelimbic cortex, anterior cingulate cortex 
(ACC), basolateral amygdala, central nucleus of amygdala and CA1 of the dorsal 
hippocampus between shocked and non-shocked (control) mice, with and without fluoxetine 
treatment by RNA sequencing. Differentially expressed (DE) genes were identified and 
clustered for in silico pathway analysis. 
Results: DE genes belonging to 11 clusters were identified and include decreased 
neurotransmitter signaling in both ACC and CA1, and increased inflammatory response in 
ACC in shocked mice. Chronic fluoxetine treatment initiated in the aftermath of the trauma 
prevented inflammatory gene expression alterations in ACC and ameliorated PTSD-like 
symptoms, implying an important role of the immune response in PTSD pathobiology. 
Conclusion: Our results provide novel insights into molecular mechanisms affected in PTSD 
and suggest therapeutic applications with anti-inflammatory agents.   
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Introduction 
According to DSM-5, posttraumatic stress disorder (PTSD), is classified as a trauma- and 
stress-related psychiatric disorder (1). PTSD develops upon encountering traumatic events 
such as natural disasters, sexual/childhood abuse or war combat. Persistent re-experiencing 
flashbacks as well as nightmares of the traumatic events (intrusion symptoms), avoiding 
thoughts and activities associated with the trauma (avoidance symptoms), decreased interest 
and negative alterations in cognition (emotional numbing symptom) and hypervigilance and 
aggressive behavior (hyperarousal symptoms) are the core features of PTSD (1).  
PTSD symptoms develop days to months following trauma exposure, indicating long-lasting 
molecular/signaling sequelae of traumatic stressor central for the underlying 
pathophysiological mechanism. Dysregulations in hypothalamic-pituitary-adrenal (HPA) and 
sympathetic-adrenal-medullary (SAM) axes activities (2-5), and serotonin (6, 7) and 
dopamine (8, 9) neurotransmitter signaling have been observed in PTSD patients. In addition, 
genetic factors are considered to contribute to PTSD pathogenesis. Previous studies have 
shown single nucleotide polymorphisms (SNP) in the corticotropin-releasing hormone 
receptor 1 (CRHR1) gene (10) and in the FK506 binding protein 5 (FKBP5) gene (11) to be 
associated with PTSD symptoms. Furthermore, a SNP in the pituitary adenylate cyclase-
activating polypeptide type I (PAC1) receptor stimulates CRH gene expression which 
regulates stress response in female PTSD patients (12, 13).  
Memory- and stress- related processes regulated by brain structures involved in fear response 
circuitry such as amygdala, prefrontal cortex, hippocampus and nucleus accumbens, play 
important roles in the development of PTSD (13). Amygdala, the brain structure associated 
with heightened arousal, learning and fear has an increased activity in response to trauma-
related stimuli in PTSD patients (14, 15). Clinical studies with PTSD patients have shown 
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decreased activity in the prefrontal cortex, the brain region related to cognition and fear 
memory extinction (15). Furthermore, hippocampus size has been reported to correlate 
inversely with PTSD susceptibility (16). These data indicate that molecular dysregulations in 
the activity and functional connectivity of the fear circuitry result in abnormal perception to 
the traumatic events which may underlie the pathological mechanism of PTSD. Although 
brain imaging has advanced functional studies it is unclear how cellular alterations in specific 
brain regions contribute to PTSD development.  
Animal models can be used to carry out targeted –omics analyses of brain regions believed to 
be part of the neural circuit relevant for the PTSD phenotype. In this study, we used a 
previously published electric foot shock-induced PTSD mouse model (17). This model is 
characterized by long-term maintenance of generalized fear, avoidance and hyperarousal (18, 
19) as well as altered hippocampus volume (20). Our goal was to correlate PTSD-like 
symptoms and response to treatment with the selective serotonin reuptake inhibitor (SSRI) 
antidepressant fluoxetine, reported to effectively ameliorate PTSD-like syndrome in mice 
(17), with molecular changes in brain regions critical for fear memory and response. We 
performed global transcriptome profiling to identify transcripts and associated pathways 
underlying PTSD pathobiology. We were able to demonstrate that fluoxetine treatment 
effectively rescued transcripts and pathway alterations in the PTSD mouse model.  
 
Methods and Materials 
Animals 
Male C57BL/6NCrl mice, 7-8 weeks old (Charles River GmbH, Sulzfeld, Germany) were 
housed in groups of four in Makrolon type II cages (23×16.5×14 cm
3
) under an inverse 12:12 
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h light-dark cycle (light off at 7:00) with food and water ad libitum. All experiments were 
carried out according to the European Community Council Directive 2010/63/EEC and 
approved by the local government of Upper Bavaria (55.2.1.54-2532-41-09 and 55.2.1.54-
2532-141-12). 
 
PTSD model (Fear conditioning) 
For the PTSD mouse model, we performed foreground contextual fear conditioning 
(administration of the foot shock (FS) in the shock chamber with house light on) during the 
active phase according to a previously published protocol (17). The outline of the PTSD 
mouse model experiment is presented in Supplementary Figure S1. In brief, mice were 
conditioned in a plexiglas cage (161632 cm3) with a grid harness package (ENV-407, 
ENV-307A, MED Associates, 7 St. Albans, VT, USA) connected to a shock generator 
(Shocker/Scrambler: ENV-414, MED Associates). After 198 sec of habituation, animals 
underwent one electric FS (1.5 mA, 2 sec of length) at moderate illumination (40 Lux). 
Animals remained in the shock chamber for another 60 sec before being returned to their 
home cages. Non-shocked (control) mice went through the same procedure, but without 
receiving FSs. To test intensity and specificity of contextual fear, animals were exposed to 
neutral environment, grid or shock context. 56 days after FS, animals were placed into the 
neutral test chamber (cylindrical shaped). After a 3 min neutral tone (80 dB, 9 kHz) 
presentation animals remained in the test chamber for another 60 sec before they were 
returned to their home cages. 57 days after FS, animals were exposed to the hexagonal 
chamber with grid floor and shock chamber with house light on for 3 min without further 
shock application. Freezing behavior was defined as immobility except for respiration 
movements. 
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Fluoxetine treatment 
Fluoxetine-ratiopharm TM solution (Ratiopharm GmbH, Ulm, Germany; produced by 
Merckle GmbH, Blaubeuren, Germany) was dissolved in water and applied via lightproof 
drinking bottles in doses of 20 mg/kg/day. 12 hours after FS application, non-shocked and 
shocked mice received either fluoxetine or tap water (vehicle) for 28 days, followed by a 28-
day wash-out period. Fluoxetine treatment efficacy was assessed by evaluating sensitized fear 
response during a presentation of 60 sec neutral tone (80 dB, 9 kHz) in a neutral context 
(cylinder) on day 28 after FS. Conditioned and sensitized fear was evaluated on days 56 to 57 
as described above (Supplementary Figure S1) to inspect long-lasting effect of fluoxetine 
treatment. 
  
Brain sampling  
On day 64 after FS, i.e.one week after development of PTSD-like symptoms, mice were 
euthanized by an overdose of isoflurane (Forene, Abbott, Wiesbaden, Germany) and 
sacrificed. Mice were decapitated and brains were harvested and immediately fixed with ice-
cold 2-methylbutane (Merck,Darmstadt, Germany), snap frozen in liquid nitrogen and stored 
at -80°C. For brain punch, brains were dissected with a cryostat (Microm, Walldorf, Germany) 
up to the appearance of target sub-regions. Punch specimens were isolated using cylindrical 
punchers (Fine Science Tools, Heidelberg, Germany) essentially as described (21). The 
location and length of the punches were selected based on a stereotaxic atlas (22) described 
as follows (in mm: starting point posterior to bregma, punch diameter, punch length): for 
prelimbic cortex (PrL) (2.3 mm rostral-caudal to bregma, 1.0 mm in diameter, 0.9 mm in 
length), anterior cingulate cortex (ACC) (0.86, 0.5, 1.0), nucleus accumbens (NAc) (1.7, 0.5, 
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1.0), basolateral amygdala (BLA) (-0.8, 0.35, 1.0), central nucleus of amygdala (CeA) (-0.9, 
0.5, 0.8), cornu ammonis 1 (CA1) region of the dorsal hippocampus (-1.5, 0.5, 0.8). Punches 
were stored at -80°C for RNA extraction. The dissection site was verified by histological 
staining with a stereomicroscope. 
 
RNA extraction and RNA sequencing  
RNA was isolated from brain sub-region cryo-punches using Trizol reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions and treated with RNase free 
DNase I (Ambion, Austin, TX) at 37°C for 30 min. The cDNA libraries were prepared by 
adding random hexamer primers (Invitrogen) to individual sample containing 300 μg total 
RNA according to manufacturer’s instructions. The Illumina sequencing libraries were 
prepared according to the single-end sample preparation protocol (HiSeq 2000, 
http://www.illumina.com), and were purified with Qiaquick PCR purification kit (Qiagen, 
Valencia, CA). The libraries (12 single-indexed samples per pool) were sequenced using the 
Illumina Genome Analyzer II system with sequenced read-length (starting after the index) of 100 
bp per read. All sequence data including quality scores are deposited in the NCBI's Short Read 
Archive, with SRA accession number SRP057486 and BioProject ID PRJNA281134. 
 
 
 
 
 
2. RESEARCH ARTICLES 
87 
 
Results 
Transcriptome characteristics of brain regions involved in fear circuit 
A posttraumatic stress disorder (PTSD) mouse model was generated by exposing adult 
C57BL/6 mice to two non-escapable electric foot shocks (FS) (1.5 mA, 2 sec) (17). After 56 
days of incubation, shocked mice developed PTSD-like symptoms, apparent by a conditioned 
fear response. The beneficial effect of fluoxetine persisted after offset of treatment until days 
56/57 (Figure 1). To investigate molecular changes at the transcriptome level in the shocked 
mice, RNA-seq analysis was performed for the brain regions involved in the fear circuit, 
including PrL, ACC, BLA, CeA, CA1 and NAc (Supplementary Methods and Materials). 
Three biological replicates were used for each brain region per group. RNA-seq resulted in 
336.1 million and 336.6 million reads with 100 nucleotide (nt) length in shocked and control 
mice, respectively. In addition, we generated RNA-seq data for mice treated with fluoxetine 
which resulted in 352.8 million and 349.4 million RNA-seq reads with 100 nt length for 
shocked and control mice, respectively (Supplementary Table S1). 
To quantify and compare gene expression, we used the STAR mapping program with default 
parameters to map all the RNA-seq reads to the mouse genome mm10 (Supplementary 
Methods and Materials). This resulted in 292.9 million reads (87.6%) in shocked mice with 
vehicle treatment, 294.8 million reads (87.6%) in control mice with vehicle treatment, 310.9 
million reads (88.1%) in shocked mice with fluoxetine treatment and 306.7 million reads 
(87.8%) in control mice with fluoxetine treatment, uniquely mapped to the genome. We used 
GENCODE M2 annotation to define gene structure. Gene expression was first quantified as 
the number of reads per kilobase per million of total mapped reads (RPKM). Only the 
protein-coding genes with maximum RPKM higher than 1 were considered. DESeq 
normalization method implemented in DESeq2 Bioconductor package was then applied to the 
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read count of the resulting 14591 protein-coding genes for normalization (Supplementary 
Methods and Materials). 
 
Identification and characterization of PTSD-related expressed genes 
To identify the protein-coding genes with expression level change between shocked and 
control mice, we applied ANOVA with generalized linear model (GLM) to the gene 
expression levels of the 14591 protein-coding genes in all the 72 samples, covering the six 
brain regions from four mouse groups (shocked with vehicle treatment, control with vehicle 
treatment, shocked with fluoxetine treatment and control with fluoxetine treatment) 
(Supplementary Methods and Materials). With Benjamini & Hochberg corrected FDR < 10 
% as cutoff, 741 protein-coding genes were identified as PTSD-related expressed genes, that 
is, genes with significant expression level changes between shocked and control mice. 
We next aimed to characterize the biological significance of the expression changes of these 
741 PTSD-related expressed genes. With the assumption that the biologically related genes 
tended to be co-expressed to collaborate, we used hierarchical clustering with 1-r, where r is 
the Pearson’s correlation coefficient calculated using the samples from vehicle-treated control 
and shocked mice, as the distance to identify the co-expressed clusters. We obtained 11 co-
expressed clusters with reasonable size (> 20 genes) (Supplementary Table S2). Each cluster 
was characterized by its distinct expression pattern across the six brain regions in control and 
shocked mice (Supplementary Figure S2). DAVID analysis (23, 24) featured three of the 11 
clusters with their distinct enriched functional categories (Supplementary Table S3). Cluster 
C4 with 86 PTSD-related expressed genes is characterized by its functional enrichment, 
among others, of synapse, neurotransmitter secretion and regulation of neurotransmitter 
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levels. Cluster C5 showed functional enrichment of glycoprotein, intrinsic to membrane and 
integral to membrane. Cluster C8 exhibited functional enrichment of chemotaxis, 
inflammation and other pathways which are related to inflammation, such as drug 
metabolism and cytokine. 
Alterations in the expression levels of the PTSD-related genes in clusters C4, C5 and C8 may 
indicate different roles for pathophysiological changes in distinct brain regions. To better 
characterize the changes in gene cluster expression, Wilcoxon’s test was applied to each brain 
region to investigate the clusters which showed alteration in shocked mice compared to 
control mice (Figure 2). Interestingly, we found significant decreases of C4 and C5 gene 
expression levels in ACC and CA1, and an increase in C8 genes in ACC. Taken together, 
these results indicate that FS-induced dysregulated synaptic function and inflammatory 
response in ACC are involved in the development of PTSD-like symptoms. 
 
Regulation of PTSD-related genes 
Synchronized expression of genes within each cluster implies the co-regulation by shared 
regulators such as transcription factors (TFs). To test this, we estimated the enrichment of TF 
binding sites (TFBSs) in the promoter regions of genes within each cluster (Supplementary 
Methods and Materials). We observed significant excess of TFBSs in cluster C8 (permutation 
test, p < 0.001, Figure 3A). In addition, the TFs with enriched TFBSs in C8 showed 
significantly better correlation with genes in the C8 clusters compared to other clusters (one-
sided Wilcoxon test, Benjamini & Hochberg correction, FDR < 0.05) (Figure 3B, 
Supplementary Table S4). These TFs also showed massive crosstalk in terms of protein-
protein interaction or regulatory relationships (Supplementary Figure S3), whose density of 
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connections between TFs was significantly higher than that of the random TF networks with 
the same number of TFs (p < 0.001), forming the regulatory network which might be 
responsible for the expression alteration of the PTSD-related genes. Furthermore, the 
enriched TFs, e.g. NFκB1 and NFκB2, regulate inflammatory response which is the enriched 
pathway in cluster C8 genes. These results imply that the PTSD-related gene alterations are 
in part driven by transcription factors, particularly for genes in cluster C8. 
 
Fluoxetine rescue effect suggests an important role of ACC in PTSD-like symptoms 
development 
Previous studies have shown the efficacy of fluoxetine treatment in human PTSD (25). In 
addition, results from our PTSD mouse model showed therapeutic potency of chronic 
fluoxetine treatment (17). Therefore we were interested whether chronic fluoxetine treatment 
is able to rescue differential brain gene expression in the shocked mice. Shocked mice were 
treated with vehicle or fluoxetine (20mg/kg/day) starting 12 hours after the FS for 28 days, 
followed by a 4-week wash-out period. This wash-out period allowed us to investigate long-
lasting effects of fluoxetine treatment while excluding acute effects of chronic fluoxetine 
treatment on fear expression. As expected, shocked mice that underwent fluoxetine treatment 
showed a significant decrease in conditioned fear response compared to shocked mice with 
vehicle treatment on day 57 after FS (Figure 1).  
To investigate the underlying mechanism of fluoxetine treatment with regard to gene 
expression, we calculated the log2-transformed fold change of gene expression level for each 
brain region by comparing 1) shocked-vehicle and control-vehicle (log2FCPTSD); and 2) 
shocked-fluoxetine and control-vehicle (log2FCrescued). Defining fluoxetine rescue as 
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|log2FCrescued| < |log2FCPTSD|, we used paired Wilcoxon’s test to check whether genes in each 
cluster tended to be rescued by fluoxetine treatment in each brain region. Most of the 
effective gene expression rescue upon fluoxetine treatment occurred in the ACC, including 
changes associated with C4, C5 and C8 clusters (Figure 4, Supplementary Figure S4). This 
observation again suggests that ACC is a critical brain region for the development of PTSD 
and the molecular alterations are causal for PTSD-like symptoms. 
 
 
Discussion 
In the present study, we applied global transcriptomics profiling to unravel altered 
neurocellular pathways in affected brain regions of a foot shock (FS) induced-PTSD mouse 
model. Chronic treatment with fluoxetine, an antidepressant drug used for PTSD patients, 
resulted in rescue of some of the affected pathways at transcriptome level in specific brain 
regions of the shocked mice. We identified PTSD-related genes by an ANOVA with 
generalized linear model (GLM) analysis and hierarchical clustering. Among the brain 
regions involved in fear circuits, we found anterior cingulate cortex (ACC) and CA1 region 
of the hippocampus to be affected the most in the shocked mice. Gene clusters enriched for 
neurotransmitter secretion and membrane integrity pathways were decreased in both ACC 
and CA1 and gene cluster enriched for inflammation pathway was increased in ACC. Further 
analyses showed that chronic fluoxetine treatment ameliorated the dysregulated expression of 
gene clusters in ACC in the shocked mice along with improved PTSD-like symptoms which 
were assessed by conditioned fear response. 
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PTSD, like other anxiety disorders, is associated with abnormalities in brain regions involved 
in the fear circuitry, including medial prefrontal cortex (mPFC), amygdala, hippocampus and 
NAc. Alterations in the functional connectivity and activation of these brain regions result in 
dysregulated perception and interpretation of traumatic events (26, 27). The mPFC regulates 
emotional control, cognition and fear extinction (28); the hippocampus is involved in 
contextual fear memory, traumatic memory consolidation and retrieval; the amygdala is 
associated with cue conditioning, hyperarousal and expressing fear response (29, 30); and the 
NAc is related to reward-related behavioral abnormalities (31). Altered emotion-cognition 
interaction plays an important role in dysregulated brain activity in PTSD (32). ACC is 
involved in generalized emotion- and cognitive-processing network, such as decision making 
(33, 34), emotion (35, 36) and impulse control (37). ACC integrates attentional and emotional 
processing and has been reported to be affected in PTSD. Neuroimaging studies revealed 
significant reduction in ACC volume (38) which might be related to attentional deficits and 
the inability to regulate emotions observed for PTSD patients. Furthermore, successful 
cognitive behavioral therapy leads to an increased activity of the right ACC (39) and larger 
rostral ACC was associated with PTSD symptom reduction (40). Another study reported 
reduced N-acetylaspartate (NAA) levels in the right ACC of PTSD patients, indicating neural 
integrity deficits (41). 
Recent clinical studies implicate an important role of the immune system in PTSD 
pathogenesis (42, 43). Lindqvist et al. showed that PTSD-afflicted male soldiers who had 
been exposed to combat have higher pro-inflammatory cytokine levels in the blood (44). Pro-
inflammatory cytokine injections into the brains of mice exposed to stress induce anxiogenic 
effects (45). Furthermore, increased microglial numbers were found in the ACC of adult male 
Sprague-Dawley rats exposed to chronic unpredictable restraint stress (46). Supporting these 
findings, in the present study we found increased expression of Cluster C8 genes, which are 
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involved in inflammatory and chemotaxis pathways, in the ACC of shocked mice 
(Supplementary Tables S2, S3). Chemokine ligand 5 (Ccl5), identified in cluster C8, is 
chemotactic and recruits leukocytes to inflammatory sites, induces proliferation of natural 
killer cells and activates an inflammatory response (47, 48). Increased neuroinflammation 
leads to demyelination and neurodegeneration which might be the cause for ACC volume 
loss in PTSD. In addition, immune response modulators have been implicated in functional 
synaptic plasticity (49). Several proinflammatory cytokines, including interleukin- (IL-) 6 (50, 
51), IL-1ß (52, 53), IL-8 (54) and interferon-α and ß (55, 56) regulate long-term potentiation 
in the hippocampus and improve long-term memory formation (57). In another study 
enhanced synaptic transmission via increased AMPA-receptor-mediated response in ACC 
neurons in rats with inflammation was observed (58). Taken together, it seems that 
inflammation induces perturbations in synaptic plasticity afflicting neurons associated with 
abnormal ACC activity, a phenomenon that has also been reported in PTSD patients when 
processing neutral and emotional information (59, 60). In summary, our findings reveal a 
long-lasting effect of inflammation in ACC which appears to result in structural and 
functional abnormalities in neurons. PTSD symptoms develop from days to weeks upon 
trauma exposure, indicating that chronic and propagated inflammation may be the underlying 
mechanisms for cognitive deficits and the inability of emotional control when confronted 
with trauma-related information is critical for PTSD development.  
Elevated inflammation has also been observed in dorsal ACC white matter of depressed 
suicidal individuals. Increased neuroinflammation involving macrophage recruitment and 
microglial priming in dorsal ACC may be associated with increased circulating pro-
inflammatory cytokines that have been reported for depressed patients (61). Setiawan et al. 
have provided further evidence that microglial activation is associated with major depressive 
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episodes. In addition, greater distribution volume of translocator protein density in ACC, a 
marker for neuroinflammation, correlated with greater depression severity (62). The results 
from our study on a PTSD mouse model provide further support for the notion that 
inflammation-induced perturbation in ACC plays an important role in the pathogenesis of 
psychiatric disorders.  
In the current study we found synchronized expression of genes within each cluster with 
cluster C4, C5, and C8 genes exhibiting significant alterations in the shocked mice (Figure 2). 
We therefore hypothesized that cluster C4, C5 and C8 genes are co-regulated by upstream 
transcription factors (TF). With the help of transcription factor binding site (TFBS) 
enrichment analysis we identified TFs for cluster C8 genes (Figure 3, Supplementary Table 
S4) which form a closely interconnected network (Supplementary Figure S3). Among the 
identified TFs, Spi1 regulates the majority of cluster C8 genes (Supplementary Table S5), 
enriched for inflammatory and chemotaxis pathways. SPI1 encodes PU.1 regulator and is 
involved in microglia activation and B-lymphoid cell development (63). Clinical and animal 
studies have shown an upregulation of immune response genes and regulatory regions, which 
are targeted by PU.1 in Alzheimer’s disease (AD) (64), suggesting its role in inflammation-
induced neurodegeneration in AD. Another study of a PTSD rat model from Daskalakis et al. 
(65) showed that Spi1 together with other TFs regulates stress-exposure-associated 
differentially expressed genes in the blood that are part of the glucocorticoid receptor 
signaling pathway. PU.1 regulator contains an ETS domain which interacts with Ets1 (66). 
Similar to SPI1, ETS1 regulates immune cell differentiation and cytokine expression (67). 
Furthermore, it was shown that upon cytokine activation Ets1 and NFκB work synergistically 
to transactivate downstream targets associated with inflammation (68). NFκB is the master 
transcriptional regulator of the immune response and is associated with neurogenesis (69). 
NFκB function can be manipulated through the activities of Toll-like-receptors (TLRs) (70, 
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71). In this regard Zimmermann et al. were able to show that peripheral administration of 
specific oligonucleotide activators of the innate immune receptor TLR9 can prevent 
posttraumatic symptoms in stressed mice (72). These findings implicate TLR9 as a key 
regulator of the pro-inflammatory NFκB pathway in posttraumatic anxiety. In accordance 
with previous studies, our findings support an important role for NFκB, Ets1, Spi1 as well as 
other TFs in the regulation of inflammatory gene expression associated with stress-related 
disorders. Our findings of an enrichment of inflammatory genes and their upstream TFs 
which have been reported to be associated with stress-related disorders lend further support to 
the hypothesis that the inflammatory response in ACC is involved in PTSD pathogenesis.   
A previous study reported a role of IL-1ß in the hippocampus after surgery in mice with 
postoperative cognitive dysfunction (73). Furthermore, elevated inflammation perturbs 
neurogenesis and is implicated in hippocampal volume loss and higher PTSD symptom 
severity in Gulf War veterans (74). Together with the current study, these findings indicate a 
possible role of inflammation in perturbed interconnection between ACC and hippocampus, 
which leads to dysregulated fear extinction learning signals and PTSD pathogenesis. 
Traumatic events induce lost-lasting changes in neurotransmitter signaling and synaptic 
plasticity in stress-vulnerable brain regions and have been implicated in the 
pathophysiological mechanisms of PTSD (75, 76). In this regard it has been suggested that an 
imbalance of gamma-aminobutyric acid (GABA) and glutamate is associated with 
hippocampal neuronal apoptosis in a PTSD animal model (77). In addition, clinical studies 
revealed lower glutamate levels in ACC in PTSD patients with alcoholism comorbidity (78). 
In our study we found a downregulation of genes that are enriched for neurotransmitter 
secretion, synapse and membrane integration pathways in CA1 and ACC of shocked mice 
(Clusters C4 and C5, Figure 2, Supplementary Table S3). This suggests that imbalanced 
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neurotransmitter secretion due to dysregulated synaptic vesicle function may be associated 
with abnormal CA1 and ACC activities and may contribute to deficits of fear extinction and 
cognition in shocked mice. Unlike for the inflammatory genes of Cluster C8 we were unable 
to find an enrichment of TFs for genes in clusters C4 and C5. We therefore submit that 
whereas an increased inflammation in ACC is mediated through upstream regulators, 
dysregulated neurotransmitter signaling may be a secondary phenomenon involved in PTSD 
development. Interestingly, we found that enriched PTSD-related genes of clusters C4, C5 
and C8 in the ACC of our mouse model resemble the expression pattern of a transcriptomics 
study on prefrontal cortex of autistic patients (79). Further investigation revealed that our 
PTSD mouse model- and autism-related alterations have a significant overlap in 14 genes 
(one-sided Fisher’s exact test p = 0.0067, odds ratio = 2.23). Furthermore, 13 of the 14 PTSD 
mouse model- and autism-related genes also exhibit consistent direction of change (one-sided 
Binomial test p = 0.0004), hinting that the underlying pathophysiological mechanisms of 
dysregulated inflammatory response and synaptic function are shared between PTSD and 
autism. 
Fluoxetine is a well-known SSRI antidepressant and has been officially approved for 
treatment of PTSD (84). Fluoxetine’s mode of action affects neurotransmission, 
neurofilament pathways, synaptic remodeling and neurogenesis (85-87). Previous studies 
with the same PTSD mouse model have demonstrated that fluoxetine treatment counteracts 
synaptic protein loss in hippocampus (88). In our study, chronic fluoxetine treatment 
ameliorates long-lasting conditioned fear response in the shocked mice (Figure 1) and rescues 
dysregulated inflammatory gene expression in ACC (Figure 4). Previous in vitro studies have 
demonstrated that fluoxetine suppresses production or expression of pro-inflammatory 
cytokines, such as TNF-α, IL-1ß and IL-6 by microglial cells (89-91). Furthermore, 
Obychowicz et al. showed that fluoxetine exerts anti-inflammatory properties in the CNS by 
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silencing overactivated glia upon lipopolysaccharide stimulation (92). In an animal of PTSD, 
rats were exposed to psychogenic stress and treated 1 hour later with minocycline, a 
tetracycline with anti-inflammatory and neuroprotective capacities (93). Minocycline 
attenuated anxious-like behavior and decreased IL-6 levels in frontal cortex, hippocampus 
and hypothalamus in stressed rats. In accordance with these previous findings our study 
showed that chronic fluoxetine treatment initiated 12 hours after shock application resulted in 
an anti-inflammatory effect in ACC and improved PTSD-like symptoms in shocked mice. 
Importantly, these effects were observed after discontinuation of treatment. Thus, early 
intervention with fluoxetine seems to prevent physiological and behavioral alterations 
resulting from stress exposure via its anti-inflammatory capacity in the CNS. 
In the current study, we identified gene clusters with significant changes, applied functional 
enrichment analysis and characterized their alterations in each brain region.  We were able to 
detect significant alterations at the transcriptome level that are related to synapse and 
inflammatory pathways in ACC and CA1. Another recently published transcriptomics study 
with a PTSD mouse model has found alterations in neuronal signaling pathways important 
for neurogenesis, cognition and extinction of fear memory in other brain structures involved 
in the fear response circuitry (94). The genome-wide analysis performed here significantly 
extends previous findings on the dysregulated inflammatory response and synaptic signaling 
in PTSD (42, 43, 76) by providing an unbiased systemic investigation of transcriptional 
alterations without acute prior challenge (i.e. tonic rather than phasic changes). We were also 
able to demonstrate that early intervention by fluoxetine treatment counteracts inflammatory 
gene expression and improves PTSD-like symptoms. Our findings provide novel insights on 
the role of the immune response in the CNS relevant for the pathogenesis of PTSD and 
suggest potential therapeutic mechanism that can be exploited with anti-inflammatory agents. 
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The knowledge of affected CNS inflammatory pathways is an important step towards clinical 
translation for improved diagnosis and treatment of PTSD. 
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Figure Legends 
Figure 1. Chronic fluoxetine treatment ameliorates conditioned fear response in shocked 
mice. Mice were exposed to neutral context, including cylindrically and hexagonally shaped 
plexiglass and shock context, a cubic-shaped chamber with metal grid for shock application. 
Shocked mice with fluoxetine treatment showed significantly decreased conditioned fear 
response in both neutral and shock contexts. N = 3 for each group. Two-way ANOVA 
analysis was applied and data are presented as mean ± SEM (* p < 0.05, ** p < 0.01, **** p 
< 0.0001). 
Figure 2. The gene expression level change of the 11 co-expressed clusters in the six brain 
regions. Upper panel: The tree represents the hierarchical clustering. Lower panel: For each 
brain region, one circle represents one cluster, with its radius proportional to the size of the 
cluster. Clusters with bold numbers represent gene clusters with significant expression level 
alterations. The X-axis represents the log10-transformed P value of Wilcoxon’s test, and the 
Y-axis represents the median of log2-transformed fold change of genes in the cluster between 
shocked mice and control mice samples. Clusters with significant gene expression level 
increase in the brain region are indicated in red, while clusters with significant gene 
expression level decrease are indicated in blue. ACC, anterior cingulate cortex; BLA, 
basolateral amygdala; CA1, cornu ammonis 1 of dorsal hippocampus; CeA, central nucleus 
of amygdala; NAc: nucleus accumbens; PrL, prelimbic cortex. 
Figure 3. Regulation of the PTSD-related genes by TFs. (A) Number of transcription factor 
binding sites (TFBSs) enriched among genes within each of the 11 co-expressed clusters. The 
grey bars represent the observed number of enriched TFBSs in each cluster (one-sided 
Fisher’s exact test, p < 0.05). The hashed bars represent the mean number of enriched TFBSs 
expected by chance, calculated by 1000 random assignment of the PTSD-related genes into 
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the 11 clusters with the same size as observed. Cluster C8 had significantly more enriched 
TFBSs than random cluster of the same size (* p < 0.05). (B) Number of transcription factors 
(TFs) with TFBSs enriched and correlated with the targets in the cluster (one-sided 
Wilcoxon’s test, Benjamini & Hochberg corrected FDR < 0.05). The hashed bars represent 
the mean number of enriched TFBSs expected by chance, calculated by 1000 random 
assignment of the PTSD-related genes into the 11 clusters with the same size as observed. 
Expression level of Cluster C8 genes showed a significant positive correlation with the 
enriched TFs (* p < 0.05). 
Figure 4. The rescue effect of fluoxetine in each brain region for each cluster. (A) The 
effective rescue for the co-expressed clusters. The cells representing the cluster with 
significant rescue effect in a certain brain region were marked with streaks. The red and blue 
cells represent the clusters with a significant increase and decrease expression alteration in 
the shocked mice compared to the control mice, respectively. (B) Gene expression patterns in 
co-expressed clusters C1, C4, C5 and C8. Gene expression alteration was rescued by 
fluoxetine treatment in ACC for control-vehicle (NS), shocked-vehicle (S) and shocked-
fluoxetine (SF) mice. 
Supplementary Figure S1. C57BL/6 mice were exposed to a single electric footshock and 
subsequently received treatment with either fluoxetine (20mg/kg/day) or vehicle (drinking 
water). On day 28, sensitized fear was measured by exposing the mice to neutral environment 
(cylinder plus tone displayed). After a 28-day drug-washout period, the intensity and 
specificity of conditioned fear response was investigated by exposing mice to cylinder plus 
tone on day 56, shock context (shocking chamber without shock application) and hexagonal 
context with grid floor as shock reminders on day 57. Mice were sacrificed one week after 
conditioned fear response evaluation. 
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Supplementary Figure S2. The average expression pattern of the 11 co-expressed clusters 
for vehicle-treated mice. The white boxes represent control (NS) mice, and the black boxes 
represent shocked (S) mice. 
Supplementary Figure S3. The crosstalk among transcription factors (TFs) with 
transcription factor binding sites (TFBSs) enriched in cluster C8. The network was generated 
using EdgeExpressDB in FANTOM 4. 
Supplementary Figure S4. The average expression pattern of the 11 co-expressed clusters 
across control-vehicle (NS), shocked-vehicle (S), and shocked-fluoxetine (SF) mice. 
Supplementary Table S1. Sample and read mapping information. 
Supplementary Table S2. PTSD-related expressed genes and hierarchical clustering result. 
Supplementary Table S3. The enriched functional terms of each co-expressed cluster output 
by DAVID. 
Supplementary Table S4. The enriched TFBSs with the corresponding TFs that 
significantly correlated with genes in the respective cluster. 
Supplementary Table S5. Transcription factor targeted genes in cluster C8. 
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Norepinephrine and corticosterone in the medial prefrontal
cortex and hippocampus predict PTSD-like symptoms in
mice
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Abstract
This study measured changes in brain extracellular norepinephrine (NE) and free corticosterone (CORT) levels in a mouse model
of post-traumatic stress disorder and related them to hyperarousal and fear memory retention. To this end, microdialysis in the
medial prefrontal cortex (mPFC) and the hippocampus (HPC) of male C57BL/6NCrl mice was performed during an acoustic
startle response (ASR) and following an electric foot shock (FS), as well as during an ASR and recall of contextual fear (CF)
1 day later. Changes in ASR-stimulated NE levels in the mPFC corresponded to ASR 34 days after FS. Changes in basal and
ASR-stimulated extracellular NE levels in the HPC, in contrast, were related to expression of early (day 2) and late (day 34) CF
after FS. The increase in extracellular NE levels correlated in a U-shape manner with arousal levels and CF, thus suggesting a
non-direct relationship. Stress of different modalities/strength (ASR, FS and CF) caused a similar relative increase in free CORT
levels both in the mPFC and the HPC. One day after FS, ASR-induced increases in the CORT content in the mPFC tended to
correlate with the FS-potentiated ASR in a U-shape manner. Taken together, these data show that the intracerebral increase in
free CORT was likely related to an immediate response to stress, whereas NE neurotransmission in the forebrain predicted arou-
sal and CF 1 month after trauma.
Introduction
Hallmark symptoms of post-traumatic stress disorder (PTSD) are the
retention of trauma memory, which is expressed in a specific and
contextual fear (CF), hyperarousal, and reactive depression (Ameri-
can Psychiatric Association, DSM-IV-TR, 2000). Dysregulation of
hypothalamic–pituitary–adrenal (HPA) axis activity is critically
involved in PTSD pathophysiology. Clinical studies have shown that
patients with PTSD exhibit abnormal corticotrophin-releasing factor
levels in cerebrospinal fluids and elevated cortisol levels in 24-h
urine samples (Pitman & Orr, 1990; Bremner et al., 1997a; Baker
et al., 1999). Under stressful conditions, an increase in norepineph-
rine (NE) signaling significantly contributes to HPA axis activation.
However, it is still unclear to what extent NE-mediated cognitive
effects are independent of its influence on stress hormones release
(Ma & Morilak, 2005; Morilak et al., 2005).
Abnormality in adrenergic signaling has been linked to the sever-
ity of PTSD symptoms (Geracioti et al., 2001). Previous studies
showed that facilitation of adrenergic signaling with the a2-selective
antagonist yohimbine increased anxiety in patients with PTSD
(Bremner et al., 1997b; Southwick et al., 1997). In addition, consol-
idation of memories associated with emotional events was mediated
by activation of the norepinephrinergic system in animals (Soeter &
Kindt, 2011; Barsegyan et al., 2014). Nonetheless, administration of
the b-receptor antagonist propranolol showed mixed results both in
clinical trials and in animal models of PTSD (Pitman et al., 2002;
Stein et al., 2007; Cohen et al., 2011; Debiec et al., 2011).
NE is involved in sleep, vigilance and arousal, as well as atten-
tion, learning and memory in a structure-dependent manner. In the
medial prefrontal cortex (mPFC), increased NE neurotransmission
facilitates cognitive performance. Because cognitive performance
contributes to coping with stress, a dual role of NE, both adaptive
and deteriorating, in the mediation of the post-stress endophenotype
has recently been proposed and studied (Lapiz & Morilak, 2006; Jett
& Morilak, 2013).
Other evidence points to a significant NE and cortisol interaction,
but fails to show any independent effects of NE signaling and sali-
vary cortisol levels in the prediction of negative intrusive memories
in patients with PTSD (Nicholson et al., 2014). It was hypothesised
that the assessment of brain NE and corticosterone (CORT) levels is
able to predict distinct PTSD outcomes. In the present study, a
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mouse model of electric foot shock (FS)-induced PTSD was
employed (Siegmund & Wotjak, 2007) in C57Bl/6N mice particu-
larly susceptible for developing PTSD-like symptoms (Golub et al.,
2009; Pamplona et al., 2011; Herrmann et al., 2012), and the tem-
poral profile of NE release and free CORT levels in the mPFC and
the hippocampus (HPC) during and after acoustic startle response
(ASR), FS and CF was evaluated. The effect of stress on NE release
in relation to HPA axis activation was compared by performing
dynamic measurements of free CORT levels. In addition, immediate
and delayed changes in arousal and fear memory retention induced
by FS were assessed.
Materials and methods
Animals
Male C57BL/6NCrl mice, 7–8 weeks old (66 animals; Charles River
GmbH, Sulzfeld, Germany) were housed in groups of four in Makr-
olon type II cages (23 9 16.5 9 14 cm3) under an inverse
12 : 12 h light : dark cycle (light off at 07:00 h) with food and
water ad libitum. Experimental procedures were approved by the
Government of Upper Bavaria. Laboratory animal care and experi-
ments were conducted according to the regulations of the current
version of The German Animal Welfare Act.
PTSD model validation
The outline of the PTSD model validation experiment is presented
in Fig. 1A. The level of arousal was assessed on day 30, and CF
memory was measured in shocked mice (see the protocol in the
respective section) on day 32 (ASR30 and CF32) after FS in con-
trast to the non-shocked control group.
Microdialysis/PTSD experiment
The outline of the microdialysis experiment is presented in Fig. 1B.
On experimental day 1, mice were subjected to a 20-min ASR test
(ASR1) in a sound-protected environment. Two hours later, mice
were subjected to FS (see next section). On experimental day 2,
mice were recurrently tested for ASR (ASR2) and re-exposed to the
FS chamber for CF examination (CF2) 2 h later. The dialysate frac-
tions corresponding to the periods of Basal 1 (samples 1–3), ASR1/
recovery (samples 4–7) and FS1/recovery (samples 8–11) on experi-
mental day 1, and Basal 2 (samples 1–3), ASR2/recovery (samples
4–7) and CF2/recovery (samples 8–11) on experimental day 2 were
collected. The levels of arousal and CF memory were assessed on
day 34 (ASR34 and CF34).
Fear conditioning and fear recall
Fear conditioning (administration of the FS in the shock chamber
with house light on) was performed during the active phase accord-
ing to a previously published protocol for the PTSD mouse model
(Siegmund & Wotjak, 2007). Mice were conditioned in a Plexiglas
cage (16 9 16 9 32 cm3) with a grid harness package (ENV-407,
ENV-307A; MED Associates, 7 St Albans, VT, USA) connected to
a shock generator (Shocker/Scrambler: ENV-414; MED Associates).
After 198 s of habituation, animals underwent two electric FSs
(1.5 mA, 2 s long) at moderate illumination (40 Lux) with a 60-s
interval inbetween. Animals remained in the shock chamber for
another 60 s before being returned to their home cages. CF (shock
chamber + light) memory was examined by evaluation of the freez-
ing response in the FS chamber at the same illumination intensity.
ASR
To test for arousal levels, ASRs were measured automatically as
described before (Golub et al., 2009; Yen et al., 2012). Mice were
placed into a Plexiglas enclosure, acclimated to the apparatus for
5 min and then presented to 136 startle pulses with interpulse
intervals (IPI) of 13–17 s. The intensities of white noise were 75,
90, 105 and 115 dB with 30 startle trials at each level in a pseudo-
random order. Additionally, animals’ startle responses were recorded
16 times under background noise. To permit a continuous dialysis
in the microdialysis experiments, a custom-made startle chamber
equipped with a commercially available ASR apparatus was used
(San Diego Instruments, San Diego, CA, USA). Response was
expressed either in mV (PTSD validation experiment) or in arbitrary
units (microdialysis experiment). At the end of each test, Plexiglas
cylinders and chamber were cleaned thoroughly with soap water.
Brain microdialysis
Microdialysis was performed as described before (Anderzhanova
et al., 2013). Guide cannulas were implanted into the right mPFC
(coordinates: AP +2.20 mm, ML 0.35 mm and DV 1.50 mm) or
the right HPC (coordinates: AP 3.0 mm, ML 3.00 mm and DV
1.80 mm) under isoflurane (Abbot, India)/Metacam (Boehringer
Ingelheim GmbH, Germany) anesthesia/analgesia, in accordance
with Paxinos & Franklin (2001). Recovery in experimental Plexiglas
home cages (16 9 16 9 32 cm3) lasted for 1 week and included
Metacam supplementation, 0.25 mg/100 mL with drinking water,
for 3 days after surgery, with daily inspection of food intake.
One day before the experiment, mice were shortly anesthetised
with isoflurane. Microdialysis probes (o.d. 0.2 mm, cuprophane
membrane 2 mm long, MAB 4.15.2.Cu, Microbiotech/se AB, Swe-
den, for the mPFC; and o.d. 0.24 mm, cuprophane membrane 3 mm
long, CMA 11, CMA Microdialysis, Sweden, for the HPC) were
inserted and connected to the perfusion lines consisting of FEP tub-
ing and low-volume liquid swivel TCS2-23 (Eicom, Japan). From
the moment of insertion, probes were continuously perfused with
sterile artificial cerebrospinal fluid (concentrations in mM: NaCl,
145; KCl, 2.7; CaCl2, 1.2; MgCl2, 1.0; Na2HPO4, 2.0; pH 7.4) at a
FS/NS ASR30 CF32
FS1ASR1 CF2ASR2 CF34ASR34
Microdialysis Microdialysis
A
B
Day 1 Day 30 Day 32
Day 1 Day 2 Day 34
Fig. 1. (A) Experimental outline for the PTSD model validation. PTSD-like
endophenotype was evaluated by acoustic startle response (ASR) on day 30
(ASR30) and contextual fear (CF) response on day 32 (CF32) after foot
shock (FS). Control mice remained non-shocked (NS). (B) Outline for micro-
dialysis experiment with PTSD model. On experimental day 1, mice were
subjected to acoustic startle stimulation (ASR1), followed by fear condition-
ing protocol (FS1). On experimental day 2, mice were subjected to recurrent
ASR2 and exposed to FS chamber for CF recall (CF2). The strength of fear
conditioning was further examined 34 days after the FS (ASR34 and CF34).
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flow rate of 0.3 lL/min. On experimental days 1 and 2, following a
1.5-h equilibration period, microdialysis fractions (30 min) were
constantly collected into 300-lL microtubes (Microbiotech/se AB,
Sweden) containing 3 lL of 0.4 M perchloric acid at a perfusion rate
of 1.5 lL/min. During collection time, tubes were kept in a refriger-
ated Univentor 820 Microsampler (Univentor, Malta). The dead vol-
ume of the outlet line was compensated by a delay in fraction
harvesting (7 min). The perfusion flow rate was reduced to 0.3 lL/
min for ongoing overnight perfusion. Once collected, samples were
split into two equal aliquots for monoamine and CORT quantifica-
tion, and stored at 80 °C prior to analysis. Each microdialysis
probe was removed from the mouse brain after finishing the sample
collection.
NE analysis
NE content in the microdialysates was determined by reversed-phase
high-performance liquid chromatography (HPLC) with electrochemi-
cal detection (UltiMate3000 HPLC system/Coulochem III, Thermo-
Fischer, USA). All reagents used for the phosphate-citrate mobile
phase (methanol 10 %, pH 5.6) were of analytical grade (Carl Roth
GmbH or MERCK KGaA, Germany). Monoamines were separated
on an analytical column (C18, 150 9 3 mm, 3 lm; YMC Triart,
YMC Europe GmbH, Germany) at a flow rate of 0.4 mL/min. The
potentials of the working electrodes were set at 75 mV, +250 mV,
and the guard cell potential was set at +350 mV. NE concentrations
were calculated by external standard curve calibration using the peak
area for quantification. Those NE data that were lower than the
detection limit of 0.05 nM were excluded from further analysis,
which may result from inefficient microdialysis probes.
CORT analysis
The microdialysis membrane strictly limits the passage of conju-
gated CORT into the probe. Therefore, the microdialysates’ content
reflects only changes in the free CORT levels. Free CORT in the
microdialysates was measured by radioimmunoassay (RIA kit, MP
Biomedicals, USA). The detection limit was 7.7 ng/mL, and the
coefficients of variation of inter-assay and intra-assay were 6.9%
and 7.3%, respectively. Microdialysates were diluted 2.5-fold and
CORT content was determined using a standard calibration curve.
Histology
The targeted regions of the mPFC and the HPC are depicted in the
schematic representation of the respective brain coronal sections
(Fig. 3A and E). Because the microdialysis probes only transiently
remained in the brain whereas animals were kept 1 month after
removal, the placement of the microdialysis membrane could not be
reliably visualised due to tissue recovery. An approximate estimation
of the microdialysis membrane placement was possible by looking
at the guide cannula residual tracks in the histological sections
stained with Cresyl violet.
Data analysis
The working hypothesis of this study was that basal and stimulated
NE and CORT levels correspond to the long-term behavioral out-
come. Median split, a simple and conservative criterion, was used to
group animals in accordance with NE and CORT levels. Only data
significantly different from median (out of median  5% range)
were used to assign animals to low- and high-level cohorts.
Normalization of neurochemical data was performed as in
Hinkelmann et al. (2010) with slight modifications. This algorithm
employs a comparison of running values (xi) and measure of the last
30 min of the baseline period (x3), applying the following equation:
xi(%) = 200(xi2)/(xi2 + x32). The data are expressed as mean 
SEM. Two-way ANOVA with Bonferroni post hoc test was used for
the microdialysis data, with brain region (mPFC and HPC) or exper-
imental day (day 1 and day 2) as the between-subjects factors, and
time as the within-subjects factor. The ASR and CF data were anal-
ysed employing a two-tailed Student’s t-test. Fitting linear models
approach was applied for the linear and polynomial (quadratic)
regression correlation analysis, with neurochemical measure (NE/
CORT) as the argument and behavioral readouts as the function (R
package, version 3.1.0, http://www.r-project.org).
Results
Validation of PTSD model
To confirm the FS protocol, two behavioral parameters representing
symptoms of PTSD-like endophenotype were examined, and non-
shocked (NS, n = 16) were compared with shocked (FS, n = 16)
mice who had not undergone surgery. FS (1.5 mA, 2 s, twice)
evoked hyperarousal, which was manifested in the elevated arousal
(ASR30) 1 month after FS [two-way ANOVA (shock 9 intensity)
F1,3 = 16.81, P = 0.0003; Fig. 2A]. Shocked mice showed a strong
CF memory (CF32; twofold increase in the freezing response) in
comparison to non-shocked mice when exposed to the shock context
32 days after FS [Student’s t-test (two-tailed): t30 = 3.098,
P < 0.01; Fig. 2B].
Stressors (ASR, FS and CF) transiently increase NE and
CORT in the mouse forebrain
Prefrontal and hippocampal NE and CORT levels were evaluated by
microdialysis in different cohorts of mice under basal condition, and
upon ASR1 and FS1 or ASR2 and CF2 on days 1 and 2, respec-
tively. Absolute mean basal extracellular NE levels were
0.84  0.06 nM and 0.16  0.01 nM in the mPFC and the HPC,
respectively. Absolute mean basal extracellular CORT levels were
286.2  33.11 ng/mL in the mPFC and 581.8  48.86 ng/mL in
the HPC. ASR1 and FS1 as well as ASR2 and CF2 were accompa-
nied by increased extracellular NE levels in the mPFC (Fig. 3B)
and the HPC (Fig. 3F). Two-way ANOVA (time, day) showed signifi-
cance of time for both the mPFC (F1,10 = 2.93, P = 0.0023) and the
HPC (F1,10 = 2.69, P = 0.0054). Post hoc analysis revealed that the
magnitude of stress-induced NE release in the mPFC on day 2 was
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Fig. 2. PTSD mouse model validation. Foot shock (FS) resulted in facilita-
tion of the acoustic startle response (ASR) (A) and retention of contextual
fear (CF) memory (B) measured on days 30 and 32 in shocked (FS, closed
circles) and non-shocked (NS, open circles) mice. **P < 0.01;
***P < 0.001. SPL, sound pressure level.
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lower than on day 1 (microdialysis fractions 5 and 9, P < 0.05; frac-
tion 6, P < 0.01). The extracellular CORT levels similarly increased
following ASR1 and FS1 on day 1 and ASR2 and CF2 on day 2 in
the mPFC (time: F1,10 = 21.23, P < 0.0001; Fig. 3C) and the HPC
(time: F1,10 = 58.95, P < 0.0001; Fig. 3G).
The dynamics of relative changes in the NE release and free
CORT content in the mPFC and HPC were juxtaposed. Stressors of
different modalities (ASR1 and FS1 on day 1, and ASR2 and CF2
on day 2), exhibiting significance of the time effect in two-way ANO-
VA, increased the extracellular NE and CORT levels in both the
mPFC (day 1, F1,10 = 6.021, P < 0.0001; day 2, F1,10 = 19.41,
P < 0.0001; Fig. 3D) and the HPC (day 1: time, F1,10 = 12.72,
P < 0.0001; day 2: F1,10 = 5.676, P < 0.0001; Fig. 3H). Notably,
the NE and CORT level peaks were not completely synchronous.
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Fig. 3. Microdialysis data. The schematic diagrams show the targeted areas for microdialysis probe implantation in the medial prefrontal cortex (mPFC) (A)
and the hippocampus (HPC) (E). The computer-based atlas by Paxinos & Franklin (2001) was used to mark probe locations; numbers refer to distances from
the bregma, mm. Stress [acoustic startle response (ASR) and foot shock (FS) on day 1, ASR and contextual fear (CF) on day 2] evoked extracellular norepi-
nephrine (NE) release in both the mPFC (B) and the HPC (F) on day 1 (closed circles) and day 2 (open circles). Dynamics of NE release were comparable on
days 1 and 2 in the HPC, but not in the mPFC. Asterisks depict a difference in the magnitude of the NE release in the mPFC revealed by post hoc test
(*P < 0.05, **P < 0.01). An increase of free corticosterone (CORT) levels concurred with the stress (ASR1, FS1, ASR2 and CF2) on day 1 (closed circles)
and day 2 (open circles) both in the mPFC (C) and the HPC (G). Arrows point to the samples corresponding to the ASR, FS and CF procedures. Vertical
dashed lines separate basal sample collection period and the epochs corresponding to the aforementioned stressful procedures. Stressors of different modalities,
ASR1 and FS1 on day 1, and ASR2 and CF2 on day 2, significantly increased the extracellular NE (closed circles, solid lines corresponding to right y-axis)
and CORT levels (open circles, dashed lines corresponding to left y-axis) in both the mPFC (D) and the HPC (H). However, NE release and CORT accumula-
tion peaks were not synchronised. Arrows point to the samples corresponding to the ASR, FS and CF procedures. Vertical dashed lines separate basal sample
collection periods and the epochs corresponding to the aforementioned stressful procedures. For statistical analysis, see the ‘Results’ section.
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While NE levels peaked 30 min after a stressor onset and then
declined, CORT levels reached at maximum values 60 min after
stress and stayed elevated for a longer time (two-way ANOVA, day 2
in the mPFC: NE/CORT: F1,10 = 0.74, P = 0.4041; time 9 NE/
CORT: F1,10 = 13.45, P < 0.0001; day 1 in the HPC: NE/CORT:
F1,10 = 2.19, P = 0.1564; time 9 NE/CORT: F1,10 = 7.087,
P < 0.0001; day 2 in the HPC: NE/CORT: F1,10 = 6.861,
P = 0.0174; time 9 NE/CORT: F1,10 = 5.923, P < 0.0001). Only
on day 1 did the courses in the NE and CORT levels in the mPFC
overlap (two-way ANOVA, NE/CORT: F1,10 = 0.06, P = 0.8130;
time 9 NE/CORT: F1,10 = 2.872, P = 0.0034). Importantly, the
measurements were done with the same samples excluding a
method-related shift.
Taken together, these data show that the NE system and the HPA
axis readily respond to recurrent different environmental challenges
with similar strength.
Changes in cortical and hippocampal NE and CORT levels
are differentially involved in the expression of hyperarousal
and CF
The changes in NE (%) and CORT (pg/mL) levels expressed as
means of the area under the curve were considered corresponding to
the following epochs: Basal 1 or Basal 2 (samples 1–3); ASR1 or
ASR2 (samples 4–7), FS1 (day 1 samples 8–11) and CF2 (day 2
samples 8–11).
First, the animals were grouped into low- and high-ASR2 NE or
ASR2 CORT cohorts by median split criterion (Fig. 4A2 and B2).
In the fear-conditioned mice with higher ASR2 NE in the mPFC,
the ASR34 was lower (Student’s t-test, t10 = 2.481, P = 0.0325),
indicating a lower degree of fear-induced hyperarousal (Fig. 4A3).
ASR2 NE in the HPC failed to show a similar relationship (Stu-
dent’s t-test, t8 = 0.6761, P = 0.5180; Fig. 4A3). In contrast to NE
groups, mice with higher CORT accumulation in the mPFC upon
ASR2 tended to show higher arousal on day 34 (Student’s t-test,
t11 = 2.134, P = 0.0562; Fig. 4B3).
Next, mice were grouped into low- and high-Basal 2 NE
(Fig. 5A2) or ASR2 + CF2 NE (Fig. 5B2). After fear conditioning,
mice with higher Basal 2 NE in the HPC showed less CF both on
day 2 (Student’s t-test: t8 = 2.562, P = 0.0335; Fig. 5A3) and on
day 34 (Student’s t-test: t8 = 2.366, P = 0.0455; Fig. 5A4). This
was not the case in the mPFC. In contrast, mice with high hippo-
campal ASR2 + CF2 NE showed elevated CF on day 2 (Student’s
t-test: t8 = 2.566, P = 0.0333; Fig. 5B3) and a tendency to express
higher CF on day 34 (Student’s t-test: t8 = 1.997, P = 0.081) com-
pared with mice with low ASR2 + CF2 NE (Fig. 5B4).
NE and CORT levels independently correspond to
hyperarousal and CF in a U-shape manner
The correlations between the total NE release (ASR1 + FS1 NE or
ASR2 + CF2 NE) and levels of arousal (ASR34) or CF (CF34)
1 month after FS were examined. It was observed that in the mPFC,
NE release during stress in na€ıve mice (ASR1 + FS1) correlated
with the hyperarousal in a U-shape manner (residual standard
error = 333.5, adjusted R2 = 0.3133, P = 0.061; Fig. 6A) on day
34. In the HPC, NE release upon repeated stressor presentations
(ASR2 + CF2) correlated with the CF response on day 34 (CF34)
in an inverted U-shape manner (residual standard error = 12.54,
adjusted R2 = 0.5616, P = 0.023; Fig. 6B).
It was found that CORT accumulation in the mPFC during ASR2
showed a strong tendency to correlate with FS-potentiated ASR
(ASR2/ASR1, %) in a U-shape manner (residual standard
error = 45.28, adjusted R2 = 0.344, P = 0.09; Fig. 7A). No correla-
tion between changes in CORT accumulation during ASR1 and
ASR2 was found (data not shown). Interestingly, basal and stress-
stimulated CORT levels did not correlate on day 1, while recurrent
stress showed a linear correlation between basal and stimulated lev-
els (R2 = 0.3958, P = 0.0022; data not shown). ASR2 NE in the
mPFC showed no correlation with FS-potentiated ASR (residual
standard error = 52.46, adjusted R2 = 0.041, P = 0.498; Fig. 7B).
Discussion
Forebrain NE and CORT levels and long-term PTSD-like
symptoms in mice
In the present study, it was initially assumed that the magnitude of
the innate ASR might be a predictor for long-term PTSD-like symp-
tom severity in mice. However, it was not possible to find any cor-
relation between ASR1 and the PTSD-like symptom strength
(P = 0.1223 for ASR34 and P = 0.3662 for CF34, data not shown).
Based on recent reports (Salehi et al., 2010; Nicholson et al., 2014),
it was hypothesised that level changes of stress mediators, specifi-
cally NE and CORT, serve as predictors for the PTSD endopheno-
type. Correlations between the stress-stimulated neurochemical
changes or the concurrent hormonal output in the mouse brain and
the acute/delayed arousal (ASR1, ASR2 and ASR34) or the strength
of aversive memories (CF2 and CF34) induced by FS were evalu-
ated. ASR2 NE levels in the mPFC on day 2 after FS were inver-
sely related to the hyperarousal assessed on day 34. NE levels in the
HPC upon challenges on day 2 were positively related to the CF on
days 2 and 34 after FS. U-shape relationships between the NE levels
during peri-FS stress and the long-term PTSD-like symptoms were
also observed, and between the free CORT contents during post-FS
stress and the acute changes in arousal.
NE signaling in the mPFC predicts emotional response to
stress
All kinds of stressors induce NE release from locus coeruleus (LC)
neurons in the upstream forebrain regions, including the PFC and
the HPC (Robertson et al., 2013), structures that are tightly involved
in the regulation of emotions and cognition.
In these experiments, ASR1, FS1, ASR2 and CF2 resulted in a
moderate increase (up to 200%) of extracellular NE levels. A faster
return of the mPFC NE levels to basal values in case of recurrent
stress (ASR2) was observed on the second experimental day com-
pared with the period of the first startle measurement (ASR1). The
difference in the NE release on days 1 and 2 cannot directly result
from acute changes in HPA axis activity, as the corresponding free
CORT levels showed the same elevations in the mPFC as well as in
the HPC (Fig. 3C and G). Nonetheless, under acute stress, NE neu-
rons in the LC show neuroplasticity both at the levels of neuronal
activity and of neurotransmitter release, which may differ from the
effects induced by chronic stress (Hajos-Korcsok et al., 2003; Je-
dema et al., 2008). Stress could induce a selective increase in a2-
adrenergic receptor activity in the mPFC and/or LC with respective
stronger suppression of the NE release via a feedback mechanism.
Reyes et al. (2012) showed the re-sensitization of a2-adrenergic
receptors due to interaction with CB1 cannabinoid receptors. Eleva-
tion in endocannabinoid levels induced by priming stress (Hillard,
2014) may therefore contribute to the decrease in NE release in the
mPFC upon the recurrent stress.
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Employing the low- and high-NE-level selection criterion, an
inverted relationship between the magnitude of the NE release in
the mPFC during repeated ASR and the arousal on day 34 was
shown (Fig. 4A). It is known that stress-induced enhancement of
NE neurotransmission bidirectionally modulates mPFC functions.
An increase of NE signaling leads to a reduction in the cognitive
set-shifting in the chronic unpredictable stress paradigm (Morilak
et al., 2005; Jett & Morilak, 2013). On the other hand, an increase
in NE neurotransmission favors stress resistance (Bondi et al.,
2010). The negative relationship between NE levels and FS out-
come found in this experiment is in line with these earlier results.
Upon further analysis, a U-shape function of the prefrontal NE
release on experimental day 1 and ASR34 was observed (Fig. 6A).
The middle NE levels in the mPFC may therefore favor an adap-
tive response, as they coincide with minimal ASR facilitation on
day 34. It was hypothesised that the extreme changes in NE neu-
rotransmission in the mPFC either do not provide an optimal atten-
tional lever to discriminate important and unimportant
informational input or promote unspecific hypervigilance. This
finding is in accordance with a previous report about an inverted
U-shape relationship between the LC neuron activity and the per-
formance of tasks that required focused attention (Aston-Jones &
Cohen, 2005). Lapiz & Morilak (2006) showed that the systemic
pretreatment with the a2-adrenergic receptor antagonist atipamezole
significantly improved the performance of an attentional task that
was blocked by the a1-blocker benoxathian microinjected in the
mPFC. Moreover, the a1-/a2-receptor-specific regulation of the
emotional and habitual responses of the amygdala and the basal
ganglia seems to depend on the extent of NE release in the mPFC
(Arnsten et al., 2015). This suggests a fine balance between the
activation of different subtypes of adrenergic receptors, which may
underlie the U-shape NE function. It also points to a critical range
of endogenous neurotransmitter release for the optimal task perfor-
mance and the top-down control of emotional states.
Overall, these results suggest a bimodal role of NE neurotransmis-
sion in the mPFC that regulates the arousal level after FS.
NE signaling in the HPC relates to CF memory
The HPC receives dense projections from the LC (Schroeter et al.,
2000). This anatomical connection supports the general role of NE
in learning/memory (Barsegyan et al., 2014; Yan et al., 2014).
Several studies have indicated the differential involvement of the
HPC NE in fear memory acquisition, consolidation and retrieval
(Fiorenza et al., 2012; Zhang et al., 2013). In this study, mice
with higher NE release in the HPC during repeated ASR and re-
exposure to FS context (ASR2 + CF2 NE) showed stronger acute
and long-term CF (CF2 and CF34; Fig. 5B3 and B4). This corrob-
orates previous reports showing that NE signaling in the HPC
mediates the effects of arousal on memory (Urry et al., 2006;
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Cerqueira et al., 2007), affects memory consolidation associated
with emotional stimulation (Izquierdo & Medina, 1997), and inter-
feres with CF memory mechanisms (Thomas & Palmiter, 1997;
Murchison et al., 2004).
Previous studies suggested the inverted U-shape dependence of
early learning and memory in HPC-dependent tasks on the stressor
intensity (Salehi et al., 2010). NE regulates fast neuromediator sig-
naling [glutamate and c-aminobutyric acid (GABA)-mediated], both
increasing and decreasing its efficiency that depends on the recep-
tors involved (Pralong et al., 2002). The innate difference in b-
adrenergic receptor activity in the HPC might play a role mediating
the U-shape relationship between fear memory and NE levels (Intro-
ini-Collison et al., 1994). In this study, the inverted U-shape rela-
tionship between stress (ASR2 + CF2)-stimulated NE level increase
in the HPC and CF memory retrieval were observed (CF34;
Fig. 6B), suggesting that intermediate NE levels promoted fear
memory consolidation. Without considering the specifics of the
memorised event, it is inappropriate to speculate about the adaptive
vs. maladaptive impact of NE. Because the HPC is involved in all
types of memory, particularly the contextual component of each
event, the middle level increase in NE levels might be considered
adaptive. The dysadaptive or adaptive character of the strong mem-
ory may be weighted only with respect to the memory modality.
Moreover, the inverted U-shape relationship between conditioned
fear expression and fear potentiated startle was shown in clinical
PTSD studies, suggesting beneficial consequences of optimal fear
level (Norrholm et al., 2014).
Taken together, these results suggest a defined range of NE neu-
rotransmission facilitation (120–170%) that mediates stress-induced
HPC-dependent CF memory.
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The role of CORT in the mPFC in mediation of hyperarousal
after FS
In contrast to the expectations of this study, stressors of different
modalities applied to either na€ıve (ASR1, FS1) or stressed mice
(ASR2, CF2) induced similar relative free CORT level increases in
both mPFC and HPC. This does not support a differential modula-
tion of the CORT level with respect to stressors, and neither sug-
gests sensitization nor desensitization/habituation of the HPA axis.
The current analytical approach based on group assignment
according to low and high values failed to demonstrate that free
CORT levels (ASR2 CORT) are strong predictors of FS outcome.
Higher ASR2 CORT levels in the mPFC only tended to correspond
to stronger fear-potentiated ASR34 (Fig. 4B3). It is known that in
the HPC, formation of memories and inhibition of unrelated infor-
mation are associated with CORT-mediated long-term potentiation
suppression and long-term depression facilitation (Karst et al., 2005;
Jo€els et al., 2006). In the amygdala, CORT gates the nucleus activ-
ity (Daskalakis et al., 2014). Elevation of CORT in the mPFC dur-
ing ASR2 would specifically favor modulation of cortical activity to
increase the next sensory input. This assumption goes along with
clinical studies showing that glucocorticoid (GC) administration in
doses corresponding to stress levels impaired delayed, but not imme-
diate, recall of episodic task performance (Wolf et al., 2001; Buss
et al., 2004).
In clinical studies, PTSD patient cortisol levels were found mostly
unchanged, but also either increased or decreased (Pitman & Orr,
1990; Yehuda et al., 1990; Eckart et al., 2009). This phenomenon
may have biological significance reflecting a dose-dependent effect
of stress hormones. A U-shape relationship between the individual
stimulated (ASR2) CORT levels and the FS-potentiated ASR
(ASR2/ASR1) was observed in the mPFC, but not in the HPC
(Fig. 7A). Even though brain CORT originates from the blood pool
and its levels should be similar in each brain region, the free hor-
mone’s content appears to be different between structures. Possible
inter-individual differences in the kinetics of the CORT–GC recep-
tors (GRs) interaction, in CORT metabolism as well as in physical
properties of brain tissue matrix (Croft et al., 2008; Little et al.,
2008), may contribute to a variation of free CORT levels between
different regions and explain the U-shape relationship with behav-
ioral readouts that was only found in the mPFC.
This observation agrees with the reported inverted U-shape rela-
tionship between stress levels and HPC-dependent learning (Salehi
et al., 2010), with the former also corresponding to CORT level
increases in blood. This may point to an involvement of CORT-
dependent hyperarousal in learning. Furthermore, changes in CORT
levels showed a limited ability to predict FS outcome in this geneti-
cally homogeneous mouse population (Fig. 4B3).
Post-FS NE and CORT levels predict long-term PTSD-like
symptoms
Notably, NE and CORT levels 1 day after the FS in most cases pre-
dicted the long-term FS outcome (elevated CF34 and ASR34; Figs 4–
6). Experimental day 1 levels on the other hand were less informative.
It was assumed that synaptic plasticity mechanisms could underlie this
phenomenon. Moreover, the strength of the acute stressor on day 1
was likely exceeding the physiological threshold. Therefore, the neu-
rochemical responses might not predict the individual differences in
response to stress (FS). However, upon priming stress, the plasticity
mechanisms of the NE/CORT system in the mPFC and the HPC were
well tuned to allow the prediction of long-term stress responses (hy-
perarousal and CF). The predictor properties of NE and CORT
showed strong time- and structure-dependency.
CORT level increases initiate the differential regulation of its
downstream targets, including several neurotransmitter systems and
elements of HPA axis regulation. CORT-induced differences in the
activity of downstream targets will determine the profile of CORT-
mediated effects during the next episode of hormone release.
Diverse systems regulating the biological activity of CORT were
considered. Firstly, two types of receptors mediate GC actions in the
brain, namely mineralocorticoid receptors (MRs) and GRs. MRs and
GRs exhibit differences in binding affinity to GC and expression
levels in distinct brain regions (Veldhuis et al., 1982). This dual
system may work in opposite directions regulating the behavioral
response (Pavlides et al., 1995). Secondly, CORT bound to cortico-
sterone-binding globulin (CBG) is believed to be biologically inac-
tive (Breuner & Orchinik, 2002). CBG levels, like CORT levels, are
not static and were shown to decrease in response to stress (Fleshner
et al., 1995). It is therefore conceivable that non-congruent changes
in CORT and CBG and/or MR and GR synthesis/activity, which
may be induced by the priming stress (ASR1, FS1), could result in
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structural adjustments of the CORT–CBG/MRs–GRs profile. This
way, free CORT levels can serve as a reporter of the behavioral out-
come, by showing a U-shape relationship with FS-potentiated ASR.
The genomic effect of CORT may regulate the hippocampal-depen-
dent fear memory (Cornelisse et al., 2014) also via changes in the
NE system (Fan et al., 2014; Hu et al., 2014) and tuning its predict-
ability 1 day after FS.
Conclusions
Acute stress-induced changes in NE and CORT signaling seem to
be translated into long-term behavioral effects of FS. Upon chal-
lenges 1 day after FS, NE and CORT levels in the mPFC predicted
arousal, whereas they predicted CF memory in the HPC. Both NE
and CORT levels showed not a linear but a U-shape relationship
with behavior. In the animal model used in this study, the ability of
brain NE and CORT to predict PTSD-like symptoms showed struc-
ture- and time-specificity. Therefore, results from an assessment of
NE and CORT levels for PTSD-like symptoms prognosis in the
periphery should be treated with caution.
Taken together, these data provide a means of early post-psycho-
physiological stress evaluation of NE signaling and CORT levels for
an accurate PTSD-like symptom prognosis and give insights into
time-specific pharmacological intervention.
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olomics platform was applied to the analysis of microdialy-
sates in a foot shock-induced mouse model of posttraumat-
ic stress disorder (PTSD). The rich metabolite data informa-
tion was then used to delineate affected prefrontal 
molecular pathways that reflect individual susceptibility for 
developing PTSD-like symptoms. We demonstrate that hy-
pothesis-free metabolomics can be adapted to the analysis 
of microdialysates for the discovery of small molecules with 
functional significance.  © 2015 S. Karger AG, Basel 
 Introduction 
 Microdialysis is used to dynamically monitor endog-
enous and exogenous substances  in vivo. The procedure 
can be performed in any tissue  [1] and body fluid  [2, 3] . 
A major focus is the analysis of brain neurotransmission, 
neurochemistry and metabolism  [4, 5] , and microdialysis 
remains the method of choice for experimental neuro-
pharmacology studies by acquiring pharmacokinetic and 
pharmacodynamic data from living animals  [6] . For this 
purpose, extracellular fluids from selected brain areas are 
analyzed for molecular components relevant for the 
 Key Words 
 Microdialysis · Metabolite profiling · Posttraumatic 
stress disorder · Molecular pathways · Biomarker · Stress 
susceptibility and resilience 
 Abstract 
 Microdialysis is a powerful method for in vivo neurochemical 
analyses. It allows fluid sampling in a dynamic manner in 
specific brain regions over an extended period of time. A par-
ticular focus has been the neurochemical analysis of extra-
cellular fluids to explore central nervous system functions. 
Brain microdialysis recovers neurotransmitters, low-molecu-
lar-weight neuromodulators and neuropeptides of special 
interest when studying behavior and drug effects. Other 
small molecules, such as central metabolites, are typically 
not assessed despite their potential to yield important infor-
mation related to brain metabolism and activity in selected 
brain regions. We have implemented a liquid chromatogra-
phy online mass spectrometry metabolomics platform for an 
expanded analysis of mouse brain microdialysates. The 
method is sensitive and delivers information for a far greater 
number of analytes than commonly used electrochemical 
and fluorescent detection or biochemical assays. The metab-
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physiological/pathological processes or drug response. 
The technique enables an assessment of the release and 
metabolism of neuroactive endogenous substances over a 
period of several days in freely moving animals. Sampling 
of specific brain regions, such as the medial prefrontal 
cortex (mPFC), paraventricular nucleus and amygdala, 
during behavioral experiments with rodents can be done 
with efficient spatial and temporal resolution of millime-
ters and minutes, respectively, reflecting the actual state 
of the animal under investigation.
 Perfusion of an implanted microdialysis probe with 
artificial cerebrospinal fluid that resembles the brain ex-
tracellular fluid with regard to pH, ion composition and 
osmolarity is not accompanied by significant fluid gain 
or loss and tissue homeostasis disturbances, thus making 
microdialysis a truly physiological method for the pur-
pose of in vivo sampling. By using a semipermeable 
membrane designed for microdialysis probes, macro-
molecules such as enzymes and proteins are excluded. 
This leaves collected extracellular matrices intact. Fur-
thermore, the absence of macromolecular complexes in 
microdialysates does not require sample purification pri-
or to analysis  [5] .
 Commonly employed methods for the analysis of mi-
crodialysates include electrochemical, UV and fluores-
cence detection coupled with high-performance liquid 
chromatography (HPLC) as well as radioimmunoassay, 
enzyme-linked immunosorbent assay, colorimetric and 
spectrophotometric biochemical assays  [1, 7] .
 The analytical methods currently used have restricted 
more comprehensive in-depth studies of the precious mi-
crodialysate samples. Small sample volumes limit the 
number of molecules, which can be simultaneously ana-
lyzed with good sensitivity using the classical detection 
methods. For this reason, microdialysate collection times 
are frequently extended, resulting in poor temporal reso-
lution. Modern analytical methods need to be imple-
mented in order to fully exploit microdialysis sample 
contents. Liquid chromatography online mass spectrom-
etry (LC-MS) allows selective identification and sensitive 
quantification of a great number of molecules. Although 
LC-MS methods have been developed for the identifica-
tion and quantification in microdialysates of neurotrans-
mitters  [8–10] , neuropeptides  [11] and exogenous com-
pounds such as drugs and their metabolites  [12–14] , most 
studies have been restricted to a small number of analytes 
and consequently have resulted in only narrow insights 
in pathophysiological mechanisms.
 LC-MS has become an important method in the field 
of metabolomics, the comprehensive analysis of metabo-
lites. When configured in the selected reaction monitor-
ing (SRM) mode, a great number of molecules can be 
identified with high confidence. This makes LC-MS the 
method of choice as a comprehensive screening tool for 
microdialysate analysis and pathway discovery pertinent 
to pathophysiological responses.
 In the present study, we have profiled and monitored 
central metabolite levels in microdialysates on a large 
scale for the first time, using an LC-MS metabolomics 
platform. We have applied this approach to a posttrau-
matic stress disorder (PTSD) mouse model  [15, 16] and 
have correlated metabolite levels measured prior to foot 
shock (FS) stress with behavioral readouts of FS resil-
ience (early and delayed post-shock changes in arousal 
levels). The method is orders of magnitude more com-
prehensive in terms of qualitative and quantitative mo-
lecular information than traditional microdialysate anal-
ysis. This information can be exploited to gain a better 
understanding of pathophysiological mechanisms in 
mouse models.
 Materials and Methods 
 Animals 
 Male C57BL/6NCrl mice, 7–8 weeks old, (Charles River GmbH, 
Sulzfeld, Germany) were housed in groups of four in Makrolon 
type II cages (23 × 16.5 × 14 cm 3 ) under an inverse 12: 12 h light-
dark cycle (light off at 7: 00) with food and water ad libitum. The 
experimental procedures were approved by the Government of 
Upper Bavaria. Laboratory animal care and the experiments were 
performed in compliance with the European Economic Commu-
nity recommendations for the care and use of laboratory animals 
(2010/63/EU).
 Fear Conditioning and Acoustic Startle Response 
 Fear conditioning for the PTSD mouse model was performed 
as described previously  [15] . In brief, after 198 s of habituation, the 
mice perceived two electric FS (1.5 mA, 2 s) with a 60-second in-
terval in between at moderate illumination (40 Lux) in a plexiglass 
shock chamber. The mice remained in the shock chamber for an-
other 60 s before they were returned to their home cages. To test 
for arousal levels, acoustic startle response (ASR) was measured 
automatically as described before  [16] . The level of ASR was as-
sessed on days 1 and 2 (ASR1 and ASR2) and FS-stimulated ASR 
changes (ASR2/ASR1, %) were calculated. For the evaluation of 
PTSD-like symptoms, the levels of ASR and contextual fear re-
sponse (CF) were assessed on day 34 (ASR34 and CF34).
 Brain Microdialysis 
 Guide cannulas were implanted into the right mPFC (coordi-
nates: AP: +2.20 mm, ML: 0.35 mm and DV: –1.50 mm) in accor-
dance to Paxinos and Franklin’s Mouse Brain Atlas  [17] under 
isoflurane (Abbot, Mumbai, India)/Metacam ® (Boehringer In-
gelheim GmbH, Ingelheim am Rhein, Germany) anesthesia/anal-
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gesia. Recovery in experimental plexiglass home cages (16 × 16 × 
32 cm 3 ) lasted for 1 week and included Metacam supplementation 
(0.25 mg/100 ml) with drinking water for 3 days after surgery, 
with daily inspection for food intake. One day before the experi-
ment, the mice were shortly anesthetized with isoflurane. Micro-
dialysis probes with a molecular cutoff of 6 kDa (o.d. 0.2 mm, 
cuprophane membrane 2 mm of length, MAB 4.15.2. Cu; Micro-
biotech/se AB, Stockholm, Sweden) were inserted and connected 
to the perfusion lines, which consist of FEP tubing and low-vol-
ume liquid swivel TCS2–23 (Eicom, Kyoto, Japan). From the mo-
ment of insertion, the probes were continuously perfused with 
sterile artificial cerebrospinal fluid (NaCl 145 mM, KCl 2.7 mM, 
CaCl 2 1.2 mM, MgCl 2 1.0 mM and Na 2 HPO 4 2.0 mM; pH 7.4) at a 
flow rate of 0.3 μl/min.
 Microdialysis fractions (30 min) were constantly collected at a 
perfusion rate of 1.5 μl/min into 300-microliter microtubes (Mi-
crobiotech/se AB) following a 1.5 h equilibration period. During 
the collection time, the tubes were kept in a refrigerated Univentor 
820 Microsampler (Univentor, Zejtun, Malta) at 4   °   C. The dead 
volume of the outlet line was compensated with a delay in fraction 
sampling (7 min). The perfusion flow rate was reduced to 0.3 μl/
min for overnight perfusion.
 The microdialysis experiment is outlined in  figure 1 . On ex-
perimental day 1, the mice were kept in the experimental plexiglass 
home cages (16 × 16 × 32 cm 3 ) for baseline microdialysis sample 
collection for 1.5 h. The mice were then subjected to a 20-minute 
ASR test in a sound and protected environment. To permit a con-
tinuous dialysis in microdialysis experiments, we used a custom-
made startle chamber equipped with a commercially available ASR 
apparatus (San Diego Instruments, San Diego, Calif., USA). Re-
sponse was expressed in arbitrary units. At the end of each test, the 
mice were transferred back to their home cages, and the chamber 
was cleaned thoroughly with soap water. Two hours later, the mice 
were subjected to a FS for fear conditioning. Microdialysis was 
done as described previously  [18] . The microdialysate fractions 
corresponding to the periods of Basal 1 (samples 1–3), ASR1 (sam-
ples 4–7) and FS1 (samples 8–11) on experimental day 1 were col-
lected. Only baseline samples were analyzed for metabolite con-
tent.
 Targeted Metabolomics Analysis 
 Four fold (v/v) ice-cold methanol was added to pooled prefron-
tal microdialysates (samples 1–3 for Basal 1) and vortexed for 
2 min. The samples were then incubated for 2 h on dry ice and 
centrifuged (2,053  g , 10 min, 4  °  C). Supernatants were transferred 
to a 0.22-micrometer cellulose acetate ultrafiltration tube (Corn-
ing Life Science, Tewksbury, Mass., USA) and centrifuged (1,105  g , 
2 min, 4   °   C) to remove undissolved particles. The filtrates were 
lyophilized and stored at –80  °  C until further analysis.
 The samples were resuspended in 20 μl LC-MS grade water. 
Ten microliters were injected and analyzed using a 5,500 QTRAP 
triple quadrupole mass spectrometer (AB/SCIEX, Framingham, 
Mass., USA) coupled to a Prominence UFLC HPLC system (Shi-
madzu, Columbia, Md., USA) via SRM of a total of 275 endoge-
nous water soluble metabolites for steady-state analyses of the 
samples. The samples were delivered to the mass spectrometer via 
normal-phase chromatography using a 4.6 mm i.d × 10 cm Amide 
Xbridge HILIC column (Waters Corp., Milford, Mass., USA) at 
350 μl/min. Gradients were run starting from 85% buffer B (HPLC 
grade acetonitrile) to 42% B from 0 to 5 min; 42 to 0% B from 5 to 
16 min; 0% B was held from 16 to 24 min; 0 to 85% B from 24 to 
25 min; 85% B was held for 7 min to re-equilibrate the column. 
Buffer A was comprised of 20 m M ammonium hydroxide/20 m M 
ammonium acetate, pH 9.0, in 95: 5 water:acetonitrile. Some me-
tabolites were targeted in both positive and negative ion modes for 
a total of 292 SRM transitions using positive/negative polarity 
switching. ESI voltage was +4,900 V in the positive ion mode and 
–4,500 V in the negative ion mode. The dwell time was 4 ms per 
SRM transition, and the total cycle time was 1.89 s. Approximate-
ly 9–12 data points were acquired per detected metabolite. Peak 
areas from the total ion current for each metabolite SRM transition 
were integrated using MultiQuant v2.0 software (AB/Sciex).
 Statistics and Data Analysis 
 Metabolites with >20% missing value and z-score >4 were con-
sidered outliers and removed from our analyses. We normalized 
the intensities of each metabolite to have a mean of zero and a 
standard deviation of 1. Correlation analyses for the metabolite 
levels and behavioral readouts were performed employing Graph-
Pad Prism 5 (GraphPad Software, La Jolla, Calif., USA). In brief, 
we correlated Basal 1 metabolite levels with behavioral readouts 
(ASR2/ASR1, ASR34 and CF34) by calculating the Pearson corre-
lation coefficient. The significant level was set to p < 0.05. Pathway 
analysis was conducted using MetaboAnalyst pathway tool (http://
www.metaboanalyst.ca).
 Results 
 Metabolite Profiling of mPFC Extracellular Fluid 
 Microdialysate fractions were subjected to high-
throughput metabolomics analyses with the help of a tar-
geted LC-MS platform interrogating a list of close to 300 
metabolites that encompass several central pathways re-
lated to energy metabolism, including citrate cycle, gly-
colysis or gluconeogenesis and pyruvate metabolism. In 
addition, the list included a number of central nervous 
Basal 1 
Day 1 
Microdialysis ASR2 
Day 2 
ASR1 FS1
ASR2/ASR1 
ASR34 CF34
Day 34 
 Fig. 1. Outline of the microdialysis experiment in combination 
with metabolomics applied to a PTSD mouse model. On experi-
mental day 1, ASR1 was measured, followed by fear-conditioning 
FS1. On experimental day 2, the mice were subjected to recurrent 
ASR2. Microdialysates collected at Basal 1 were subjected to me-
tabolite profiling. On experimental day 34, PTSD-like symptoms, 
including ASR and CF, were assessed. 
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 Fig. 2. Linear correlations between Basal 1 metabolite levels and FS-induced behavioral changes. Basal 1 metab-
olite levels correlated with FS-induced ASR2/ASR1 ( a ), ASR34 ( b ) and CF34 ( c ). 
(For Figure 2b and c see next page.)
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system-relevant molecules that are typically analyzed in 
microdialysis experiments including neurotransmitters 
(glutamate and glycine) and endogenous ion channel ag-
onists/antagonists (aspartate, alanine, kynurenic acid 
and phenylalanine) (online suppl. table S1; see wwww.
karger.com/doi/10.1159/000381855 for all online supple-
mentary material). In our PTSD mouse model, we were 
able to quantify 120 metabolites after data filtering and 
normalization (online suppl. table S1). 
 mPFC Metabolic Fingerprints under Basal Conditions 
Predict FS Impact on Arousal 
 Metabolic profiling of prefrontal extracellular fluid al-
lowed us to correlate molecular data with behavioral mea-
sures in the PTSD mouse model. We identified several 
central metabolites, which showed linear correlations 
with the FS-related early changes in arousal (ASR2/ASR1; 
 fig. 2 a). We then subjected the metabolites that predicted 
the FS-induced arousal changes and the highly correlat-
ing expression profile metabolites (online suppl. table S2) 
to pathway analyses. Citrate cycle metabolism and glyox-
ylate and dicarboxylate metabolism were significantly en-
riched ( table 1 ). These findings demonstrate the power of 
metabolite profiling for predicting early behavioral con-
sequences of FS and investigating affected pathways in 
the PTSD mouse model.
 mPFC Metabolic Fingerprints under Basal Conditions 
Predict Long-Term PTSD-Like Symptoms 
 In addition to the identified correlations for FS-in-
duced early changes in arousal, a number of central me-
tabolites showed prediction power for longer-term 
PTSD-symptoms, including ASR and CF 34 days after FS 
( fig. 2 b, c). Basal 1 xanthurenic acid and glucose-1-phos-
phate levels positively predicted ASR34, while sarcosine 
levels negatively predicted ASR34. Basal 1 spermidine 
levels negatively predicted the CF34 outcome.
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 Table 1. Pathways enriched by metabolites correlating with FS-
induced ASR2/ASR1 and metabolites with a correlating expression 
profile
Pathway Holm-Bonferroni-
adjusted p value
False 
discovery 
rate
Citrate cycle 0.0002 0.0002
Glyoxylate and dicarboxylate
metabolism 0.0219 0.0111
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 Discussion 
 The analysis of brain microdialysate samples from in-
dividual mice with an LC-MS metabolomics platform en-
abled us to detect and quantify the levels of close to 120 
metabolites. Our approach significantly extends the spec-
trum of microdialysate analytes and is able to delineate 
molecular pathways involved in pathological changes re-
lated to brain metabolism in a mouse model for PTSD. 
Metabolomics data analysis revealed numerous correla-
tions between basal mPFC metabolite profiles and FS-as-
sociated arousal and contextual fear. Our results demon-
strate that combining microdialysis with LC-MS provides 
a sensitive approach of a high-prediction power for deci-
phering the molecular signatures associated with individ-
ual susceptibility for developing PTSD-like symptoms in 
a given brain region. In an extension of this approach, 
microdialysis experiments could provide important in-
sights into affected brain circuits underlying pathophysi-
ological mechanisms by targeting different brain regions.
 Microdialysis has been widely applied for the evalua-
tion of extracellular dynamics of neurotransmitters and 
pharmacological substances in defined brain regions. 
Targeted quantification of up to 20 monoamines and 
their metabolites from microdialysis is feasible but pro-
vides rather limited insights for specific biological ques-
tions  [18] . Microdialysis is also routinely used to explore 
changes in the extracellular levels of neuroactive amino 
acids including aspartate, glutamate, glutamine and ala-
nine that are relevant not only for neurotransmission fo-
cused studies but also for neurotoxicity experiments  [19, 
20] . However, for sensitivity reasons, the electrochemical 
or fluorescent detection of amino acids in microdialysates 
requires pre- or post-column derivatization, which can 
lead to sample loss and/or measurement variability. In the 
present study, we were able to quantitate all 20 natural 
and several additional modified amino acids without de-
rivatization by applying modern metabolomics LC-MS 
technology as readout for the comprehensive profiling of 
brain microdialysates (online suppl. table S1). This al-
lowed us to reveal significant amino acid pathways af-
fected by stressors and associated with PTSD-like symp-
tom severity ( table 1 ).
 In an earlier study  [21] applying the same experimen-
tal design, no significant linear correlations were found 
between basal prefrontal norepinephrine and corticoste-
rone levels and behavioral responses to stress. When ana-
lyzing the here presented metabolomics data, Pearson 
correlation analysis showed prediction power for the me-
tabolites with regard to behavioral changes of the PTSD 
mice ( fig. 2 ). The correlations between baseline metabo-
lite levels and FS-induced arousal and PTSD-like symp-
toms demonstrate the power of microdialysate metabo-
lite profiling for the investigation of interindividual vari-
ability, in this case susceptibility or resilience towards 
coping with psychophysiological stress and the develop-
ment of PTSD endophenotype, in an inbred mouse strain.
 Several of the metabolites that show correlations to the 
early (day 2) and delayed (day 34) behavioral changes in-
duced by stress have relevance for psychiatric pheno-
types. Sarcosine, a glycine reuptake inhibitor, has been 
implicated in the regulation of synaptic plasticity, mem-
ory and cognition  [22] . Our data show a positive correla-
tion between Basal 1 sarcosine levels and FS-induced 
ASR2/ASR1. On the other hand, Basal 1 sarcosine levels 
negatively predicted the FS-induced ASR34. These data 
suggest that sarcosine-dependent prefrontal mechanisms 
of plasticity show biphasic dynamics with respect to 
arousal state regulation. We were also able to quantify 
neurokynurenines, including kynurenic acid, xanthuren-
ic acid and nicotinate from prefrontal microdialysates. 
The kynurenine pathway is the major route for trypto-
phan metabolism and has been implicated in the patho-
physiology of depression and stress-related disorders  [23, 
24] . Mice subjected to unpredictable chronic mild stress 
exhibited an elevation of the peripheral kynurenine path-
way  [25] . In the same study, a correlation between the 
peripheral kynurenine/tryptophan ratio and anxiode-
pressive-like behavior in mice subjected to unpredictable 
chronic mild stress was found. Previous studies showed 
that treatment with nicotinate resulted in improved hu-
man sensory register and short-term memory, possibly 
by facilitating neurotransmission  [26] . By binding with 
neuronal transporters, nicotinate can be utilized as cel-
lular precursor for nicotinamide adenine nucleotide and 
nicotinamide adenine dinucleotide phosphate synthesis, 
key events in regulating energy metabolism that has been 
implicated in the pathogenesis of psychiatric disorders 
 [27–29] . In the current study, we found prefrontal nico-
tinate levels to positively correlate with FS-induced ASR2/
ASR1 change and xanthurenic acid levels to positively 
predict the arousal response 34 days after shock (ASR34). 
These results support a possible role for neurokynuren-
ines in mediating neuronal activity, specifically relevant 
for arousal mechanisms.
 An additional benefit of using a great number of ana-
lytes for the interrogation of microdialysates is the ability 
to get information about affected molecular pathways rel-
evant for symptom development in the mouse model un-
der investigation. When subjecting the enriched metabo-
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lites to pathway analyses, we found energy metabolism, 
specifically the citrate cycle pathway, to be affected in the 
PTSD mouse model. Previous studies have shown in-
creased citrate cycle activity in synaptosomes of high-
anxiety mice  [30] . Functional synapses are enriched with 
mitochondria, which supply ATP and regulate calcium 
levels, modulating neuronal transmembrane potential 
 [31] , synaptic neurotransmission  [32] , receptor signaling 
 [33] and synaptic plasticity  [34] . A dysregulated citrate 
cycle metabolism leads to abnormal energy production 
that can impair neurotransmission. This may be of par-
ticular relevance in the mPFC, which exerts top-down 
control of emotional states. Anxiolytic medications such 
as monoamine oxidase inhibitors were shown to improve 
mitochondrial function  [35] . Based on our findings, we 
assume that differential regulation of the citrate cycle may 
be involved in endophenotype-specific neurotransmis-
sion in the PTSD mouse model.
 With the help of the LC-MS metabolomics platform, 
we were also able to quantify a number of metabolites that 
are directly related to neurotransmission, including glu-
tamate, hydroxyphenylacetic acid, phenylalanine, trypto-
phan and the N-methyl- D -aspartate receptor agonists al-
anine and aspartate. Further applications of the LC-MS 
metabolomics platform could include studies of neu-
rotransmitter dynamics and help delineate affected path-
ways involved in neuronal plasticity.
 LC-MS microdialysate analysis yields high sensitivity 
and selectivity compared to the commonly used detection 
methods  [36] . The method allows a reliable qualitative 
and quantitative determination of a wide range of me-
tabolites. With the help of the LC-MS metabolomics plat-
form, we were able to reveal alterations in intracellular 
metabolic pathways reflected as changes in metabolite 
profiles in the extracellular fluid. The method enables hy-
pothesis-free physiological studies, is applicable to any 
rodent model and may illuminate novel targets for phar-
macological intervention.
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3. DISCUSSION AND FUTURE PERSPECTIVES 
 
In the present study I applied transcriptomics, proteomics and metabolomics technologies in 
combination with in silico pathway analyses, as well as neurochemical microdialysis to 
identify molecular pathways affected in a mouse model of PTSD. For this purpose adult male 
C57BL/6NCrl mice were exposed to non-escapable electric FS, and tissue punches 
representing specific brain regions subjected to the various –omics analyses. As a second step 
mice were treated with either fluoxetine, an antidepressant drug used for treatment of PTSD 
patients, or vehicle. Affected molecular pathways were identified by interrogating 
transcriptomics, proteomics and metabolomics data with the help of computational biology 
methods. In addition, I analyzed the relationship between neuroendocrine levels, including 
norepinephrine and corticosterone, and PTSD-like symptoms in a structure- and time-
dependent manner. 
In further support of the association of the identified pathways and PTSD pathogenesis I was 
able to show that fluoxetine treatment rescues/prevents pathway alterations upon FS 
application and ameliorates PTSD-like symptoms. My results suggest new molecular 
mechanisms involved in PTSD pathobiology that can benefit future investigations aimed at 
improving PTSD diagnosis and treatment. 
 
3.1. Energy metabolism  
3.1.1. Altered energy metabolism in psychiatric diseases 
My results indicate that a dysregulated citric acid cycle pathway in specific brain regions is 
associated with PTSD pathogenesis. Altered energy metabolism has previously been 
implicated in other psychiatric disorders. Filiou et al. identified decreased glycolysis and 
increased electron transport chain (ETC) pathways in the cingulate cortex synaptosome from 
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a high anxiety-related behavior mouse model (Filiou et al, 2011). Increased ETC activity 
enhances oxidative stress and results in oxidative damage and cell death. Mitochondria-
targeted antioxidant treatment was shown to reduce anxiety-related behaviour in mice and 
rats, indicating that a dysfunctional antioxidant defense is associated with anxiety. In 
schizophrenia (SCZ) post-mortem prefrontal cortex specimens increased glucose demand was 
observed, with higher lactate level accumulation and cellular acidosis, again implying 
mitochondrial dysfunction (Rajasekaran et al, 2015). A combined transcriptomics, 
proteomics and metabolomics analysis also revealed altered oxidative stress in post-mortem 
SCZ prefrontal cortex (Prabakaran et al, 2004). In autism spectrum disorders (ASD) 
biomarkers indicative of mitochondrial dysfunction were identified, including elevated lactate, 
pyruvate and alanine levels and an altered lactate-to-pyruvate ratio (Correia et al, 2006; 
Germanò et al, 2006; László et al, 1994). 
Mitochondria are involved in neurotransmission by regulating presynaptic calcium levels at 
central glutamatergic terminals (Billups and Forsythe, 2002). An alteration of mitochondrial 
function can lead to neurotransmission disequilibrium reported to be involved in anxiety 
disorders (Calabresi et al, 2001) and ASD (Banerjee et al, 2013). Glutamate accumulation 
leads to mitochondrial β-oxidation inhibition, ROS generation and GSH depletion causing 
secondary mitochondrial dysfunction (Pastural et al, 2009; Tirosh et al, 2000). ROS impede 
mitochondrial oxidative phosphorylation and result in oxidative damage of membrane lipids 
and proteins that have been implicated in neurodegenerative disorders (Davis et al, 2014; 
Halliwell, 2006). Changes in mitochondrial function may influence downstream energy 
metabolism, resulting in compromised ATP production and neuronal differentiation, 
ultimately perturbing neuronal activity that has been associated with neurological disorders 
(Ben-Shachar and Laifenfeld, 2004; Mattson et al, 2008). Furthermore, it was suggested that 
mitochondrial deficits might result in progressive disturbances in astrocyte function relevant 
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in SCZ pathogenesis (Kolomeets and Uranova, 2010). Taken together, there is accumulating 
evidence that mitochondrial dysfunction results in dysregulated energy metabolism and 
synaptic plasticity, which in turn affect neuronal circuits and brain function implicated in 
various psychiatric disorders. Further studies are needed in order to elucidate the specific role 
of mitochondrial deficits in distinct psychiatric diseases and the interactions between 
environmental/epigenetics factors and mitochondrial dysfunction in disease pathogenesis.  
      
3.1.2. Interaction between energy metabolism, inflammatory response and 
neuroendocrine function 
My results indicate an increased inflammatory pathway activity and decreased energy 
metabolism in the ACC of shocked mice. A cross-talk between mitochondrial function and 
inflammation has been recognized in various pathological conditions. ROS generated by 
mitochondria act as signaling molecules in inflammatory pathways and regulate the 
production of pro-inflammatory cytokines (Naik and Dixit, 2011). Exposure to infections 
during early gestation in mice activates an inflammatory response and results in a long-
lasting decrease of splenocyte mitochondrial activity in the offspring (Schwartzer et al, 2013). 
In several recent reports inflammation has been linked to PTSD (Gola et al, 2013; Lindqvist 
et al, 2014; Pace and Heim, 2011). Increased levels of pro-inflammatory cytokine mRNA and 
ROS were identified in the brain, adrenal glands and systemic circulation in a rat model of 
PTSD (Wilson et al, 2013).  The mitochondrial deficits and oxidative stress found in PTSD 
could be associated with inflammation as mitochondria are the major targets of inflammation-
induced damage. Furthermore, long-lasting inflammation observed in chronic disease, such 
as PTSD, is sustained by reparative mechanisms fueled mainly by ATP produced by 
mitochondria, which in the long term can result in mitochondrial malfunction (Liu et al, 
2012).  
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Adrenergic agents and GCs are also important mediators implicated in inflammatory pathway 
activity through their binding to receptors on immune precursor cells (Ader et al, 1995); 
(Elenkov et al, 2000). Lower GC production and fewer GC receptors have been observed in 
PTSD patients (Yehuda, 2001). A decreased GC receptor number may lead to a dysregulated 
inflammatory response due to a reduced capacity of immune cells to respond to anti-
inflammatory signals (Miller et al, 2002b). In conclusion, the above findings suggest that 
exposure to psychosocial stressors induces adrenergic agent and GC production which affects 
the pro-inflammatory cytokine network and mitochondrial activity. The interaction of 
neuroendocrine, inflammation and mitochondrial function is critical for neuronal activity 
involved in PTSD pathogenesis. 
 
3.1.3. Role of energy metabolism in different neurons     
I found an altered energy metabolism in PrL, ACC and NAc of the shocked mice. Further 
interrogation of altered mitochondrial function at the neuronal level is needed for a better 
understanding of the association between dysregulated neuronal activity and PTSD 
development. Since astrocytes communicate with both GABAergic and glutamatergic 
neurons it is plausible that inhibitory or excitatory neurotransmitters are involved in their 
function. During excitatory activity oxidative metabolism is much higher in glutamatergic 
neurons, with more ATP produced than in other neuron types (Calvetti and Somersalo, 2012). 
Previous studies have indicated that alterations in hippocampal function induced by 
glutamatergic and GC-driven changes result in a long-term anxiety-related behavior response 
upon exposure to psychological stressors (Reul, 2014). GABAergic tonic inhibitory control 
has been suggested to regulate epigenomic responses to psychologic events in dentate gyrus 
granule neurons via modulation of NMDA receptor function, implying a role for 
hippocampal GABAergic neurons in PTSD (Papadopoulos et al, 2011). Mitochondrial 
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dysfunction can lead to reduced synaptic neurotransmitter release in GABAergic interneurons 
(Anderson and Schönborn, 2008). Without proper GABAergic neuronal function resulting 
from perturbed mitochondrial activity the brain may be susceptible to excitotoxicity.  
Astrocytes are relevant for the preservation of neural environments, including maintenance of 
the extracellular milieu (Suzuki et al, 2011) and regulation of neurotransmitter synthesis (Ota 
et al, 2013) and ions (Lian and Stringer, 2004). Mitochondrial dysfunction in astrocytes 
results in neuronal glutamate excitotoxicity which is likely to be associated with their 
inability to covert glutamate to glutamine, a process that requires ATP (Voloboueva et al, 
2007). Furthermore, co-compartmentalization of astrocytic mitochondria and glutamate 
transporter-1 (GLT-1) has been observed in hippocampal sections (Genda et al, 2011), and 
the number of astrocytic mitochondria near GLT-1 is associated with glutamate uptake 
(Jackson et al, 2014). Since extracellular glutamate levels regulate synaptic transmission, 
astrocyte mitochondrial function plays an important role in this process. 
  
3.2. Systemic view of PTSD brain circuitry 
PTSD is associated with abnormal activity in brain regions involved in fear circuitry, such as 
medial prefrontal cortex, amygdala, hippocampus and NAc (Chaudhury et al, 2013; Maroun, 
2013; Zelikowsky et al, 2014; Zhang et al, 2014) Alterations in the functional connectivity 
and activities of these brain regions result in perturbed perception and interpretation of 
traumatic events and lead to the development of PTSD (Antoniadis and McDonald, 2006; 
Belzung et al, 2014).  
An emerging view of prefrontal cortex (PFC) function is that multiple PFC subregions (e.g. 
ACC, PrL and infralimbic cortex) dynamically interact and process information in parallel, 
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rather than working as distinct modules during attention and fear expression. PrL receives 
sensory inputs from amygdala, hippocampus as well as other cortical regions involved in fear 
conditioning (Herry and Johansen, 2014) and projects back to neurons in BLA for fear 
expression (Anglada-Figueroa and Quirk, 2005). Previous electrophysiology studies in rats 
suggest that ACC neurons drive beta local field potential within PrL and induce beta rhythm 
in local PrL neurons during a sustained attentional task (Totah et al, 2013). In a fear 
conditioning rat model Almada et al. revealed that medial PFC modulates the expression of 
contextual fear in combination with PrL via both serotonergic and GABAergic mechanisms 
and ACC via GABAergic mechanism (Almada et al, 2015). These findings suggest that 
parallel, but distinct activities of PrL and ACC contribute to the modulation of contextual fear 
conditioning. Over the course of my study, FS-induced long term energy metabolism 
alterations were found in ACC and PrL with opposite directions. Decreased ACC activity 
may result in cognitive deficits in trauma-related information processing and interferes with 
synaptic plasticity in the PrL. Perturbed ACC activity together with PrL hyperactivation 
results in exaggerated fear expression critical for the development of PTSD. 
Anxiety-like behaviors are regulated by various neuronal circuitries, such as dopaminergic 
outputs from ventral tegmental area to NAc (da Cunha et al, 2008; Doherty and Gratton, 
2007). It has been shown that ventral PFC projects fibers to NAc, and PFC glutamatergic 
system regulates the emotional behaviors directly through the NAc (Ongür and Price, 2000; 
Robbins, 2000). Furthermore, previous studies suggested that dopaminergic signaling in NAc 
shell exerts a modulatory effect on prelimbic NMDA-induced anxiolytic-like behaviors 
(Ahmadi et al, 2013). In my thesis project I found a downregulation of energy metabolism in 
NAc and an upregulation in PrL of shocked mice. It is conceivable that upon exposure to 
stressors an increased PrL activity leads to perturbed neuronal signaling and cellular 
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metabolism in NAc, which in turn results in deficits in modulatory NAc effects on PrL 
function and anxiety-like behavior. In addition to PrL, results from animal studies suggest 
that projections from ACC to NAc regulate impulsive activity (Fineberg et al, 2010), which is 
associated with PTSD symptoms (Miles et al, 2015). Decreased mitochondrial activity in 
ACC might lead to abnormal neurotransmission and synaptic signaling to NAc, which may 
further disturb cellular metabolism in NAc and result in anxiety-like behavior in shocked 
mice. Further time course studies are needed to investigate the role of distinct affected brain 
regions in PTSD pathogenesis. 
 
3.3. Fluoxetine treatment 
Early intervention by fluoxetine treatment ameliorated PTSD-like symptoms in shocked mice. 
Results from my thesis project suggest a prominent role of the drug in the modulation of 
energy metabolism and the inflammatory response. 
Clinical studies have resulted in mixed outcomes when PTSD patients were treated with 
fluoxetine (Hertzberg et al, 2000; Martenyi et al, 2007; Martenyi et al, 2002; van der Kolk et 
al, 1994). Hertzberg et al. found that young or female PTSD patients responded better to 
fluoxetine treatment than older or male combat veterans (Hertzberg et al, 2000). Fluoxetine’s 
mode of action includes an involvement in synaptic remodeling, neurogenesis (Guest et al, 
2004).  
Karpova et al. found that chronic fluoxetine treatment combined with extinction training, but 
neither treatment alone, induces a sustained loss of conditioned fear memory in adult animals. 
It was shown that fluoxetine treatment increased synaptic plasticity through local brain-
derived neurotrophic factor and converted fear memory circuitry to a more vulnerable state 
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(Karpova et al, 2011). The reactivation of juvenile plasticity by fluoxetine treatment may 
allow behavioral training to modify maladapted networks for better adjustment to the 
environment (Castrén, 2005; Maya Vetencourt et al, 2008). In conclusion, early treatment 
with fluoxetine upon trauma exposure seems to regulate neuronal activity and may open a 
window for reshaping neuronal circuitry, thereby allowing in combination with 
psychotherapy to improve PTSD symptoms. 
 
3.4. Future perspectives 
In my thesis project I have integrated data from state of the art transcriptomics, proteomics 
and metabolomics analyses to identify dysregulated molecular pathways associated with 
PTSD. With the help of computational biology methods I have delineated interconnected 
pathways in brain regions implicated in the fear response. The results reveal novel insights 
into the complex etiology of PTSD. 
Genome-wide association studies (GWAS) are complementary to the –omics analyses carried 
out in my thesis project and also allow the discovery of genes and molecular pathways 
contributing to PTSD pathobiology. The recently established Psychiatric Genomics 
Consortium (PGC) group studying PTSD genetics (PGC-PTSD) has investigated over 10,000 
cases and 30,000 trauma-exposed controls from several countries (Logue et al, 2015). This 
large-scale GWAS will without doubt lead to significant genetic associations and further 
insights into the pathobiology of PTSD.  
Future PTSD pathway discovery should also extend to lipidomics analysis. Lipids play an 
important role in signal transduction events in the central nervous system (CNS). CNS lipids 
are reported to be involved in neurotransmitter secretion and mitochondria function 
(Appikatla et al, 2014; Lane-Donovan et al, 2014). Alterations at the lipidome level will shed 
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additional light on the connection between psychiatric disorders and lipid metabolism, and 
may provide new targets and strategies for therapeutic intervention. Applying modern 
metabolomics to the analysis of brain microdialysates, which was also carried out as part of 
my thesis project, allows the interrogation of altered intracellular molecular pathways during 
stress response in targeted brain regions of mice. The method has great potential to better 
understand molecular pathways affected by stressors, and can be applied to animal models for 
psychiatric disorders. 
In addition to hypothesis-free –omics studies, further research on targeted biological 
parameters/candidates, such as mRNA turnover (Mitchell and Tollervey, 2001; Munchel et al, 
2011), protein turnover (Price et al, 2010; Zhang et al, 2011), protein post-translational 
modifications (Christensen et al, 2010) in combination with alternative platforms such as 
single-cell analyses (Shi et al, 2012) or multimodal imaging studies (Yerys and Herrington, 
2014) will lead to a more comprehensive understanding of PTSD pathobiology. The 
integration of data from diverse technologies and well characterized mouse models and 
clinical samples will bring novel insights into the biological underpinnings of PTSD and 
eventually lead to better diagnosis and treatment strategies.   
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